US20050153329A1 - Method for determining immune system affecting compounds - Google Patents
Method for determining immune system affecting compounds Download PDFInfo
- Publication number
- US20050153329A1 US20050153329A1 US10/997,985 US99798504A US2005153329A1 US 20050153329 A1 US20050153329 A1 US 20050153329A1 US 99798504 A US99798504 A US 99798504A US 2005153329 A1 US2005153329 A1 US 2005153329A1
- Authority
- US
- United States
- Prior art keywords
- production
- factor
- cancer
- tumour
- substances
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 81
- 150000001875 compounds Chemical class 0.000 title claims abstract description 45
- 210000000987 immune system Anatomy 0.000 title description 25
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 340
- 238000004519 manufacturing process Methods 0.000 claims abstract description 221
- 201000011510 cancer Diseases 0.000 claims abstract description 188
- 230000001939 inductive effect Effects 0.000 claims abstract description 179
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 170
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 169
- 239000000126 substance Substances 0.000 claims abstract description 126
- 102000004127 Cytokines Human genes 0.000 claims abstract description 89
- 108090000695 Cytokines Proteins 0.000 claims abstract description 89
- 230000004957 immunoregulator effect Effects 0.000 claims abstract description 70
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 60
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 60
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 59
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 52
- 230000001965 increasing effect Effects 0.000 claims abstract description 46
- 230000007246 mechanism Effects 0.000 claims abstract description 44
- 102000003814 Interleukin-10 Human genes 0.000 claims abstract description 43
- 108090000174 Interleukin-10 Proteins 0.000 claims abstract description 43
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 43
- 102000013691 Interleukin-17 Human genes 0.000 claims abstract description 36
- 108050003558 Interleukin-17 Proteins 0.000 claims abstract description 36
- -1 IL-1β Proteins 0.000 claims abstract description 30
- 230000001575 pathological effect Effects 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims abstract 13
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims abstract 13
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 218
- 239000012634 fragment Substances 0.000 claims description 158
- 230000000694 effects Effects 0.000 claims description 109
- 210000001519 tissue Anatomy 0.000 claims description 83
- 210000002966 serum Anatomy 0.000 claims description 81
- 210000002700 urine Anatomy 0.000 claims description 81
- 210000004027 cell Anatomy 0.000 claims description 67
- 230000000903 blocking effect Effects 0.000 claims description 61
- 230000002401 inhibitory effect Effects 0.000 claims description 61
- 102000009027 Albumins Human genes 0.000 claims description 58
- 108010088751 Albumins Proteins 0.000 claims description 58
- 238000004132 cross linking Methods 0.000 claims description 52
- 108010002350 Interleukin-2 Proteins 0.000 claims description 49
- 102000000588 Interleukin-2 Human genes 0.000 claims description 49
- 230000027455 binding Effects 0.000 claims description 49
- 102000005962 receptors Human genes 0.000 claims description 47
- 108020003175 receptors Proteins 0.000 claims description 47
- 230000001506 immunosuppresive effect Effects 0.000 claims description 37
- 108060003951 Immunoglobulin Proteins 0.000 claims description 35
- 102000018358 immunoglobulin Human genes 0.000 claims description 35
- 230000017306 interleukin-6 production Effects 0.000 claims description 35
- 230000002519 immonomodulatory effect Effects 0.000 claims description 34
- 102000004190 Enzymes Human genes 0.000 claims description 33
- 108090000790 Enzymes Proteins 0.000 claims description 33
- 229940088598 enzyme Drugs 0.000 claims description 33
- 238000010186 staining Methods 0.000 claims description 33
- 230000009257 reactivity Effects 0.000 claims description 31
- 230000002797 proteolythic effect Effects 0.000 claims description 26
- 210000004881 tumor cell Anatomy 0.000 claims description 26
- 210000004698 lymphocyte Anatomy 0.000 claims description 25
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 22
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 22
- 230000001404 mediated effect Effects 0.000 claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 230000004913 activation Effects 0.000 claims description 20
- 210000002744 extracellular matrix Anatomy 0.000 claims description 20
- 230000003828 downregulation Effects 0.000 claims description 19
- 230000000638 stimulation Effects 0.000 claims description 17
- 230000009885 systemic effect Effects 0.000 claims description 17
- 102000008186 Collagen Human genes 0.000 claims description 16
- 108010035532 Collagen Proteins 0.000 claims description 16
- 229920001436 collagen Polymers 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 230000004044 response Effects 0.000 claims description 16
- 238000002965 ELISA Methods 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 210000005087 mononuclear cell Anatomy 0.000 claims description 15
- 230000004071 biological effect Effects 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 102000035195 Peptidases Human genes 0.000 claims description 13
- 108091005804 Peptidases Proteins 0.000 claims description 13
- 230000001276 controlling effect Effects 0.000 claims description 13
- 238000009169 immunotherapy Methods 0.000 claims description 13
- 230000002255 enzymatic effect Effects 0.000 claims description 12
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims description 12
- 210000004969 inflammatory cell Anatomy 0.000 claims description 11
- 108010067306 Fibronectins Proteins 0.000 claims description 10
- 102000016359 Fibronectins Human genes 0.000 claims description 10
- 102000007562 Serum Albumin Human genes 0.000 claims description 10
- 108010071390 Serum Albumin Proteins 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 238000004393 prognosis Methods 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 10
- 102000004506 Blood Proteins Human genes 0.000 claims description 9
- 108010017384 Blood Proteins Proteins 0.000 claims description 9
- 230000000259 anti-tumor effect Effects 0.000 claims description 9
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 8
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 8
- 210000002865 immune cell Anatomy 0.000 claims description 8
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims description 8
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims description 8
- 108010049003 Fibrinogen Proteins 0.000 claims description 7
- 102000008946 Fibrinogen Human genes 0.000 claims description 7
- 238000002512 chemotherapy Methods 0.000 claims description 7
- 238000001962 electrophoresis Methods 0.000 claims description 7
- 229940012952 fibrinogen Drugs 0.000 claims description 7
- 229940072221 immunoglobulins Drugs 0.000 claims description 7
- 238000003556 assay Methods 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 230000016396 cytokine production Effects 0.000 claims description 6
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 6
- 230000008844 regulatory mechanism Effects 0.000 claims description 6
- 230000006433 tumor necrosis factor production Effects 0.000 claims description 6
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 claims description 4
- 239000002532 enzyme inhibitor Substances 0.000 claims description 4
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 4
- 238000000684 flow cytometry Methods 0.000 claims description 4
- 230000019189 interleukin-1 beta production Effects 0.000 claims description 4
- 230000031261 interleukin-10 production Effects 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 206010003445 Ascites Diseases 0.000 claims description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 3
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims description 3
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims description 3
- 102000005741 Metalloproteases Human genes 0.000 claims description 3
- 108010006035 Metalloproteases Proteins 0.000 claims description 3
- 102000007079 Peptide Fragments Human genes 0.000 claims description 3
- 108010033276 Peptide Fragments Proteins 0.000 claims description 3
- 208000002151 Pleural effusion Diseases 0.000 claims description 3
- 208000033809 Suppuration Diseases 0.000 claims description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 3
- 238000011394 anticancer treatment Methods 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 210000003608 fece Anatomy 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 230000001926 lymphatic effect Effects 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 238000000018 DNA microarray Methods 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 238000002105 Southern blotting Methods 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 238000004166 bioassay Methods 0.000 claims description 2
- 239000002981 blocking agent Substances 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 238000003757 reverse transcription PCR Methods 0.000 claims description 2
- 238000012090 tissue culture technique Methods 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 102000007547 Laminin Human genes 0.000 claims 6
- 108010085895 Laminin Proteins 0.000 claims 6
- 239000011159 matrix material Substances 0.000 claims 4
- 102000002262 Thromboplastin Human genes 0.000 claims 3
- 108010000499 Thromboplastin Proteins 0.000 claims 3
- 238000001815 biotherapy Methods 0.000 claims 3
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102100027995 Collagenase 3 Human genes 0.000 claims 1
- 108050005238 Collagenase 3 Proteins 0.000 claims 1
- 102100030417 Matrilysin Human genes 0.000 claims 1
- 108090000855 Matrilysin Proteins 0.000 claims 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 210000004976 peripheral blood cell Anatomy 0.000 claims 1
- 238000004458 analytical method Methods 0.000 abstract description 14
- 229940100601 interleukin-6 Drugs 0.000 description 159
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 84
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 84
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 83
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 83
- 108091006905 Human Serum Albumin Proteins 0.000 description 74
- 102000008100 Human Serum Albumin Human genes 0.000 description 74
- 102000004169 proteins and genes Human genes 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 49
- 208000006265 Renal cell carcinoma Diseases 0.000 description 45
- 238000011534 incubation Methods 0.000 description 39
- 239000006228 supernatant Substances 0.000 description 38
- 201000001441 melanoma Diseases 0.000 description 33
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 27
- 230000035755 proliferation Effects 0.000 description 26
- 239000007790 solid phase Substances 0.000 description 24
- 206010062016 Immunosuppression Diseases 0.000 description 23
- 239000012980 RPMI-1640 medium Substances 0.000 description 23
- 238000001574 biopsy Methods 0.000 description 21
- 208000019465 refractory cytopenia of childhood Diseases 0.000 description 20
- 239000000872 buffer Substances 0.000 description 19
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 19
- 108010047620 Phytohemagglutinins Proteins 0.000 description 18
- 230000001885 phytohemagglutinin Effects 0.000 description 18
- 206010009944 Colon cancer Diseases 0.000 description 17
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 17
- 239000002953 phosphate buffered saline Substances 0.000 description 17
- 210000001616 monocyte Anatomy 0.000 description 16
- 230000009696 proliferative response Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 239000000284 extract Substances 0.000 description 15
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 14
- 206010061218 Inflammation Diseases 0.000 description 14
- 229930182555 Penicillin Natural products 0.000 description 14
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 14
- 241000607479 Yersinia pestis Species 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 229940049954 penicillin Drugs 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 230000004936 stimulating effect Effects 0.000 description 14
- 229960005322 streptomycin Drugs 0.000 description 14
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 13
- 229920002684 Sepharose Polymers 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 12
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 12
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 12
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 12
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 12
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 12
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 12
- 229960004630 chlorambucil Drugs 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 238000001502 gel electrophoresis Methods 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 12
- 239000003656 tris buffered saline Substances 0.000 description 12
- 102000000589 Interleukin-1 Human genes 0.000 description 11
- 108010002352 Interleukin-1 Proteins 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 10
- 229930182816 L-glutamine Natural products 0.000 description 10
- 239000003636 conditioned culture medium Substances 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 241000283707 Capra Species 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 9
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000008482 dysregulation Effects 0.000 description 9
- 230000003308 immunostimulating effect Effects 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 9
- 101710120037 Toxin CcdB Proteins 0.000 description 8
- 238000001042 affinity chromatography Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 7
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 7
- 238000013467 fragmentation Methods 0.000 description 7
- 238000006062 fragmentation reaction Methods 0.000 description 7
- 239000000411 inducer Substances 0.000 description 7
- 238000001155 isoelectric focusing Methods 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 238000001179 sorption measurement Methods 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 108010074051 C-Reactive Protein Proteins 0.000 description 6
- 102100032752 C-reactive protein Human genes 0.000 description 6
- 102100022002 CD59 glycoprotein Human genes 0.000 description 6
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 6
- 102000004388 Interleukin-4 Human genes 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 238000002523 gelfiltration Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 5
- 238000011533 pre-incubation Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 108010062580 Concanavalin A Proteins 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 108091006004 biotinylated proteins Proteins 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000011033 desalting Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 230000003832 immune regulation Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 238000013188 needle biopsy Methods 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 238000010837 poor prognosis Methods 0.000 description 4
- 230000004797 therapeutic response Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 3
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 3
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 3
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 3
- 101710160939 Lithostathine-1-alpha Proteins 0.000 description 3
- 102100027361 Lithostathine-1-alpha Human genes 0.000 description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
- 102000013967 Monokines Human genes 0.000 description 3
- 108010050619 Monokines Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000003305 autocrine Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000012137 double-staining Methods 0.000 description 3
- 230000002222 downregulating effect Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 229960001614 levamisole Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000010979 ruby Substances 0.000 description 3
- 229910001750 ruby Inorganic materials 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 3
- MISZALMBODQYFT-URVXVIKDSA-N 125-69-9 Chemical compound Br.C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21 MISZALMBODQYFT-URVXVIKDSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- VKYZDCTWJGBFDW-UHFFFAOYSA-N 4-chloro-2-methylaniline;hydron;chloride Chemical compound Cl.CC1=CC(Cl)=CC=C1N VKYZDCTWJGBFDW-UHFFFAOYSA-N 0.000 description 2
- 102000003966 Alpha-1-microglobulin Human genes 0.000 description 2
- 101800001761 Alpha-1-microglobulin Proteins 0.000 description 2
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000048176 Prostaglandin-D synthases Human genes 0.000 description 2
- 108030003866 Prostaglandin-D synthases Proteins 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 102100038246 Retinol-binding protein 4 Human genes 0.000 description 2
- 101710137011 Retinol-binding protein 4 Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 108700025316 aldesleukin Proteins 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 102000009732 beta-microseminoprotein Human genes 0.000 description 2
- 108010020169 beta-microseminoprotein Proteins 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 102000005311 colipase Human genes 0.000 description 2
- 108020002632 colipase Proteins 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229940009600 gammagard Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 108010093564 inter-alpha-inhibitor Proteins 0.000 description 2
- 230000024949 interleukin-17 production Effects 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 108010049224 perlecan Proteins 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 229940087463 proleukin Drugs 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000001373 regressive effect Effects 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- MPVDXIMFBOLMNW-ISLYRVAYSA-N 7-hydroxy-8-[(E)-phenyldiazenyl]naphthalene-1,3-disulfonic acid Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1\N=N\C1=CC=CC=C1 MPVDXIMFBOLMNW-ISLYRVAYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101150049192 ERP29 gene Proteins 0.000 description 1
- 102100031857 Endoplasmic reticulum resident protein 29 Human genes 0.000 description 1
- 102100038083 Endosialin Human genes 0.000 description 1
- 101710144543 Endosialin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102100021189 GMP reductase 2 Human genes 0.000 description 1
- 101710193290 GMP reductase 2 Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 101000999311 Homo sapiens Immunoglobulin superfamily member 8 Proteins 0.000 description 1
- 101001003135 Homo sapiens Interleukin-13 receptor subunit alpha-1 Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000664418 Homo sapiens Secreted Ly-6/uPAR-related protein 1 Proteins 0.000 description 1
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 description 1
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 description 1
- 102100036489 Immunoglobulin superfamily member 8 Human genes 0.000 description 1
- 102100027003 Inhibin beta B chain Human genes 0.000 description 1
- 101710104543 Inhibin beta B chain Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 description 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 description 1
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000005712 Keratin-8 Human genes 0.000 description 1
- 108010070511 Keratin-8 Proteins 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000001746 Pancreatic alpha-Amylases Human genes 0.000 description 1
- 108010029785 Pancreatic alpha-Amylases Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100038583 Secreted Ly-6/uPAR-related protein 1 Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 1
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 101710086987 X protein Proteins 0.000 description 1
- 102100021144 Zinc-alpha-2-glycoprotein Human genes 0.000 description 1
- 101710201241 Zinc-alpha-2-glycoprotein Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical class [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000011293 immunotherapeutic strategy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000025220 protein targeting to vacuole Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011849 radiological investigation Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- UONOETXJSWQNOL-UHFFFAOYSA-N tungsten carbide Chemical compound [W+]#[C-] UONOETXJSWQNOL-UHFFFAOYSA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present invention relates to method for treating cancer, method for determining immunoregulatory substances, kit for carrying out said determination, use of certain compounds for preparation of pharmaceutical compositions, as well as pharmaceutical compositions.
- Immunosuppression of TIMC can, however, at least to some extent be overcome, either by washing, preincubation before stimulation, or culturing in interleukin-2.
- the down-regulation of the immune system which relates to cancer, does not result in a seriously increased incidence of infectious diseases in these patients.
- Extracts or supernatants from tumours are often immunosuppressive (Sulitzeanu, 1993).
- TGF- ⁇ , PGE 2 , IL-10, IL-4 and others either being produced by the tumour cells as such or by tumour-infiltrating lymphocytes (TIL) or tumour associated macrophages (TAM) (e.g. Menetrier-Caux et al., 1999; Heimdal et al., 2000; Heimdal et al., 2001).
- TIL tumour-infiltrating lymphocytes
- TAM tumour associated macrophages
- Immunostimulatory treatment of the dysregulated immune system of cancer patients might be counter-productive. If the immune system in cancer is directed to down-regulation of the chronic inflammatory reaction there is a risk that further therapeutic immunostimulation will enhance the immunosuppression and thereby further down-regulate the immune reactivity against the tumour cells. The strategy should therefore be to eliminate mediators of immunosuppression before the immune system is stimulated.
- tumour For initiation of an immune response the tumour has to be recognised as non-self.
- the initial induction of an immune response to tumour associated antigens takes place at an early stage of the malignant disease while the tumour burden is still reasonably small and tumour related immunosuppressive mechanisms are not yet activated. In this situation the immune reactivity to the tumour is beneficial and control the malignant growth for some time.
- APCs antigen presenting cells
- lymphocytes In order to get an immune response a proper interaction between antigen presenting cells (APCs) and lymphocytes has to take place with a well-orchestrated production of cytokines and expression/interaction of co-stimulatory molecules.
- Tumour related immunosuppression takes place at four levels: Activation, recruitment of effector cells to the tumour, migration of these cells from stromal areas close to the tumour cells and cytotoxic activity.
- Stimulation of the inhibited immune reactivity to the tumour can be achieved using several therapeutic strategies. However, several function parameters are down-regulated during the treatment, particularly in tumour areas with the most pronounced regressive changes.
- the object of the present invention is thus to obtain a method for increasing the possibility of treating cancer, a method for determining factor(-s) related to prognosis and allowing prediction and monitoring therapy of cancer, and a kit for determining such factor(-s), use of substances to prepare pharmaceutical compositions, as well as pharmaceutical compositions.
- any regulatory mechanism including inducing factor/s, of the production of immunoregulatory substances, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others, is therapeutically controlled to minimise pathological production of such immunosuppressive immunoregulatory substances or to stimulate the production of immunosupportive immunoregulatory substances to enhance the performance status of a patient and/or to enhance the therapeutic control of a malignant tumour in a subject suffering from a cancer.
- any dysregulatory mechanism of immunoregulatory substances including one or more cytokines, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ and others, production in a patient suffering from cancer is modulated by therapeutically treating the patient to provide a FcR modulation by administering a therapeutically effective amount of a FcR modulating agent.
- cytokines including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ and others
- any dysregulatory mechanism of immunoregulatory substances including one or more cytokines, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others, production in a patient suffering from cancer is modulated by therapeutically treating the patient to provide a FcR/Fc ⁇ R modulation by administering a therapeutically effective amount of a FcR/Fc ⁇ R blocking agent.
- cytokines including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others
- any dysregulatory mechanism of immunoregulatory substances including one or more cytokines, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others, production in a patient suffering from cancer is modulated by therapeutically treating the patient to provide a FcR/Fc ⁇ R modulation by administering a therapeutically effective amount of a FcR/Fc ⁇ R cross-linking agent.
- cytokines including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others
- blocking or cross-linking of FcR is carried out using a therapeutically active amount of at least one immunoglobulin, FcR antibodies or fragments of antibodies or synthetic constructs including peptides directed to FcR.
- At least one FcR-modulating substance minimising production of interleukin-1 receptor antagonist is administered in a therapeutically effective amount.
- the modulation is carried out by blocking FcR by administering F(ab), or F(ab′)2-fragments.
- the modulating substance is a soluble receptor, fragment, peptide or synthetic construct directed to the Fc-part of immunoglobulins.
- Fc ⁇ R I, Fc ⁇ R II and/or Fc ⁇ R III is modulated to stimulate IL-2 stimulation of clonal expansion of lymphocytes.
- any compound blocking the production or biological activity of a factor inducing pathological production of any dysregulatory mechanism of immunoregulatory substances including one or more cytokines, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others, production, is administered in a therapeutically effective amount.
- the blocking compound is a receptor blocking compound.
- the blocking compound is a monoclonal antibody, fragments thereof, peptides or synthetic constructs.
- a compound having the ability of inhibiting the activation or activity of enzymes generating immunomodulatory fragments is administered in a therapeutically effective amount.
- the inhibiting compound is a monoclonal antibody, an anti-integrin antibody, peptides and/or synthetic constructs.
- the modulating substance is an enzyme inhibitor.
- the inhibiting compound is a matrix metalloproteinase inhibitor.
- any compound blocking the factor inducing IL-6 production is administered in a therapeutically effective amount.
- any compound blocking the factor inducing IL-1 ⁇ production is administered in a therapeutically effective amount.
- any compound blocking the factor inducing IL-10 production is administered in a therapeutically effective amount.
- any compound blocking the factor inducing TNF- ⁇ production is administered in a therapeutically effective amount.
- any compound blocking the factor inducing IL-1Ra production is administered in a therapeutically effective amount.
- monoclonal antibodies directed to enzymes generating immunomodulatory fragments are administered in a therapeutically effective amount.
- At least one anti-integrin antibody, peptide or construct is administered in a therapeutically effective amount.
- blocking cross-linking of FcR is carried out using a therapeutically active amount of FcR antibodies or fragments of monoclonal antibodies directed to FcR, preferably the FcR cross-linking is obtained by administering a therapeutically effective amount of at least one immunoglobulin, more preferably the FcR cross-linking is obtained by administering a therapeutically effective amount of IgG or complex bound IgG, and/or the FcR cross-linking is obtained by administering a therapeutically effective amount of IgA or complex bound IgA.
- a therapeutically effective amount of Fc part of at least one immunoglobulin is administered, preferably a therapeutically effective amount of Fc part of IgG or complex bound IgG is administered, and/or a therapeutically effective amount of Fc part of IgA or complex bound IgA is administered.
- any cross-linking of Fc ⁇ R I, Fc ⁇ R II and/or Fc ⁇ R III is carried out.
- FcR is down-regulated using an inhibitor of its expression.
- blocking of Fc ⁇ R is carried out by administering a therapeutically effective amount of anti-Fc ⁇ R I antibodies.
- At least one FcR-blocking substance minimising production of interleukin-1 receptor antagonist is administered in an amount necessary to block the activity of interleukin-1.
- a further aspect of the invention includes a method for analysing the amount and/or certain pattern of dysregulatory mechanism substances, including their mRNA, including any inducing factor, inducing the production of immunoregulatory substances, including one or more cytokines, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others, whereby the amount of such dysregulatory mechanism substances is determined in a tissue sample, whereby the prognosis of a subject suffering from cancer can be determined and/or the therapeutic efficacy of any anti-cancer treatment can be predicted and monitored.
- tissue is whole blood, serum, plasma, lymphatic fluid, saliva, urine, faeces, ascites, pleural effusion, pus, as well as any tissue, including inflammatory cells.
- any compound having the ability of inhibiting the activation or activity of enzymes generating fragments of intra-tumoural tissue are determined.
- any fragment or new epitopes generated by the activity of intratumoural enzymes is determined in any tissue from a cancer patient.
- the activity of any compound having the ability of inhibiting the activation or activity of enzymes generating fragments is monitored by determining these fragments or new epitopes exposed by the enzymatic activity in any tissue from a cancer patient.
- the inhibiting compound is a matrix metalloproteinase inhibitor.
- any compound blocking production or biological activity of a factor inducing pathological production of any dys-regulatory mechanism of immunoregulatory substances including one or more cytokines, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others, production, is determined.
- the amount of any inducing factor or mRNA thereof inducing the production of immunoregulatory substances is determined by determining the production of immunoregulatory substances, including cytokines, including, including IL-1Ra, IL-6, IL-1 ⁇ and/or TNF- ⁇ and others produced by PBMC after exposure to these factors.
- samples are obtained in a way, including tubes and syringes, not binding or inactivating immunoregulatory substances, including inducing factors.
- the amount of any inducing factor inducing the production of immunoregulatory substances including one or more cytokines including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others, is determined directly.
- the amount/occurrence of any cell bound factor inducing the production of immunoregulatory substances is determined.
- the amount of any urine present inducing factor inducing the production of immunoregulatory substances is determined by using an urine dip stick containing binding substance/s binding said inducing factor and/or colour developing reagents to said inducing factor.
- the amount of cell bound immune complexes, CBIC is determined.
- peripheral blood mononuclear cells PBMC being positive for any immunoglobulin staining are determined.
- PBMC being positive for IgG staining are determined.
- PBMC being positive for IgA staining are determined.
- FcR positive to any immunoglobulin staining is determined, such positive for IgG staining and/or IgA staining.
- the production of O 2 ⁇ is determined.
- down-regulation of the ⁇ -chain of TCR is determined.
- fine needle biopsy TIMC tumor infiltrating mononuclear cell
- fine needle biopsy TIMC being positive to IgG are determined.
- fine needle biopsy TIMC being positive to IgA are determined.
- IL-1Ra is determined.
- down-regulation of CD28 on CD4+ and/or CD8+ lymphocytes is determined.
- down-regulation of CD80 and/or CD86 is determined.
- the content of IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, and/or TNF- ⁇ is determined by using an assay, to determine the amount of an inducing factor inducing IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others, activity.
- the assay utilises any tissue and the determinations are made using any immuno-cyto-histochemical method, any immunoassay including, ELISA, Elispot, RIA and others any blotting technique, including Western blotting, Southern blotting and others, any bioassay, any tissue culture technique, RT-PCR, flow cytometry, cytometric bead array, DNA microarray and/or proteomics.
- any immuno-cyto-histochemical method any immunoassay including, ELISA, Elispot, RIA and others any blotting technique, including Western blotting, Southern blotting and others, any bioassay, any tissue culture technique, RT-PCR, flow cytometry, cytometric bead array, DNA microarray and/or proteomics.
- dys-regulatory mechanism substances in tissue from cancer patients, which substances suppress the immune mediated systemic protection resulting in establishment of micrometastases, are identified.
- patients suffering from potential risk are candidates for adjuvant treatment.
- the invention encompasses specific staining methods for IgG in PBMC or biopsies, whereby a first method for determining IgG/IC complexes using a staining, is characterized in that peripheral blood mononuclear cells are separated by centrifugation and spun onto microscope slides; the cells are pre-hydrated using Hank's balanced solution and Hepes solution and human serum albumin, are fixed in phosphate-buffered paraformaldehyde supplemented with glucose, are incubated with biotinylated protein G, followed by incubation with alkaline phosphatase-labelled streptavidin, are incubated in alkaline phosphatase substrate in Tris buffer with dimethylformamide, levamisole and Fast-Red TR salt, are counterstained in Mayer's haematoxylin and mounted in Glycergel; or alternatively, after fixation and a washing in Hank's balance solution containing goat serum, the cells are blocked in goat serum and are incubated
- a further aspect of the invention includes a kit for quantitative and/or qualitative analysis of amount of and/or certain pattern of dys-regulatory factor and/or factors inducing the production and/or activation of immunoregulatory substances, whereby prognosis of cancer can be determined and the therapeutic efficacy of any anti-cancer treatment can be predicted and monitored, comprising an indicator for the presence of said dys-regulatory factor/s including inducing factor/s.
- the kit comprises an indicator for the presence of any factor inducing immunoregulatory substances, including cytokines, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, and/or TNF- ⁇ , and others, activity.
- cytokines including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, and/or TNF- ⁇ , and others, activity.
- the kit comprises a nutrient for peripheral blood mononuclear cells and a determinant for inducing factor for inducing immunoregulatory substances including inducing factors of IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others.
- a urine dip stick comprising binding substance/s and/or colour developing reagents.
- the kit comprises determinants for enzymatic degradation products of tumour substances/extra cellular matrix, ECM.
- a matrix metalloproteinaseinhibitor is monitored.
- the kit comprises a determinant for dys-regulatory substances in tissue from cancer patients, which substances suppress the immune mediated systemic protection resulting in the establishment of micrometastases.
- the amount of cell bound immune complexes, CBIC is determined.
- a still further aspect of the invention includes use of at least one regulatory mechanism controlling factor of at least one immunoregulatory substance, including inducing factor of the production or biological activity of immunoregulatory substances including cytokines, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others, for the production of a pharmaceutical preparation to be used for therapeutic control and for minimisation of pathological production of immunosuppresive immunoregulatory substances, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, and/or TNF- ⁇ , and others or to stimulate production of immunosupportive immunoregulatory substances in a patient suffering from a cancer and to enhance the efficacy and/or possibility of therapeutic treatment of cancer or modulation of dys-regulatory factors to enhance performance status.
- immunoregulatory substances including cytokines, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others
- a FcR modulating agent is used in the manufacture of a pharmaceuticai preparation for controlling immunoregulatory substances, including one or more cytokines, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, and/or TNF- ⁇ , and others, production in a patient suffering from cancer by therapeutically modulating FcR activity.
- immunoregulatory substances including one or more cytokines, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, and/or TNF- ⁇ , and others, production in a patient suffering from cancer by therapeutically modulating FcR activity.
- a FcR modulating agent is used in the manufacture of a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokines, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others, production in a patient suffering from cancer is modulated by therapeutically blocking FcR/Fc ⁇ R activity.
- immunoregulatory substances including one or more cytokines, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others
- a FcR modulating agent is used in the manufacture of a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokines, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others, production in a patient suffering from cancer is modulated by cross-linking FcR/Fc ⁇ R activity.
- immunoregulatory substances including one or more cytokines, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others
- At least one immunoglobulin, FcR antibodies or fragments of antibodies or synthetic constructs including peptides directed to FcR is used in the manufacture of a pharmaceutical preparation for blocking or cross-linking FcR cross-linking.
- an agent modulating Fc ⁇ R I, Fc ⁇ R II and/or Fc ⁇ R III used to stimulate IL-2 stimulation of clonal expansion of lymphocytes is used in the manufacture of a pharmaceutical preparation.
- FcR antibodies or fragments of FcR antibodies directed to FcR is used in the manufacture of a pharmaceutical preparation for blocking cross-linking of FcR.
- anti-Fc ⁇ R I, Fc ⁇ R II and/or Fc ⁇ R III antibodies is used in the manufacture of a pharmaceutical preparation for blocking of Fc ⁇ R.
- a compound being able to down-regulate the expression of FcR is used in the manufacture of a pharmaceutical preparation for down-regulating FcR.
- At least one FcR-blocking substance minimising production of interleukin-1 receptor antagonist is used in the manufacture of a pharmaceutical preparation for blocking the activity of interleukin-1.
- At least one FcR-modulating soluble receptor, fragment, peptide or synthetic construct directed to the Fc-part of immunoglobulins is used in the manufacture of a pharmaceutical preparation.
- At least one FcR-modulating enzyme inhibitor is used in the manufacture of a pharmaceutical preparation.
- At least one FcR-inhibiting matrix metalloproteinase inhibitor is used in the manufacture of a pharmaceutical preparation.
- any compound blocking production or biological activity of any factor inducing pathological production of one or more cytokines is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokines.
- any factor inducing IL-6 production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.
- any factor inducing IL-1 ⁇ production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.
- any factor inducing IL-10 production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.
- any factor inducing IL-17 production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.
- any factor inducing TNF- ⁇ production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.
- any factor inducing IL-1Ra production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.
- a compound having the ability of inhibiting the activation and/or activity of enzymes generating immunomodulatory fragments is used in the manufacture of a pharmaceutical preparation for inhibiting the activation or activity of enzymes generating immunomodulatory fragments.
- antibodies directed to enzymes generating immuno-modulatory fragments are used in the manufacture of a pharmaceutical preparation.
- At least one monoclonal antibody, anti-integrin antibody, peptide and/or synthetic construct thereof is used in the manufacture of a pharmaceutical preparation.
- a further aspect of the invention includes a pharmaceutical composition
- a pharmaceutical composition comprising a regulatory mechanism controlling factor of an inducing factor of the production or biological activity of immunoregulatory substances including one or more cytokines, for the production of a pharmaceutical preparation to be used for therapeutically control and minimise pathological production of immunosuppresive immunoregulatory substances including one or more cytokine, or or to stimulate production of an immunosupportive immunoregulatory substance in a patient suffering from a cancer to enhance the efficacy and/or possibility of therapeutic treatment of cancer, optionally in combination with therapeutically inert additive to enhance performance status.
- a FcR modulating agent is present in a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokine production in a patient suffering from cancer by therapeutically modulating FcR activity.
- a FcR modulating agent is used in the manufacture of a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokines, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others, production in a patient suffering from cancer is modulated by therapeutically blocking FcR/Fc ⁇ R activity.
- immunoregulatory substances including one or more cytokines, including IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, TNF- ⁇ , and others
- At least one immunoglobulin, FcR antibodies or fragments of antibodies or synthetic constructs including peptides directed to FcR is used in the manufacture of a pharmaceutical preparation for blocking or cross-linking FcR activity.
- an agent modulating Fc ⁇ R I, Fc ⁇ R II and/or Fc ⁇ R III is present to stimulate IL-2 stimulation of clonal expansion of lymphocytes.
- anti-Fc ⁇ R I antibodies is present in a pharmaceutical preparation for blocking of Fc ⁇ R.
- a compound being able to down-regulate the expression of FcR is present in the pharmaceutical preparation for down-regulating FcR.
- At least one FcR-blocking substance minimising production of interieukin-1 receptor antagonist is present in the pharmaceutical preparation for blocking the activity of interleukin-1.
- At least one FcR-modulating soluble receptor is used.
- At least one FcR-modulating enzyme innibitor is used.
- At least one FcR-inhibiting matrix metalloproteinase inhibitor is used.
- a compound having the ability of inhibiting the activation of enzymes generating immunomodulatory fragments is present in the pharmaceutical preparation for inhibiting the activation of enzymes generating immunomodulatory fragments.
- any factor inducing IL-6 production is used.
- any factor inducing IL-1 ⁇ production is used.
- any factor inducing IL-10 production is used.
- any factor inducing IL-17 production is used.
- any factor inducing TNF- ⁇ production is used.
- any factor inducing IL-1Ra production is used in the manufacture of a pharmaceutical preparation for
- a compound blocking a factor inducing pathological production of immunoregulatory substainces, including one or more cytokine production is present in the pharmaceutical preparation for blocking a factor inducing pathological production of such immunoregulatory substances.
- antibodies directed to enzymes generating immuno-modulatory fragments are present.
- At least one monoclonal antibody, anti-integrin antibody, peptide and/or synthetic construct thereof, is used.
- Flow-chart 1 shows a summary of the immunoregulatory mechanisms described in this invention. Connections between FcR mediated and dysregulatory factor mediated mechanisms are shown with Roman numericals.
- IC can modulate the immune system
- receptors for the Fc-part of immunoglobulins and complement receptors.
- IC can activate complement and receptors for various complement factors are expressed on different types of cells of the immune system.
- large ICs are more complement activating than small ones, which are more immunosuppressive.
- binding of complement factors activated by ICs is not a major pathway for induction of immunosuppression.
- Immune complexes can influence the activity of various types of cells of the immune system. The effect is highly dependent on the type of cell, which is involved and the characteristics of the immune complexes. In particular the size and whether the immune cells are exposed to soluble or solid phase IC seems to be of importance. Immunocomplexes can be either immunostimulatory or inhibitory depending on their sizes and interaction with different FcRs on immune cells. Large ICs have been demonstrated to be stimulatory whereby small complexes in antigen excess have been demonstrated to be inhibitory to mitogen induced proliferation (e.g. Gupta and Morton, 1981). It has been demonstrated that there is a correlation between the tumour burden and the immunosuppressive activity of immune complexes.
- Serum blocking factors play a major role in immunosuppression in cancer. They have been shown to inhibit both cytotoxic and proliferative activity of lymphocytes from cancer patients (Baldwin, 1976; Bansal et al., 1976; Hellstrbm and Hellstrom, 1974). SBRs were demonstrated to be immunocomplexes (ICs), as their inhibitory activity was lost after dissociation at low pH, but reappeared after reconstitution at neutral pH (Sjögren et al.,1971). Tumour associated antigens can frequently be bound in IC (Kirkwood and Vlock, 1984; Vlock and Kirkwood, 1985). Removal of ICs from cancer patient sera, using protein A, also reduced the inhibitory effect of these sera.
- ICs immunocomplexes
- CICs circulating immunocomplexes
- Th1 helper cells are considered to support the development of cytotoxic activity against the tumour. In malignant tumours, however, a predominance of Th2 over Th1 helper cells has been demonstrated repeatedly.
- Cross-linking of Fc ⁇ Rs is of importance also for this diversion of the immune system, as cross-linking induces production of PEG2 (e.g. Berger et al. 1996), which favours a Th2 situation with production of IL-4, IL-10, etc.
- IL-4 then inhibits the immune reactivity to the tumour partly by down-regulating monokine production in general, but also by stimulating the production of IL-1Ra .
- IL-4 stimulates the expression of the inhibitory Fc ⁇ R II, CD32b, and inhibits expression of the stimulatory receptor CD32a (Pricop et al., 2001).
- blockade of the Fc ⁇ R mediated triggering of the Th2 predominance in malignant tumours would certainly improve the immune reactivity to the tumour.
- Cross-linking of Fc ⁇ R by IC can result in activation or inhibition.
- the latter can be mediated in several ways:
- interleukin-2 stimulated proliferation of PBMC and IL-1Ra production and was chosen as relevant markers for Fc ⁇ R mediated immunostimulation/suppression.
- solid phase IgG results in a significantly increased proliferative response to PBMCs from healthy individuals, as well as cancer patients compared to cultures where solid phase binding was blocked by pre-incubation with human serum albumin (HSA).
- HSA human serum albumin
- This effect is most clearly shown when the culture plates were pre-coated with HSA/IgG allowing a high degree of cross-iinking of Fc ⁇ R.
- the proliferative response to IL-2 could be normalised in cancer patients (compared to controls) using this technique.
- a stimulatory effect of solid phase IgG was also seen when IgG from serum in the culture medium is allowed to bind to the surface of culture wells.
- blockade of Fc ⁇ R I can be overcome by providing more extensive cross-linking similar to what is achieved in cultures with solid phase IgG.
- the immunomodulatory role of cross-linking of Fc ⁇ R by solid phase IgG has furthermore been shown by analysing cytokine production in short term cultures of PBMCs with solid phase bound IgG, which in healthy individuals inhibited the production of IL-6.
- IL-6 in PBMC cultures from both cancer patients and healthy individuals (less frequently) the production of IL-6, IL-1 ⁇ as well as TNF- ⁇ were frequently markedly increased when binding of serum IgG was blocked by pre-incubation of the culture wells with HSA.
- IL-1Ra which is induced by IC or solid phase IgG, was reduced in cultures where solid phase binding of IgG was blocked by pre-incubation with HSA.
- Interleukin-1 plays a fundamental role for the initiation of an immune response.
- IL-1 Interleukin-1
- soluble IL-1 receptors e.g., soluble IL-1 receptors, and IL-1 receptor antagonist (IL-1Ra)
- IL-1Ra IL-1 receptor antagonist
- the inhibitory role of IL-1Ra has been clearly demonstrated in studies on autoimmune diseases and rejection after allogen organ transplantation.
- CBICs cell bound immuno-complexes
- IL-1Ra obviously plays a central role in down-regulation of immune reactivity. As demonstrated here it is frequently expressed in large areas of malignant tumours. This finding is highly compatible with the occurrence of tissue bound IgG in the tumours as IC or solid phase IgG are the most potent inducers of this cytokine.
- the inhibitory effect due to binding of IC to Fc ⁇ R can be treated using various techniques, e.g. by blocking the inhibitory receptors (see below), by down-modulating the sensitivity of receptors by protease inhibitors or by overcoming the inhibitory effects using more competitive binders/more extensive cross-linking of the receptors.
- blocking the inhibitory receptors see below
- down-modulating the sensitivity of receptors by protease inhibitors or by overcoming the inhibitory effects using more competitive binders/more extensive cross-linking of the receptors.
- IL-6 an increased serum concentration of IL-6 is often found in cancer patients, especially in patients with advanced disease (Barton, 2001; Blay et al., 1992; Blay et al., 1997; Gadducci et al., 2001; Walther et al., 1998).
- the source of serum IL-6 is still somewhat unclear and it is generally assumed to be derived from the tumour. It is shown herein that this cytokine is produced in large amounts, in short term cultures, by PBMCs from cancer patients and to a much lesser extent, or not at all, by unstimulated PBMCs from healthy individuals.
- a high serum concentration of IL-6 is generally related to a paraneoplastic syndrome, poor response to immunotherapy and some types of chemotherapy, as well as a poor prognosis.
- IL-6 large amounts of IL-6 is produced by PBMCs from about 50% of the cancer patients, as shown in malignant melanoma, renal cell carcinoma, and colorectal cancer.
- An increased production of IL-6 is also found in patients with only a minimal tumour burden, as about 50% of the patients with radically resected stage III melanoma have a significantly increased production of IL-6.
- IL-6 is a pleiotropic cytokine, which acts as an autocrine growth factor in for example renal cell carcinoma and multiple myeloma. It promotes the inflammatory response, induces acute phase reactants as well as IL-1Ra and is involved in the detrimental chronic inflammatory reaction in patients with malignant tumours. It is thus a good marker for dysregulation of the immune system in cancer patients and the paraneoplastic syndrome.
- IL-6 can be induced in various ways, e.g., by IL-1 ⁇ , and TNF- ⁇ , and under certain circumstances also by cross-linking of FcR/Fc ⁇ R.
- the degree of cross-linking is of importance for the regulatory effect on the production of IL-6.
- the degree of cross-linking achieved by solid phase binding of serum IgG inhibits production of IL-6, as pre-coating the culture wells with HSA (thereby blockIng the binding of IgG) results in a significantly higher production of IL-6 in about 30% of cancer patients with various diagnoses.
- IL-6 production was significantly inhibited in cultures of PBMCs from healthy individuals when the culture wells were coated with IgG instead of HSA alone.
- This IL-6 inducing factor has been further characterised by fractionated ultrafiltration, which demonstrates a factor having a molecular weight of less than 50 kD. This factor has also been identified in the urine from cancer patients. The source of this factor was studied and various tumours were minced and extracted with physiological buffers. An IL-6 inducing factor, IL-6IF, is identified in about 60% of the analysed tumours. Similarly, an IL-6 inducing activity has been found in culture conditioned media from squamous cell carcinoma cell lines from the oral cavity.
- IL-6IF which has been found in serum and urine, seems to be produced intratumourally. It is neither IL-1 ⁇ , TNF- ⁇ or interleukin-17, as these cytokines could not be found in fractions inducing IL-6.
- IL-6IF in the urine opens interesting diagnostic possibilities. Based on the urine concentration of IL-6IF a simple diagnostic test can be developed which will give essential information about prognosis and the likelihood of therapeutic success, in particular for treatment where IL-6 is related to a poor response rate. This test will of course also be extremely valuable when it comes to treatment strategies dealing with the elimination of IL-6IF/treatment of the chronic inflammatory reaction in cancer patients.
- TNF- ⁇ IL-1 ⁇ and IL-10 Similar to the situation with IL-6 we have also found inducing activity for TNF- ⁇ IL-1 ⁇ and IL-10 in serum and ultra-filtered urine. The number of inducing factors is for the moment unknown but TNF- ⁇ inducing activity was found in samples not inducing IL-6. Thus, reasonably several inducing factors are involved in dysregulation of the immune system in cancer.
- the immunosuppressor factor in trauma patients was also found to inhibit migration of inflammatory cells. This mechanism might be of importance in immunosuppression in cancer as in untreated patients, inflammatory cells recruited to the tumour generally are found in the stromal areas surrounding the tumour nodules presumably because of inhibition of their migration close to the tumour cells.
- fibronectin is of importance for migration it can be envisioned that if the cell receptors normally binding to fibronectin or other ECM-substances in the migration process are blocked by fragments of these substances the cells will no longer be able to migrate.
- the phenomenon of leukocyte adherence inhibition is of interest as PBMCs from cancer patients under certain conditions demonstrate a highly reduced ability to adhere to plastic or glass surfaces.
- IL-6 has by others been shown to be an inducer of IL-1Ra. However, in the present work based on the available malignant melanoma and renal cell carcinoma materials no correlation between IL-6 and IL-1Ra has been found rather the contrary. Fc ⁇ R cross-linking inhibits production of IL-6 as shown herein and stimulates IL-1Ra production.
- IL-6IF containing sera in the immunoregulation in cancer is demonstrated by its effect on the proliferative response to IL-2.
- the type of solid phase IgG binding is obviously of importance for the effect of IL-2.
- Coating the wells with purified IgG mixed with HSA gives a more powerful stimulatory signal than binding of serum IgG from the culture medium (uncoated cultures).
- This difference can be inhibited by sera containing IL-6IF, either by interfering with stimulatory mechanisms or by modulating monocytes to increased production of inhibitors, such as PGE 2 or IL-1Ra.
- the inhibitory effect has not been shown in IgG coated cultures, probably because the more forceful effect on the proliferative response to IL-2 under the conditions used.
- MMPs Matrixmetalloproteases
- ECMs extra cellular matrix proteins
- This activity is considered to be a pre-requisite for metastatic spread, and neo-angiogenesis. Occurrence of MMPs has, in several studies been shown to correlate to a poor prognosis.
- proteolytic activity of MMPs will result in various types of degradation products, some of which are known to modulate angiogenesis and the activity of chemokines.
- the low molecular weight fraction, IL-6IF, described herein can be a proteolytic fragment.
- Factors derived from enzymatic degradation of ECM can most likely be both stimulatory and inhibitory as various cytokine patterns have been induced by various fibronectin fragments (Beezhold and Personius, 1992 ; López-Moratlla et al., 1995; Takizawa et al., 1995) and also it was recently demonstrated that the expression of various MMPs in malignant melanoma was related to therapeutic response and prognosis (Nikkola et al., 2001).
- the generally found immunosuppressive effect of malignant tumours can thus very well be due to the increased enzymatic/proteolytic activity of the turnours resulting in various immunomoduiatory fragments/fragments of ECM or other tumour substances.
- the proteolytic activity can also explain the frequent occurrence of a large number of soluble factors of importance for immune reactivity in cancer patients (Salih et al., 2001; Sheu et al., 2001), e.g. sIL-2 receptor, sTNF- ⁇ receptors, sCD8, sCD4, sICAM-1, sMHC I, sFcR etc.
- Intra-tumoural enzymatic activity also seems to be of importance for activtion of pro-TGF- ⁇ to active TGF- ⁇ (Huber et al., 1992). Based on these considerations intra-tumoural proteolytic activity seems to be a fundamental mechanism by which the malignant tumour manage to divert the tumour bearers defence to the disease.
- proteolytic fragments of ECM in serum and urine from cancer patients also opens the possibility to identify various types of fragments and analyse their prognostic significance.
- therapeutic efficacy of matrixmetalloprotease inhibitors (MMPIs) resulting in a reduction/inhibition of the production of fragments of certain importance can be determined by analysing the amount of these fragments in serum or urine. Determination of these fragments will thus be proper surrogate endpoints for MMPI therapy and have the potential to significantly increase the therapeutic activity of these drugs by allowing monitoring whereby efficacious dose schedules can be developed.
- MMPIs matrixmetalloprotease inhibitors
- Dysregulation of the immune system by enzymatic/proteolytic fragments from various tumour substances has so far not been described.
- a large number of inhibitory as well as stimulatory fragments can be produced as a result of the intra-tumoural enzymatic activity. This provides for a new understanding of immunosuppression in cancer patients and new therapeutic possibilities based on proper diagnostic tests.
- the dysregulatory inducing factors were further characterised by using 2D-gel electrophoresis and identified after fragmentation using masspectrometry and N-terminal sequence analysis (proteomics technique).
- the low molecular weight fraction ( ⁇ 30 kD) from urine was analysed by comparing samples from normal healthy controls with samples from patients; by comparing urine samples with and without IL-6 inducing activity; by comparing samples adsorbed and not adsorbed with a surplus of normal PBMCs (responding to IL-6IF).
- proteins/fragments of potential immunoregulatory activity were thereby identified as described below, e.g. fragments of ⁇ 2-microglobulin, serum albumin and immunoglobulin.
- IgG fragments possibly could have a modulatory activity on antibody dependent cellular cytotoxicity (ADCC), but the possibility that these fragments have an immunoregulatory activity in cancer has to our knowledge never been suggested.
- ADCC antibody dependent cellular cytotoxicity
- IL-6IF can be extracted from malignant tumours, e.g. malignant melanoma, renal cell carcinoma, colorectal cancer. These results were confirmed in a new series of experiments, where homogenised tumours were washed three times in PBS or RPMI in order to collect cytokine inducing factors already present in the tumours, so called “preformed inducing factors” (PIF).
- malignant tumours e.g. malignant melanoma, renal cell carcinoma, colorectal cancer.
- tumour sections/homogenates (after being thoroughly washed) were incubated for 24 hours at 37° C. together with MMP-2. IL-6 inducing activity could then be demonstrated in of supernatants from several tumours.
- tumour tissue conditioned culture media from cancer cell lines, serum and urine.
- Control of the intra-tumoural enzymatic/proteolytic activity is thus a fundamental mechanism to control the malignant tumour management of diverting the immune mediated defence system of the tumour bearer against the disease.
- Fc ⁇ R cross-linking and dysregulatory inducing factors (ECM enzymatic/proteolytic fragments) play a fundamental role in immunosuppression in cancer patients.
- Therapeutic control of these dys-regulatory mechanisms will thus improve quality of life, therapeutic response and increased over-all survival.
- IL-6 is only one product of the dys-regulated inflammatory reaction mentioned herein and often is correlated to production of other cytokines such as IL-1 and TNF- ⁇ ; the strategy is to block the fundamental dys-regulatory mechanisms in order to down-regulate the detrimental chronic inflammatory reaction.
- the present invention is thus not based on suppression of the activity of e.g., IL-1 ⁇ , IL-1Ra, IL-6, IL-10, IL-17, and/or TNF- ⁇ , and others, but to prevent or minimise their production.
- tissue shall be understood to encompass whole blood, serum, plasma, lymphatic fluid, saliva, urine, faeces, ascites, pleural effusion, pus, as well as any tissue, as such including inflammatory cells.
- cancer means: Any new and abnormal growth, specifically a new growth of tissue in which the growth is uncontrolled and progressive.
- FcR By modulation of FcR either relief of immunosuppression or an enhanced immune activation can be achieved as demonstrated in the present document.
- Several substances can be used to block FcRs e.g. antibodies or fragments thereof (e.g. F(ab′) 2 or Fab-fragments, of Mab directed to Fc ⁇ R) , peptides (e.g. from the Fc-part of IgG) or synthetic constructs.
- the interaction between receptor binding ligands and the receptor can also be achieved by blocking the binding site of the ligand by using, soluble FcRs (recombinant) or peptides or synthetic constructs with a specific high binding affinity.
- the signal transduction resulting from ligand binding to FcRs can be inhibited by signal transduction inhibitors.
- their reactivity is influenced by proteolytic activity and can thus be modulated by protease inhibitors.
- MMPIs can be of special interest.
- the ligands of FcRs, immunoglobulins or complexed immunoglobulins can be eliminated and their immunosuppressive activity can thereby be avoided.
- Recombinant FcRs or synthetic constructs with this reactivity of proper affinity and size can be administered in order that CIC (especially small CICs) are bound and eliminated.
- CIC especially small CICs
- binders of these substances can be linked to small microspheres (less than 3-5 mm if diameter, possibly degradable) which are rapidly taken up by the reticulendothelial system/monocyte macrophage phagocyte system.
- Another therapeutic possibility is to reduce the number of FcRs which can have a negative effect of the immune reactivity to the malignant tumour, e.g. by increasing their shedding or by down-regulation of their expression.
- FcRs which result in down-regulation of the immune reactivity
- FcRs can, as has been demonstrated in this document, be to cross-link FcRs in order to overcome immunosuppression.
- Several possibilities can be used for this pupose, e.g. complexed immunoglobulines/monoclonal antibodies or fragments (Fc) thereof binding to the receptors or synthetic FcR-binding constructs, cross-linking FcR to a degree (number of FcRs of one or several types) achieving optimal immune activation.
- PBMC Peripheral blood mononuclear cells
- HSA human serum albumin
- PFA paraformaldehyde
- the cells were blocked in 10% goat serum for 20 minutes and incubated with mouse anti-human IgG monoclonal antibody (Nordic Immunology) at 1 or 10 ⁇ g/ml, washed in BSS containing 2% goat serum, incubated with Envision (Dakopatts AB, SE) for 30 minutes, washed in TBS and incubated with the alkaline phosphatase substrate for 20 minutes after which the sections were again washed in TBS. They were then counterstained in Mayer s haematoxylin for 1 minute and mounted in Glycergel (Dakopatts AB,SE). All incubations were performed in a moist chamber and all antibody solutions contained 2% normal goat serum.
- Biopsies from the resected metastases were immediately snap frozen and stored at ⁇ 700C until further processed. Frozen tissue sections, 6-7 ⁇ m thick, were fixed with 4% PFA for 5 minutes and then washed three times in BSS-HSA. For double-staining, sections were incubated with primary antibody, mouse IgGl anti-human CD3 (Dakopatts AB), at 1 ⁇ g/ml for 30 minutes, washed in BSS-HSA followed by incubation with goat-anti-mouse immunoglobulin (Dakopatts AB, SE) at a ⁇ fraction (1/25) ⁇ dilution in BSS-HSA.
- primary antibody mouse IgGl anti-human CD3
- Dakopatts AB goat-anti-mouse immunoglobulin
- Monoclonal mouse IgG1 against an irrelevant antigen (Dakopatts AB, SE) was used as a negative control.
- the sections were then incubated with PAP mouse monoclonal antibody (Dakopatts AB, SE) at a ⁇ fraction (1/25) ⁇ dilution in BSS-HSA for 30 minutes.
- 3,3′-Diaminobenzidine (DAB, Sigma) was used as a substrate, which resulted in a brown colour.
- IgG was then identified using 1 or 10 ⁇ g/ml biotinylated protein G (Sigma) which was incubated for 30 minutes, washed in BSS-HSA, followed by incubation with alkaline phosphatase-labelled streptavidin (Dakopatts AB, SE) at a ⁇ fraction (1/100) ⁇ dilution in BSS-HSA for 30 minutes. After washes in TBS and incubation with alkaline phosphatase substrate for 20 minutes, the sections were again washed in TBS. They were then counterstained in Mayer's haematoxylin for 1 minute and mounted in Glycergel (Dakopatts AB, SE).
- IL.1Ra interleukin-1 receptor antagonist
- the sections were first blocked with 10% normal human AB-serum before staining and were then incubated with biotinylated goat IgG antibodies directed either to interleukin-la or interleukin-1 receptor antagonist (both from R&D Systems, UK) at 10 ⁇ g/ml over night, washed in BSS-saponin, incubated with alkaline phosphatase-labelled streptavidin (DAKO, SE) at a ⁇ fraction (1/100) ⁇ dilution in BSS-saponin containing 2% human AB-serum for 30 minutes.
- biotinylated goat IgG antibodies directed either to interleukin-la or interleukin-1 receptor antagonist (both from R&D Systems, UK) at 10 ⁇ g/ml over night, washed in BSS-saponin, incubated with alkaline phosphatase-labelled streptavidin (DAKO, SE) at a ⁇ fraction (1/100) ⁇ dilution in BSS
- PBMC peripheral blood mononuclear cells
- Mononuclear cells were then isolated by Ficoll-paque Plus (Pharmacia AB, SE) density gradient centrifugation after which the cells were washed twice in RPMI1640 Dutch's modification (RPMI) (Gibco BRL, Scotland) with 2% human serum albumin (HSA) (Pharmacia & Upjohn, SE). Cell viability was assessed by exclusion of 0.05% Trypan Blue and was always above 95%. The cell suspension was stained with Turks solution and the number of lymphocytes and monocytes in the PBMC preparation were counted in a hemocytometer. PBMCs were suspended in RPMI with 2% HSA and the cell concentration were adjusted to 5 ⁇ 10 5 lymphocytes/ml.
- Mononuclear cells were isolated by Ficoll-Isopaque (Pharmacia, SE) density gradient centrifugation. 5 ⁇ 10 4 PBMC in a final volume of 200 ⁇ l were seeded into round-bottomed microtiter plates (Corning Inc. NY, US) in culture medium consisting of RPMI 1640 supplemented with 100 IU/ml Penicillin, 100 ⁇ g/ml Streptomycin (Flow laboratories) and 10% heat-inactivated, autologous fresh serum.
- Phytohemagglutinin (PHA, Sigma Chemical Co, MO, US), at a final concentration of 20 ⁇ g/ml, and Chlorambucil (CHL, Sigma), at a final concentration of 1 ⁇ g/ml, were then added.
- Cells were cultured for 3 days in a humidified 5% CO 2 atmosphere at 37° C. Proliferation was assayed by incorporation of 1.6 ⁇ Ci/well of [ 3 H]thymidine (Amersham Int, UK) during the last 18 hr. Mean values of dpm (disintegrations per minute) of triplicate cultures were used for the calculations.
- TNF- ⁇ in PHA stimulated cultures PHA-stimulated cultures with or without chlorambucil (1 ⁇ g/ml) were set up in parallel as described above for mitogen-stimulated cultures. Supernatants were collected after 72 hours and cells were removed by centrifugation for 5 minutes at 4000 RPM. The SNs were frozen immediately and stored at ⁇ 70° C. The amount of TNF- ⁇ in the SNs was evaluated with an ELISA kit from Immunotech S.A., FR, according to the manufacturer's instructions. The lower limit of detection in this assay was 10 ⁇ g/ml.
- HSA HSA/IgG Round-bottomed
- 96 ⁇ well tissue culture plates (Costar, Corning Inc. NY, US) were pre-coated with HSA only or HSA and pooled human IgG for intravenous injection (Gammagard, Baxter AS, DK).
- HSA was diluted in RPMI1640 without supplements to a concentration of 10 mg/ml.
- 1 mg/ml IgG was mixed into a solution of 9 mg/ml HSA in RPMI (HSA/IgG). 200 ⁇ l of HSA or HSA/IgG were then added to each well of the plate. The plates were incubated at 4° C. for 30 minutes after which the wells were washed twice with 200 ⁇ l of RPMI1640. The coated plates were used immediately.
- PBMC isolated from healthy individuals or patients with metastatic renal cell carcinoma, were diluted in RPMI/2% HSA at a concentration of 5 ⁇ 10 5 /ml and 100 ⁇ l were added to the microtiter wells.
- Interleukin-2 (IL-2, Proleukin, Chiron, NL), at a final concentration of 120 IU/well, was added to some wells. Cells were cuitured for 7 days in a humidified, 5% CO 2 -atmosphere at 37° C. Proliferation was assayed by incorporation of 1.6 ⁇ Ci/well of [3H]-thymidine (Amersham Int., UK) during the last 18 hrs. Mean values of dpm (disintegrations per minute) of triplicates were used for the calculations.
- PBMC peripheral blood mononuclear cells
- F(ab′)2 mouse anti-human CD16 Fc ⁇ R III
- CD 32 Fc ⁇ R II
- CD 64 Fc ⁇ R I
- SNs Supernatants were harvested after 24 hrs and residual cells were removed by centrifugation in a refrigerated centrifuge (Beckman) at 2600 ⁇ g for 5 minutes. SNs were frozen and stored at ⁇ 70° C. until monokine concentrations were measured by ELISA.
- Monokines were assessed by ELISA using the DuoSet ELISA development system for human IL-6, TNF- ⁇ or IL-1 ⁇ (R&D Systems Europe, Ltd. UK) following the manufacturer's recommended procedures.
- Lower limit of detection was 3.1 ⁇ g/ml for IL-6, 15.6 pg/ml for TNF- ⁇ and 3.9 ⁇ g/ml for IL-1 ⁇ .
- IL-10 was detected with a kit from Diaclone Research, FR. The lower limit of detection was 5 ⁇ g/ml.
- Human IL-1Ra was detected with a quantitative sandwich ELISA using a monoclonal mouse anti-human IL-1Ra as capture antibody and a biotinylated goat anti-human IL-1Ra as developing antibody (both from R&D Systems). Briefly, enhanced binding 96-well microtiter plates (Labsystems AB, SE) were coated overnight at room temperature with 10 ⁇ g/ml of capture antibody diluted in PBS. After washing in PBS with 0.05% Tween 20 (Sigma Chemical, MO, US) plates were blocked with a blocking buffer consisting of 1% bovine serum albumin (BSA, Sigma), 5% sucrose (Sigma) and 0.05% NaN 3 in PBS.
- BSA bovine serum albumin
- sucrose sucrose
- PBMC culture SNs or recombinant human IL-1Ra standard were diluted in 0.1% BSA and 0.01% Tween 20 in PBS (dilution buffer) and incubated over night at room temperature. After washing, the biotinylated-developing antibody was added at 100 ng/ml in dilution buffer. This was incubated for 1 hr at room temperature. Plates were washed and alkaline phosphatase (ALP)-conjugated Extravedin (Sigma), at a dilution of 1:10000 in Tris buffered saline with 0.1% BSA was added.
- ALP alkaline phosphatase
- IL-1Ra was measured by hydrolysis of paranitrophenyl phosphate (Sigma). Optical density was read at dual wavelengths, 405 nm and 570 nm, respectively, in a Multiscan EX microplate reader (Labsystems). The lower limit of detection in this assay was 39 pg IL-1Ra/ml
- IL-1Ra Production by PBMC with Antibodies against Fc ⁇ R II PBMCs isolated from healthy volunteers were pre-incubated at 1 ⁇ 10 6 /ml in RPMI1640+2% HSA with 5 or 50 ⁇ g/ml of azide-free, mouse anti-human CD32 Fab (Medarex Inc. NJ, US) for 1 hr at 37° C. under gentle agitation.
- the cells (5 ⁇ 10 5 /well) were immediately seeded onto s uncoated or HSA/IgG coated tissue culture microtiter plates in RPMI1640 with 10% heat-inactivated, pooled human AB sera.
- Supernatants were harvested after 24 hrs, as described under “generations of cell culture supernatants”, and the production of IL-1Ra was measured by ELISA.
- PBMC peripheral blood mononuclear cells
- ⁇ l of culture medium consisting of RPMI1640 supplemented with 200 IU/ml penicillin, 200 ⁇ g/ml streptomycin, 4 mM L-glutamine (all from Sigma) and 20% fresh heat-inactivated autologous serum were added to the HSA or HSA/IgG pre-coated microtiter plates followed by 100 ⁇ l of the PBMC suspensions (5 ⁇ 10 4 lymphocytes) in RPMI/2% HSA. Cells were cultured in a humidified, 5% CO 2 atmosphere at 37° C. Viability of cultured PBMCs were also assessed after 24 hrs by Trypan blue exclusion and found to be 100%.
- SNs were harvested after 24 hrs and residual cells removed by centrifugation in a refrigerated centrifuge at 2600 ⁇ g for 5 minutes. SNs were frozen and stored at ⁇ 70° C. until IL-1Ra concentration was determined by ELISA.
- Heat-inactivated human serum was passed over a HiTrap protein G-Sepharose HP affinity column (Amersham Pharmacia Biotech AB, SE). The non-binding fraction was eluted with RPMI1640, giving a final dilution effect of 1 ⁇ 5 (20% ) of the original serum. 200 IU/ml penicillin, 200 ⁇ g/ml streptomycin, 4 mM L-glutamine (all from Sigma) were added. The eluate was then sterile filtered with a 0.45 ⁇ m Millex syringe filter (Millipore Co. MA, US) and used immediately for culture with control PBMC.
- Sera collected from cancer patients or from normal healthy individuals, were heat-inactivated for 30 minutes at 56° C. and frozen at ⁇ 70° C. After thawing, sera were diluted in RPMI1640 to a concentration of 20% and either used unfiltered or ultra-filtered, as described below, in co-culture experiments for monokine-induction with control PBMC.
- Ultra filtered serum fractions consisted of filtrates from 100000 mw cut-off filters, retentates or filtrates from 50000 mw cut-off filters or retentates from serum fractions that had been sequentially spun on a 50000 mw cut-off filter followed by concentration on a 3000 mw cut-off filter.
- Retentates were reconstituted in RPMI1640 with 200 IU/ml penicillin, 200 ⁇ g/ml streptomycin, 4 mM L-glutamine (Sigma) to their original volume. 100 ⁇ l of diluted sera (20% ) or ultra filtered serum fractions were added to uncoated or HSA-coated microtiter plates together with 100 ⁇ l PBMC suspension (5 ⁇ 10 5 /ml). Cell-free SNs were harvested after over-night incubation and tested for monokine activity by ELISA, as described above.
- tumour biopsies from patients with renal cell carcinoma, malignant melanoma or colon carcinoma were embedded in glycergel (Dakopatts AB, SE) and frozen at ⁇ 70° C.
- glycergel Dakopatts AB, SE
- 50 ⁇ m cryostat sections were cut and transferred to 4 ml of cold RPM1640 with 200 IU/ml penicillin, and 200 ⁇ g/ml streptomycin (RPMI/PEST) (Gibco BRL) and kept on ice.
- the sections were centrifuged and resuspended in 0.5 ml fresh RPMI/PEST after-which they were disaggregated in a Medimachine (Dako A/S, DK) using a sterile Medicon 50 ⁇ m unit.
- the disaggregated sample was suspended in 2 ml RPMI/PEST, vortexed and kept on ice for 0.5 to 2 hrs.
- the sample was centrifuged 10 minutes at 300 ⁇ g and the supernatant was harvested.
- the supernatant was then filter sterilised through a 0.45 ⁇ m Millex-HV syringe filter (Millipore).
- a newly excised biopsy (about 5 mm 3 ) was disaggregated in a Medimachine (Dako AS), using a sterile Medicon 50 ⁇ m unit and resuspended in a total volume of 5 ml TCN buffer (50 mM Tris, 50 mM NaCl, 10 mM CaCl 2 +200 IU/ml penicillin and 200 ⁇ g/ml streptomycin).
- the cell suspension was incubated on ice for 1 hr.
- the sample contained 2.7 ⁇ 10 6 cells/ml with a viability of 15%.
- a cell-free supernatant was harvested after the cells had been pelleted for 10 minutes at 300 ⁇ g.
- squamous cell carcinoma cell lines UT-SCC-10 and UT-SCC-20A (a gift from Dr. R. Grenman, University of Turku, Finland) were cultured in 5 ml media consisting of Dulbecco's modified Eagle's medium (DMEM) supplemented with 1 mM L-glutamine, 18 mM Hepes, 0.9% non-essential amino acid solution, 100 IU/ml penicillin, 100 ⁇ g/ml streptomycin (all from Gibco) and 100/% heat-inactivated human AB-serum (DMEM) in 25 cm 3 cell culture flasks (Costar) at 37° C. and 5% CO 2 .
- DMEM Dulbecco's modified Eagle's medium
- DMEM heat-inactivated human AB-serum
- the medium was decanted off and replaced every 2 to 3 days. When the cells had reached confluence they were trypsinated and reseeded in new flasks. The decanted medium was centrifuged at is 1000 ⁇ g to remove residual cells and debris and then ultra filtered on Centriplus filters with a 50000 mw cut-off. The filtrate was then concentrated on a 3000 mw filter. In some experiments the retentate from the 50000 mw cut-off filter was also saved. Retentates were resuspended in RPMI1640 to 2.5 ml.
- SNs 100 ⁇ l, were added to uncoated or HSA-coated microtiter plates together with 100 ⁇ l PBMC suspension (5 ⁇ 10 5 /ml). Cell-free SNs were harvested after over-night incubation and tested for monokine activity by ELISA, as described above.
- Pre-swelled gelatine Sepharose 4B (Pharmacia Biotech AB, SE) was washed three times in PBS or RPMI1640. 0.3-0.5 ml Sepharose gel was incubated together with the 3-50 kD fractions of ultra filtered serum, diluted in 2-2.5 ml RPMI1640 for 30 minutes at room temperature. The gel was mixed gently by inversion approximately every 10 minutes. An equal portion of the ultra filtered serum sample was incubated in parallel without gelatine Sepharose, as a negative control. The gel was allowed to settle and the supernatant collected.
- Buffer exchange to RPMI1640 with 200 IU/ml penicillin, 200 ⁇ g/ml streptomycin, 4 mM L-glutamine (Sigma) was performed by gel filtration over a Sephadex-G25 (PD-10) desalting column (Pharmacia) followed by filtration on a 0.45 ⁇ m Millex-HV syringe filter (Millipore).
- SNs, 100 ⁇ l, were added to uncoated microtiter plates together with 100 ⁇ l of control PBMC suspension (5 ⁇ 10 5 /ml). Cell free SNs were harvested after over-night incubation and tested for monokine activity by ELISA as described above.
- Urine samples (100-450 ml) from cancer patients or healthy controls were ultra centrifuged on Jumbosep centrifugal devices (Pall Life Science, MI, US) using a 30 K membrane insert or alternatively, with a Proflux M12 system using a 30 K Pellicon 2 mini filter (Millipore, Mass., US) followed by concentration on Jumbosep with a 3K membrane insert.
- Samples were desalted over a Sephadex-G25 (PD-10) column (Amersham Biosciences, SE), lyophilised and dissolved in rehydration buffer (8M urea, 4% CHAPS, 10 mM DTT, 0.5% v/v IPG buffer and a trace of orange G). Samples were centrifuged to remove undissolved material.
- rehydration buffer 8M urea, 4% CHAPS, 10 mM DTT, 0.5% v/v IPG buffer and a trace of orange G.
- 2-DE was performed in a horizontal 2-DE set-up (Multiphore/IPGphore, Pharmacia Biotech, SE) as described (Lindahl M. et.al 1998) based on isoelectric focusing (IEF) in the first dimension and molecular mass in the second dimension. Briefly, samples (230 ⁇ g, 350 ⁇ g, 600 ⁇ g) were applied to IPG gels, pH 4-7, (Amersham Pharmacia Biotech, SE) and focused overnight for 48000 Vh. SDS-PAGE was then carried out with 16% T/1% C polyacrylamide casted slab gels. Molecular weight standards were included in each run. Separated proteins were detected by Coomassie blue staining or SYPRO Ruby staining.
- the protein patterns in the gels were analyzed as digitised images using a CCD (Charged-Coupled Device) camera (1340 ⁇ 1040 pixels) in combination with a computerized imaging 12-bit system, PDQuest Version 6.1.0, in the case of fluorescent stained gels using UV scanning illumination mode (Fluor-S Multi-imager, Bio-Rad).
- the amount of protein in a spot was assessed as background-corrected optical density, integrated over all pixels in the spot and expressed as integrated optical density (IOD).
- Selected protein spots were electro transferred to PVDF membranes and subjected to N-terminal sequence analysis by Edman degradation in a Procise cLC or a Procise HT sequencer (PE-Applied Biosystems) at the Protein Analysis Center, Karolinska Institute, Sweden.
- PBMC peripheral blood from normal controls as described above. Monokine production by the PBMCs in response to urine fractions from cancer patients was verified as described above. Remaining PBMC were frozen at ⁇ 70° C. until use. For adsorption of urine fractions, the PBMCs were thawed and washed carefully in cold phosphate buffered saline (PBS). Approximately 50 ⁇ 10 6 PBMC were added to 2.7 or 2.6 ml, respectively, of ultra centrifuged (3-30 KD) urine fractions pooled from two patients with renal cell carcinoma or from one patient with malignant melanoma.
- PBS cold phosphate buffered saline
- MMPs Matrix Metalloproteinases
- MMP -1, -2, -13 (R&D Systems) and MMP-3 and -7 (Chemicon, UK) were activated according to instructions of the manufacturer. 1-50 ng/ml of the indicated MMPs were then incubated with 1 mg/ml of either human serum albumin (HSA, Octapharma, SE) or pooled human IgG for intravenous injection (IvIg, Gammagard, Baxter, DK) as substrate in RPMI or in 50 mM Tris-HCl, pH 7.5 (containing 0.15 M NaCl, 10 mM CaCl 2 and 0.05% Brij35). The mixtures were incubated for 5-20 hours at 37° C.
- HSA human serum albumin
- IvIg intravenous injection
- the pelleted, washed tissue was cut into pieces of approximately the same size and each piece was homogenised using a Mikro-Dismembrator U (B. Braun Biotech International, GE).
- the tissue was transferred to a PTFE shaking flask together with 1 ml RPMI/PEST or PBS/PEST and a tungsten carbide grinding ball and homogenised during 15-20 seconds with a shaking frequency of 1500-2000 RPM.
- the homogenised tissue suspension was transferred to a test tube and kept on ice.
- tumour cryo sections (3 ⁇ 300 ⁇ m) were carried out as described above.
- the pelleted tumour tissue was suspended in 0.5 ml cold RPMI/PEST.
- MMP-2 (R&D Systems, UK), activated according to instructions from the manufacturer, was added at a final concentration of 5 ng/ml.
- the tumour tissue suspension was incubated with MMP-2 for 20 h at 37° C. and the supernatant collected after centrifugation. Parallel incubation of tumour tissue with no addition of MMP-2 was set up as a control.
- the mixtures were buffer exchanged to RPMI by gel filtration through a Sephadex-G25 (PD-10) column (Amersham Biosciences, SE) and filtered through a 0.45 ⁇ m Millex-HV syringe filter (Millipore, Mass., US). Finally, the mixtures were analysed by gel-electrophoresis and tested for monokine inducing activity in fresh normal PBMC as described above.
- PD-10 Sephadex-G25
- Millex-HV syringe filter Millex-HV syringe filter
- the pelleted homogenised tumour tissue formed during preparation of PIF was kept on ice and stored at ⁇ 70° C.
- PIF were prepared as described above.
- the homogenised sections were washed once more to collect a fourth supernatant, used as a control reflecting the IL-6 inducing activity in tumour sections before incubation.
- the fourth supernatant was divided into two parts, to one of which was added 20 mg/ml of HSA and directly frozen at ⁇ 70° C.
- tumour tissue with 20 mg/ml HSA or with 10 mg/ml pooled human IgG for intravenous injection (IvIg), as well as the mixtures of PIF with 20 mg/ml HSA or with 10 mg/ml IvIg, all in RPMI/PEST, were incubated for 18-21.5 h at 37° C.
- the mixtures were centrifuged and supernatants collected.
- the supernatants were buffer exchanged to RPMI as described previously and filtered through a 0.45 ⁇ m Millex-HV syringe filter (Millipore, Mass., US) and stored at ⁇ 70° C. until testing for monokine inducing activity in fresh, normal PBMC as described above.
- Comparisons of the means of different patient groups or different test occasions were performed using an unpaired t-test. Time to progression and survival was analyzed using the Kaplan-Meier method and Logrank test.
- MI modulation index
- IL-1Ra is a potent inhibitor of immune stimulation/reactivity as it blocks the activity of IL-1. It is therefore of considerable importance that it is frequently expressed by tumour cells and tumour infiltrating mononuclear cells. Based on the results presented in the above, it is highly reasonable to assume that tissue bound IgG is the inducer of this cytokine. Thus either tissue bound antibodies or intra-tumourally precipitated ICs can play a major role in intra-tumoural down-regulation of the immune response.
- FIG. 1 shows melanoma biopsies stained for the expression of IL1Ra. Different patterns are hereby found, viz. A) tumour cells are generally stained with some positive infiltrating mononuclear cells, and B) large numbers of infiltrating cells staining for IL-1Ra, tumour cells only faintly positive.
- IL-1Ra Production of IL-1Ra can be induced by some cytokines (Tilg et al., 1994), but Fc ⁇ R cross-linking by solid phase IgG or ICs seems to be the most efficient inducer of this substance. It has been shown that in cultures where binding of IgG to the surface of the culture well is allowed (uncoated wells) the production of IL-1Ra is significantly enhanced (p ⁇ 0.0001) compared to cultures where binding of IgG has been reduced by pre-coating with HSA. This immunomodulatory effect has been studied in healthy individuals, patients with malignant melanoma and renal cell carcinoma ( FIG. 2 ). If purified human IgG is added to the HSA in coated wells (HSA/IgG), IL-1Ra production by control PBMC is restored. Based on these results it is obvious that solid phase IgG will play a major role in immune regulation.
- tissue bound IgG exposing the Fc-parts, in tumour tissue inducing production of IL-1Ra as described herein is thus highly relevant to the down-regulation of the anti-tumour immune reactivity.
- FIG. 4 shows inhibition of ILlRa production by Tosyl.
- the effect of Tosyl on IL-1Ra production by PBMC from healthy individuals (n 9) in 10% autologous sera cultured in microtiter plates pre-coated with A) HSA, and B) HSA/IgG.
- FIG. 5 shows IL-2 induced proliferation by PBMC from normal healthy individuals (first three bars) and PBMC from RCC patients (last three bars) cultured in 10% autologous sera on uncoated and pre-coated microtiter plates. Significant (p ⁇ 0.011) difference in proliferation between PBMC from healthy individuals and RCC patients on uncoated plates.
- Solid phase IgG results in a broad cross-linking, which can elicit stimulation of the immune response in normal healthy individuals by eliciting a cytokine cascade including TNF- ⁇ and IL-1, which sensitises the response to IL-2 (increased numbers of receptors).
- This model reflects the situation when opsonised antigens or large ICs elicits an immune response. In HSA coated wells this stimulatory cross-linking can not take place, which results in a significantly lower response to IL-2.
- the difference in IL-2 induced proliferative response can be due to an immunomodulatory effect by the cross-linking per se and not a stimulatory cytokine cascade.
- Inhibitory signals in monocytes/macrophages might be overcome by broad cross-linking of Fc ⁇ R.
- Flow cytometry was performed to verify binding of the F(ab′)2 monoclonal antibodies to PBMC.
- the inhibitory anti-CD64 antibodies bound to a higher percentage of monocytes that anti-CD16, but fewer monocytes than anti-CD32 antibodies, in both experiments. Furthermore, the mean fluorescent intensity of both anti-CD16 and anti-CD32 binding was higher than anti-CD64 in both experiments. Thus, increased binding of the anti-CD64 F(ab′)2 antibody, compared to anti-CD16 and anti-CD32 does not explain the inhibitory effect.
- the culture model described above provides for excellent opportunities of studying immunosuppressive regulatory mechanisms in cancer patients.
- CBIC cell-bound ICs
- Immune complexes can be determined in different ways. Standard methods for determining circulating ICs (CIC) are by indirect non-functional parameters as complement binding and activation, PEG-precipitation, phagocytosis, platelet aggregation.
- CIC Determination of CIC, to obtain prognostic information or to diagnose possible occurrence of ICs modulating the immune system, is likely to be irrelevant, as IC has to be bound to cellular receptors to have any immunomodulatory effect. Thus CBIC will have full immunomodulatory effect long before the amount of ICs is enough to saturate these receptors and ICs appear in the circulation. In the present case direct methods has been used to demonstrate the presence of cell/tissue bound IgG or ICs.
- CBIC can be demonstrated using flow cytometry, or CBIC on blood cells has been demonstrated using immunocytochemistry (IHC) on cytospin preparations. Further CBIC has been demonstrated in tumour tissue (tumour cells, endothelium, tumour infiltrating inflammatory cells) using IHC.
- the identified substance is considered being IC. Otherwise it is not possible to discriminate between IgG and IC as the monoclonal antibody and protein G might be able to bind to monomeric IgG as well. However, if IgG is bound to the tissue directly or in IC might be of minor importance as it will anyhow be recognised as “solid phase” IgG.
- tumour biopsies stained for the presence of tissue bound IgG/IC red
- T-lymphocytes brown
- Different staining patterns are shown, viz. A) staining of vascular areas/endothelial cells and some lymphocytes for IgG. Some lymphocytes are not stained for IgG/IC.
- tumour infiltrating mononuclear cells B) a diffuse staining of the tumour tissue for IgG/IC, whereby the majority of the lymphocytes are not stained for IgG/IC, C) staining tumour infiltrating macrophages and some lymphocytes for IgG/IC, but tumour cells are generally negative, D) extensive staining of vascular areas for IgG/IC with very low numbers of infiltrating mononuclear cells.
- tissue bound IgG exposing Fc parts are inversely correlated to the presence of tumour infiltrating mononuclear cells and hence plays a major role in the down-regulation of the immune response to the tumour.
- Interleukin-6 is a proinflammatory cytokine of importance for the initiation of immune reactivity (Barton, 1996; Barton, 2001). However, in cancer patients, its occurrence has a number of detrimental effects. Inflammatory cells, vascular endothelium and several types of tumour cells produce it. It has activity as autocrine growth factor in at least some malignancies, e.g., myeloma and renal carcinoma. It can interfere with the cytotoxic activity of cisplatinum (Borsellino et al., 1995; Mitzutani et al., 1995).
- CBIC is of importance for the dys-regulation of the immune system in cancer.
- IL-1 ⁇ IL-1 ⁇
- IL-6 TNF- ⁇
- PGE 2 TGF- ⁇
- TGF- ⁇ TGF- ⁇
- PGE 2 is well known to be a potent inhibitor of immune reactivity. Thus patients with high serum levels of PGE 2 before treatment or having an increased production of PGE 2 during the early treatment period will not respond to immunotherapy. (Deehan et al., 1994)
- Therapeutic control of the dys-regulatory mechanisms of IL-6 production will thus improve quality of life, therapeutic response to immuno- and chemotherapy, and increase over- ⁇ ll survival.
- IL-6 is only one product of the dys-regulated inflammatory reaction mentioned, and often correlates to production of the other cytokines such as IL-1 ⁇ and TNF- ⁇ , the strategy is to find the fundamental dys-regulatory mechanisms and block them in order to completely down-regulate the inflammatory reaction.
- IL-6 production in cancer patients correlation to prognosis
- the present analysis includes IL-6 production from PBMCs from three types of cancer patients. As shown in Table 3, 30 patients with radically resected stage III melanoma (MMO), 43 patients with previously untreated metastatic melanoma (MR1) 36 with previously untreated metastatic renal cell carcinoma (RCC1) and 46 patients with primary colorectal cancer (CRC) were studied. The cytokine production is, compared to that of healthy individuals (K), significantly increased in all categories.
- IL-6 production is not restricted to patients with advanced disease as IL-6 is produced also by PBMCs from patients with primary colorectal cancers and radically resected stage III melanoma (MM 0), whereby in the latter group no metastatic lesions could be demonstrated by clinical or radiological investigations.
- MM 0 stage III melanoma
- the serum concentration of IL-6 was determined in melanoma, colon and renal cell carcinoma patients and was generally below the detection limit of the ELISA-technique used. In only a few cases measurable amounts of IL-6 were found but these were quite negligible compared to those found in cultures. TABLE 3 Production of IL-6 by PBMCs from healthy individuals and various types of cancer patients.
- FIG. 9 shows the production of IL-6 by PBMCs from different subsets of colorectal cancer patients, viz. A), without LPS stimulation and B) with LPS stimulation.
- IL-6 production is of prognostic significance as evident from FIG. 10 .
- Production of IL-6 by PBMCs from in particular cancer patients in vitro means that either are the producing cells triggered in vivo and maintain this status when placed in culture or there is a serum factor which continuously stimulates production of IL-6.
- sera from cancer patients, with a high IL-6 production in autologous PBMC cultures were used in the medium of five cultures with PBMCs from healthy individuals.
- a high IL-6 production was induced in all these cultures demonstrating occurrence of an IL-6 inducing serum factor.
- CIC are not involved in inducing IL-6 production, but either CIC or IgG obviously modulate the production as it increased when IgG was removed from the culture medium. This is compatible with the results above where Fc ⁇ R cross-linking by solid phase IgG inhibited IL-6 production.
- IgG is removed from the culture medium, the inhibitory effect is relieved.
- Affinity chromatography with proteinG-Sepharose had no effect on control sera not inducing IL-6 production. Determination of IgG after affinity chromatography did not find detectable amounts of IgG ( ⁇ 0.01 mg/ml).
- IL-6 inducing factor (IL-6IF) by ultrafiltration
- sera from cancer patients and healthy individuals were diluted (1:5) and ultrafiltered with a filter cut-off at 100, 50 and 3 kD.
- IL-6IF was at least to some extent also found in the other fractions, but this activity could always be demonstrated in the less than 50 kD fraction.
- IL-6 inducing activity was generally not found in the fraction with a molecular weight of less than 3 kD.
- IL-6IF has a low molecular weight and thus IgG or CIC can not be involved.
- the former case is compatible with the assumption that this factor is a proteolytic fragment of some large molecule, and that the activity is present in fragments of different sizes. If the IL-6IF were a small fragment it is certainly likely that it is bound to other serum proteins as it would otherwise immediately be excreted in the urine.
- fractions obtained during ultrafiltration of sera described above were also analysed using PAGE electrophoresis of reduced proteins.
- a band having a molecular weight of about 20 kD was identified. This was either very weak or not present in all fractions of control sera or patient sera with no IL-6 inducing activity.
- IL-6IF As IL-6IF was found to have a molecular weight of less than 50 kD, it is assumed that this factor will at least, to some extent be excreted in the urine. Thus the less than 50 kD fraction was prepared and concentrated using the 3 kD filter. When these fractions from cancer patients were tested for IL-6 production in cultures with PBMCs from healthy individuals an IL-6 inducing activity was found.
- IL-6IF or any other inducing factor of an immunoregulatory substance, in the urine opens interesting diagnostic and therapeutic possibilities.
- concentration of IL-6IF of urine is related to the serum concentration a simple diagnostic test is made which provides essential information about prognosis and the likelihood of therapeutic success.
- the diagnosis will also be of value to determine treatment strategies dealing with the elimination of IL-6IF—treatment of the chronic inflammatory reaction in cancer patients.
- IL-6IF The origin of IL-6IF is so far unknown. However, it is related to the presence of a malignant tumour.
- IL-6IF has a low molecular weight is compatible with its being an enzymatic fragment of some large molecule. It is assumed that this factor is produced in the tumour or by substances released from the tumour.
- tumours were minced using a stainless steel mesh and extracted in physiological buffer during various times. In fact, 5 out of 7 analysed tumours produced the factor when the extracts were tested in cultures of PBMCs from healthy individuals.
- Immunomodulating factors have been identified in large numbers at studies of either tumour extracts or conditioned culture media from tumour cell lines. It has now turned out that IL-6IF is produced by squamous cell carcinomas from the oral cavity. Conditioned media were collected and tested using PBMCs from healthy individuals as described. An IL-6 inducing activity was demonstrated and this will facilitate studying therapeutic possibilities such as reduction of IL-6IF by inhibiting different types of tumour related enzymes, such as MMPIs.
- IL-6 inducing activity in ultrafiltered (3 to 50 kD) condition media from a squamous cell carcinoma (SCC) cell line grown in media with fetal calf serum (FCS) or pooled human AB-sera from two different batches AB7, and AB8, respectively.
- SCC squamous cell carcinoma
- FCS fetal calf serum
- TNF- ⁇ and IL-1 ⁇ Similar to the situation with IL-6 we have also found inducing activity for TNF- ⁇ and IL-1 ⁇ (Table 10) and IL-10 in serum and ultrafiltered urine. IL-10 was found in four sera/serum fractions and one urine fraction also inducing IL-6. In addition, one serum and one urine fraction inducing IL-6 did not induce IL-10. TABLE 10 TNF- ⁇ and IL-1 ⁇ inducing activity in IL-6 inducing serum and ultrafiltered urine from cancer patients IL-6 TNF- ⁇ IL-1 ⁇ Source Control PBMC pg/ml pg/ml pg/ml Patient serum 1 None ⁇ 31.3 N.D. N.D.
- control pool Comparison between healthy controls and cancer patients Comparisons were made between a pool of 11 healthy controls (control pool) and four individual controls and 1. a pool of one breast and one pancreas cancer patient, 2. a pool of two renal cell carcinoma patients and 3. three individual melanoma patients.
- Proteins or fragments of proteins found in the urine fraction from different types of cancer patients but not in healthy controls are shown in Table 11. Some proteins/fragments were found in the urine of several different cancer patients, e.g. albumin/albumin fragments, CD59, plasma retinol binding protein and prostaglandin D2 synthase TABLE 11 Proteins/protein fragments found in urine fractions from cancer patients, but not in the pool of healthy controls Breast/pancreas Renal cell Malignant Proteins cancer carcinoma melanoma Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Alpha-a
- Proteins over represented in urine fraction from patient with IL-6 inducing activity Alternative protein/s Protein according to spot on Protein/protein fragment analysed masspectormetry 2D gel by masspectometry analysis 1
- Beta-microsemino protein 2 CD59 3
- CD59 4 CD59 5
- Colipase Inhibin beta 6 Extracellular superoxide dismutase 7
- Heparan sulphate proteoglycan (Perlecan) 8
- Immunoglobulin kappa light chain 9
- Immunoglobulin superfamily LIR-D1 precursor member 8
- IL-13 receptor alpha-1 chain Urokinase plasmin activator surface 11
- Inter-alpha-trypsin inhibitor, chain 2 Endoplasmic reticulum protein ERP29 12 Lithostathine 1 alpha 13 Lithostathine 1 alpha
- MMP Matrix Metalloproteinases
- IgG or serum albumin was incubated with MMPs under well-defined conditions. Two different buffer systems were used in these experiments ( FIG. 16 ). The supernatants were analysed using gel-electrophoresis and their cytokine inducing activity was analysed in cultures with normal PBMCs. As demonstrated in FIG. 16 several MMPs released fragments of IgG and serum albumin, which induced or modulated IL-6 inducing production. In particular, MMP-1, -2, -3, -13 released active fragments from albumin and MMP-2, -3, -7 and ⁇ 13 from IgG.
- IL-6IF can be extracted from malignant tumours, e.g. malignant melanoma, renal cell carcinoma, colorectal cancer. These results were confirmed in a new series of experiments, where homogenised tumours were washed three times in PBS or RPMI in order to collect cytokine inducing factors already present in the tumours, so called “preformed inducing factors” (PIF).
- malignant tumours e.g. malignant melanoma, renal cell carcinoma, colorectal cancer.
- cytokine inducing factors PEFs
- tissue sections/homogenates were thoroughly washed before addition of proteolytic enzymes, such as MMPs.
- the tumour sections/homogenates were then incubated for 20 hours at 37° C.
- IL-6 inducing activity of the supernatants was then analysed in cultures of normal PBMCs.
- FIG. 18 addition of MMP-2 modulated the release of IL-6 inducing activity.
- the albumin band was found to be better preserved in incubations, to which MMP-2 was added. This is reasonably due to an effect of MMP-2 on the degradation of enzymes degrading albumin.
- MMPs can degrade tumour tissue substances into fragments with cytokine inducing activity.
- the effect of MMP-2 on the preservation of albumin in these incubations also demonstrates that proteolytic enzymes are involved in the regulation of the intra-tumoural proteolytic activity. A complex interaction of proteolytic enzymes is thus demonstrated and this results in generation and/or modulation of the production of dysregulatory inducing factors.
- albumin was added to fresh PIF-fractions and incubated at 37° C. for 18 h.
- the IL-6 inducing activity was lower when albumin was added, which shows that the markedly increased IL-6 inducing activity after adding albumin to washed homogenates is not due to any protective activity of albumin but rather that albumin acts as a substrate for intra-tumoural proteolytic enzymes.
- immuno-modulating IgG and albumin fragments are produced in the intra-tumoural milieu.
- FIG. 1 shows melanoma biopsies stained for the expression of IL1Ra. Different patterns are hereby found, viz. A) tumour cells are generally stained with some positive infiltrating mononuclear cells, and B) large numbers of infiltrating cells staining IL-1Ra, tumour cells only faintly positive.
- FIG. 2 shows production of IL-1Ra in short term cultures of PBMC from healthy controls and cancer patients. The effect of pre-coating of the culture wells is shown.
- FIG. 3 shows comparison of IL-1Ra production by PBMCs from healthy individuals and melanoma and renal cell carcinoma patients, cultured in A) HSA pre coated wells or B) uncoated wells.
- FIG. 4 shows inhibition of IL1Ra production by Tosyl.
- FIG. 5 shows IL-2 induced proliferation in healthy individuals and RCC patients.
- IL-2 induced proliferation (mean ⁇ S.D.) by PBMC from normal healthy individuals (grey bars, 21-29 individuals) and PBMC from RCC patients (black bars, 12-18 individuals) cultured in 10% autologous sera on uncoated and pre-coated microtiter plates.
- Significant (p 0.011) difference in proliferation between PBMC from healthy individuals and RCC patients on uncoated plates, but not on HSA coated or on HSA/IgG coated plates.
- Significant (p 0.0045) difference in proliferation between PBMC from RCC patients cultured on uncoated and HSA/IgG coated plates.
- FIG. 6 shows normal PBMC cultured in autologous sera (black bars) or sera from cancer patients (open bars) in the presence of IL-2. Proliferation was measured by 3H-uptake on day 7. Patients 88 and 124 had previously been shown to induce high levels of IL-6 production, whereas patient 112 did not.
- FIG. 7 shows tumour biopsies stained for the presence of tissue bound IgG/IC and T-lymphocytes using a double staining technique with recombinant protein G (not binding to albumin). Different staining patterns are shown, viz. A) staining of vascular areas/endothelial cells and some lymphocytes for IgG. Some lymphocytes are not stained for IgG/IC.
- tumour infiltrating mononuclear cells B) a diffuse staining of the tumour tissue for IgG/IC, whereby the majority of the lymphocytes are not stained for IgG/IC, C) staining tumour infiltrating macrophages and some lymphocytes for IgG/IC, but tumour cells are generally negative, D) extensive staining of vascular areas for IgG/IC with very low numbers of infiltrating mononuclear cells.
- FIG. 8 shows cytospins of PBMC from two patients with malignant melanoma stained for the presence of IgG/IC, using recombinant protein-G (A) or monoclonal directed against the Fc-part of IgG.
- FIG. 9 shows IL-6 production by PBMCs from different subsets of colorectal cancer patients. A) without LPS stimulation and B) with LPS-stimulation.
- FIG. 10 shows survival in renal cell carcinoma patients according to IL-6 production by PBMCs in short term cultures where the microtitre plates were coated with HSA. High production is >2500 pg/ml.
- FIG. 12 shows the effect of chlorambucil on PHA-induced proliferation of PBL from RCC patients before treatment with IL-2.
- Modulation Index (MI) was calculated as described under Materials and Methods. The assays were performed at the following time points: 1) before start of treatment, 2) one week later, 48 hours after five days of IL-2 treatment, 3) after one week without IL-2 administration and 4) after an additional week, 48 hours after another five days of IL-2 treatment combined with chlorambucil.
- FIG. 13 shows the effect of chlorambucil (CHL) on TNF- ⁇ production and proliferation of PHA-stimulated PBMC from RCC patients.
- PBMC were cultured with PHA in the presence or absence of CHL for 72 hours and the cellular 3 H-uptake and the TN- ⁇ concentration in cell-free culture supernatants were assessed. Modulation Index was calculated as described under Materials and Methods. Each circle represents one patient.
- FIG. 14 2D gel electrophoresis of PBMC-adsorbed and unadsorbed urine fractions pooled from two patients with renal cell carcinoma. 230 ug of protein was loaded per 2D gel. Separated proteins (based on isoelectric focusing in the first dimension and molecular mass in the second dimension) were detected by SYPRO Ruby staining.
- FIG. 15 2D gel electrophoresis of PBMC- ⁇ dsorbed and unadsorbed urine fractions from a patient with malignant melanoma. 350 ug of protein was loaded per 2D gel. Separated proteins (based on isoelectric focusing in the first dimension and molecular mass in the second dimension) were detected by SYPRO Ruby staining.
- FIG. 16 Generation of IL-6 inducing factors by incubation of IgG (A and C) and albumin (B and D) with MMPs. Two experiments using different buffer systems are shown (as described in Material and Methods). The substrates were incubated with MMPs for 20 hours in experiments A, B, C and for 5 hours in experiment D. The production of IL-6 was then tested in cultures of PBMCs from healthy controls.
- FIG. 17 Effect of collagen/collagen fragments on the proliferative response (measured as incorporation of 3 H-TdR) of normal PBMCs to IL-2. As can be seen a strong inhibitory effect was demonstrated in two out of three experiments.
- FIG. 18 Modulation of IL-6 inducing factors by incubation of homogenised, washed tumour tissue with MMP-2.
- a and B represent two separate experiments with two different tumour tissues in each. The effect of this enzyme varies, dependent on the intra-tumoural milieu of different tumours, but it is clearly shown that MMP-2 has a modulatory effect on the production of IL-6 inducing factor/activity, which was tested in cultures of PBMCs from healthy controls.
- FIG. 19 Generation of IL-6 inducing factors/activity by incubation of IgG and albumin with homogenised, washed tumour tissue.
- a and B represent two separate experiments. As shown in these two experiments adding IgG and in particular albumin to tumour tissue markedly increases the production of IL-6 inducing factor/activity, which was tested in cultures of PBMCs from healthy controls.
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to a method for increasing efficacy and/or possibility of therapeutic treatment of cancer, wherein any dys-regulatory mechanism, including inducing factor/s, of the production of immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, is therapeutically controlled to minimise pathological production of such immunoregulatory substances, to enhance the therapeutic control of a malignant tumour in a subject suffering from a cancer, a method for analysing dys-regulatory mechanism controlling substances, kit for such analysis, use of certain compounds for preparing pharmaceutical preparations, and pharmaceutical preparations.
Description
- The present invention relates to method for treating cancer, method for determining immunoregulatory substances, kit for carrying out said determination, use of certain compounds for preparation of pharmaceutical compositions, as well as pharmaceutical compositions.
- Evidence of the occurrence of immunogenic tumours among a majority of different types of human cancers is increasing, e.g., specific cytotoxic T-lymphocytes, CTLs, are found in the blood of cancer patients, antibodies against tumour associated antigens have been identified, inflammatory cells are infiltrating the tumours, there is often a correlation between these cells and prognosis or response to immunotherapy and an immune mediated anti-tumour reactivity has been demonstrated after therapy.
- The function of immune cells in cancer patients is, however, often impaired. Generally this is more pronounced in tumour infiltrating mononuclear cells (Vose et al., 1977), TIMC, than in cells obtained from peripheral blood. It has for example repeatedly been demonstrated that the proliferative response to mitogens, such as phytohemagglutinin (PHA) or concanavalin A (ConA), is inhibited, natural killer cell (NK-cell) activity and cytotoxic activity of CTLs are reduced as is the maturation and function of dendritic cells and the immune balance seems to be directed to a T-
helper 2 situation (Pawelec et al. 2000). - Immunosuppression of TIMC can, however, at least to some extent be overcome, either by washing, preincubation before stimulation, or culturing in interleukin-2. Amazingly, the down-regulation of the immune system, which relates to cancer, does not result in a seriously increased incidence of infectious diseases in these patients.
- The demonstration of concomitant immunity shows the existence of regional immunosuppression in the absence of systemic suppression, indicating a regional—systemic gradient of immunosuppression (North, 1985). Systemic immunosuppression can thus be regarded as a systemic dissemination, or “spill-over” of intra-tumoural suppression.
- Extracts or supernatants from tumours are often immunosuppressive (Sulitzeanu, 1993). Several factors have been suggested to mediate this suppression, e.g., TGF-β, PGE2, IL-10, IL-4 and others, either being produced by the tumour cells as such or by tumour-infiltrating lymphocytes (TIL) or tumour associated macrophages (TAM) (e.g. Menetrier-Caux et al., 1999; Heimdal et al., 2000; Heimdal et al., 2001). However, no fundamental mechanism has been identified so far (Mocellin, 2001).
- The immunosuppression of cancer patients described above often involves an ongoing systemic, chronic inflammation with an increased production of cytokines, in particular IL-6 and TNF-α seems to be important mediators in this process. This results in a paraneoplastic syndrome with a poor performance status—impaired general condition, which is characterized by anorexia, fatigue, subfebrility and distortion of various biochemical laboratory parameters, e.g., low haemoglobin concentration, high numbers of platelets, increased numbers of blood monocytes, increased concentration of acute phase reactants, increased c-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) and other factors (Barton , 2001; Blay et al., 1992; Blay et al., 1997; Gadducci et al., 2001; Walther et al., 1998). This condition is correlated to the tumour burden of the patient, being worse in more advanced disease. In the clinical situation, attempts are often made to ameliorate the poor general condition of these patients by corticosteroid treatment.
- Chronic inflammatory reactions in cancer patients often result in a poor response to the immunotherapy (Blay et al. 1992; Deehan et al., 1994; Lissoni et al., 1999; Tartour et al., 1996). There are some animal and human reports on the importance of the immune status of tumour bearers for response to cytotoxic treatment/chemotherapy or radiotherapy. (Goldin et al., 1980; Milas et al., 2001)
- Immunostimulatory treatment of the dysregulated immune system of cancer patients might be counter-productive. If the immune system in cancer is directed to down-regulation of the chronic inflammatory reaction there is a risk that further therapeutic immunostimulation will enhance the immunosuppression and thereby further down-regulate the immune reactivity against the tumour cells. The strategy should therefore be to eliminate mediators of immunosuppression before the immune system is stimulated.
- In developing immunotherapeutic strategies in cancer several critical steps, of major importance for initiation and maintenance of immune mediated anti-tumour reactivity, have to be considered.
- For initiation of an immune response the tumour has to be recognised as non-self. The initial induction of an immune response to tumour associated antigens takes place at an early stage of the malignant disease while the tumour burden is still reasonably small and tumour related immunosuppressive mechanisms are not yet activated. In this situation the immune reactivity to the tumour is beneficial and control the malignant growth for some time.
- In order to get an immune response a proper interaction between antigen presenting cells (APCs) and lymphocytes has to take place with a well-orchestrated production of cytokines and expression/interaction of co-stimulatory molecules.
- In cancer patients with macroscopic, progressive tumour a different situation prevails. The anti-tumour immune reactivity has been suppressed. In a small subset of patients the immunostimulatory therapeutic strategies, which are available, e.g., interferons, interleukins, vaccination, can overcome this immunosuppression, which results in objective tumour regression in only about 10-15 percent of the patients and short-lasting minor regressions in some more. The poor efficacy of such treatment strategy depends on the occurrence of non-immunogenic tumours, serious immunosuppression (which can not be overcome by current therapeutic methods) and down-regulation of the immune reactivity during immunotherapy. Tumour related suppressor substances might interfere with these mechanisms during development of immunosuppression. Immune mediated anti-tumour reactivity also seems to be down regulated via interaction with FcR, in particular FcγR.
- Tumour related immunosuppression takes place at four levels: Activation, recruitment of effector cells to the tumour, migration of these cells from stromal areas close to the tumour cells and cytotoxic activity.
- Mechanisms by which malignant tumours can down-regulate the immune system are
-
- tumour derived non-immunogenic substances with suppressor activity;
- well-characterized immunomodulating substances, cytokines, e.g., transforming growth factor beta (TGF-β), IL-10, as well as PGE2,
- tumour associated antigen (TAA) resulting in antigenic overload, production of antibody and immunocomplex (IC);
- serum blocking factors, which are probably related to immune complexes, cross-linking Fc receptor (FcγR);
- proteolytic fragments from tumour substances, e.g., extracellular matrix (ECM);
- T-
helper 1/T helper 2 (Th1/Th2) balance
- Stimulation of the inhibited immune reactivity to the tumour can be achieved using several therapeutic strategies. However, several function parameters are down-regulated during the treatment, particularly in tumour areas with the most pronounced regressive changes.
- It would thus be of great importance in the treatment of cancer patients to identify the mechanisms by which the immune system is dys-regulated and to develop proper diagnostic tests of this condition. The ultimate goal is then, based on these tests to find measures to treat, eliminate the immunosuppression, and thereby improve the general condition of cancer patients and increase the therapeutic efficacy in cancer.
- It has been found that efficacy and possibility of therapeutic treatment of cancer can be increased, whereby any dysregulatory mechanism of the production of immunoregulatory substances, is therapeutically controlled to minimise pathological production of such immunoregulatory substances, to enhance the therapeutic control of a malignant tumour in a subject suffering from a cancer and the chronic inflammatory reaction in cancer patients which latter reaction plays an important role in cancer therapy.
- The object of the present invention is thus to obtain a method for increasing the possibility of treating cancer, a method for determining factor(-s) related to prognosis and allowing prediction and monitoring therapy of cancer, and a kit for determining such factor(-s), use of substances to prepare pharmaceutical compositions, as well as pharmaceutical compositions.
- It has now surprisingly been found a method for increasing efficacy is and possibility of therapeutic treatment of cancer, wherein any regulatory mechanism, including inducing factor/s, of the production of immunoregulatory substances, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, is therapeutically controlled to minimise pathological production of such immunosuppressive immunoregulatory substances or to stimulate the production of immunosupportive immunoregulatory substances to enhance the performance status of a patient and/or to enhance the therapeutic control of a malignant tumour in a subject suffering from a cancer.
- According to a preferred embodiment any dysregulatory mechanism of immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α and others, production in a patient suffering from cancer is modulated by therapeutically treating the patient to provide a FcR modulation by administering a therapeutically effective amount of a FcR modulating agent.
- According to another preferred embodiment any dysregulatory mechanism of immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, production in a patient suffering from cancer is modulated by therapeutically treating the patient to provide a FcR/FcγR modulation by administering a therapeutically effective amount of a FcR/FcγR blocking agent.
- According to another preferred embodiment any dysregulatory mechanism of immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, production in a patient suffering from cancer is modulated by therapeutically treating the patient to provide a FcR/FcγR modulation by administering a therapeutically effective amount of a FcR/FcγR cross-linking agent.
- According to another preferred embodiment blocking or cross-linking of FcR is carried out using a therapeutically active amount of at least one immunoglobulin, FcR antibodies or fragments of antibodies or synthetic constructs including peptides directed to FcR.
- According to another preferred embodiment at least one FcR-modulating substance minimising production of interleukin-1 receptor antagonist is administered in a therapeutically effective amount.
- According to another preferred embodiment wherein the modulation is carried out by blocking FcR by administering F(ab), or F(ab′)2-fragments.
- According to another preferred embodiment the modulating substance is a soluble receptor, fragment, peptide or synthetic construct directed to the Fc-part of immunoglobulins.
- According to another preferred embodiment FcγR I, FcγR II and/or FcγR III is modulated to stimulate IL-2 stimulation of clonal expansion of lymphocytes.
- According to another preferred embodiment any compound blocking the production or biological activity of a factor inducing pathological production of any dysregulatory mechanism of immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, production, is administered in a therapeutically effective amount.
- According to another preferred embodiment the blocking compound is a receptor blocking compound.
- According to another preferred embodiment the blocking compound is a monoclonal antibody, fragments thereof, peptides or synthetic constructs.
- According to another preferred embodiment a compound having the ability of inhibiting the activation or activity of enzymes generating immunomodulatory fragments is administered in a therapeutically effective amount.
- According to another preferred embodiment the inhibiting compound is a monoclonal antibody, an anti-integrin antibody, peptides and/or synthetic constructs.
- According to another preferred embodiment the modulating substance is an enzyme inhibitor.
- According to another preferred embodiment the inhibiting compound is a matrix metalloproteinase inhibitor.
- According to another preferred embodiment any compound blocking the factor inducing IL-6 production is administered in a therapeutically effective amount.
- According to another preferred embodiment any compound blocking the factor inducing IL-1β production is administered in a therapeutically effective amount.
- According to another preferred embodiment any compound blocking the factor inducing IL-10 production is administered in a therapeutically effective amount.
- According to another preferred embodiment any compound blocking the factor inducing TNF-α production is administered in a therapeutically effective amount.
- According to another preferred embodiment any compound blocking the factor inducing IL-1Ra production is administered in a therapeutically effective amount.
- According to another preferred embodiment monoclonal antibodies directed to enzymes generating immunomodulatory fragments are administered in a therapeutically effective amount.
- According to another preferred embodiment at least one anti-integrin antibody, peptide or construct is administered in a therapeutically effective amount.
- Further preferred embodiments are as follows.
- According to another preferred embodiment blocking cross-linking of FcR is carried out using a therapeutically active amount of FcR antibodies or fragments of monoclonal antibodies directed to FcR, preferably the FcR cross-linking is obtained by administering a therapeutically effective amount of at least one immunoglobulin, more preferably the FcR cross-linking is obtained by administering a therapeutically effective amount of IgG or complex bound IgG, and/or the FcR cross-linking is obtained by administering a therapeutically effective amount of IgA or complex bound IgA.
- According to a further preferred embodiment a therapeutically effective amount of Fc part of at least one immunoglobulin is administered, preferably a therapeutically effective amount of Fc part of IgG or complex bound IgG is administered, and/or a therapeutically effective amount of Fc part of IgA or complex bound IgA is administered.
- According to a further preferred embodiment any cross-linking of FcγR I, FcγR II and/or FcγR III is carried out.
- According to a further preferred embodiment FcR is down-regulated using an inhibitor of its expression.
- According to another, further preferred embodiment blocking of FcγR is carried out by administering a therapeutically effective amount of anti-FcγR I antibodies.
- According to another preferred embodiment at least one FcR-blocking substance minimising production of interleukin-1 receptor antagonist is administered in an amount necessary to block the activity of interleukin-1.
- A further aspect of the invention includes a method for analysing the amount and/or certain pattern of dysregulatory mechanism substances, including their mRNA, including any inducing factor, inducing the production of immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, whereby the amount of such dysregulatory mechanism substances is determined in a tissue sample, whereby the prognosis of a subject suffering from cancer can be determined and/or the therapeutic efficacy of any anti-cancer treatment can be predicted and monitored.
- According to a preferred embodiment tissue is whole blood, serum, plasma, lymphatic fluid, saliva, urine, faeces, ascites, pleural effusion, pus, as well as any tissue, including inflammatory cells.
- According to another preferred embodiment any compound having the ability of inhibiting the activation or activity of enzymes generating fragments of intra-tumoural tissue are determined.
- According to another preferred embodiment any fragment or new epitopes generated by the activity of intratumoural enzymes is determined in any tissue from a cancer patient.
- According to another preferred embodiment the activity of any compound having the ability of inhibiting the activation or activity of enzymes generating fragments is monitored by determining these fragments or new epitopes exposed by the enzymatic activity in any tissue from a cancer patient.
- According to another preferred embodiment the inhibiting compound is a matrix metalloproteinase inhibitor.
- According to another preferred embodiment any compound blocking production or biological activity of a factor inducing pathological production of any dys-regulatory mechanism of immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, production, is determined.
- According to another preferred embodiment the amount of any inducing factor or mRNA thereof inducing the production of immunoregulatory substances, including one or more cytokines including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α and others, found in tissue, is determined by determining the production of immunoregulatory substances, including cytokines, including, including IL-1Ra, IL-6, IL-1β and/or TNF-α and others produced by PBMC after exposure to these factors.
- According to another preferred embodiment samples are obtained in a way, including tubes and syringes, not binding or inactivating immunoregulatory substances, including inducing factors.
- According to another preferred embodiment the amount of any inducing factor inducing the production of immunoregulatory substances, including one or more cytokines including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, is determined directly.
- According to another preferred embodiment the amount/occurrence of any cell bound factor inducing the production of immunoregulatory substances, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, is determined.
- According to another preferred embodiment the amount of any urine present inducing factor inducing the production of immunoregulatory substances, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, is determined by using an urine dip stick containing binding substance/s binding said inducing factor and/or colour developing reagents to said inducing factor.
- According to another preferred embodiment the amount of cell bound immune complexes, CBIC, is determined.
- According to another preferred embodiment peripheral blood mononuclear cells PBMC being positive for any immunoglobulin staining are determined.
- According to another preferred embodiment PBMC being positive for IgG staining are determined.
- According to another preferred embodiment PBMC being positive for IgA staining are determined.
- According to another preferred embodiment FcR positive to any immunoglobulin staining is determined, such positive for IgG staining and/or IgA staining.
- According to another preferred embodiment the production of O2 − is determined.
- According to another preferred embodiment down-regulation of the ζ-chain of TCR is determined.
- According to another, further preferred embodiment fine needle biopsy TIMC (tumour infiltrating mononuclear cell) being positive to immunoglobulins are determined.
- According to another preferred embodiment fine needle biopsy TIMC being positive to IgG are determined.
- According to a further preferred embodiment fine needle biopsy TIMC being positive to IgA are determined.
- According to another preferred embodiment IL-1Ra is determined.
- According to another preferred embodiment down-regulation of CD28 on CD4+ and/or CD8+ lymphocytes is determined.
- According to another preferred embodiment down-regulation of CD80 and/or CD86 is determined.
- According to another preferred embodiment determination of any other modulation of other immunoregulatory substances is made.
- According to another preferred embodiment the content of IL-1β, IL-1Ra, IL-6, IL-10, IL-17, and/or TNF-α, is determined by using an assay, to determine the amount of an inducing factor inducing IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, activity.
- According to another preferred embodiment the assay utilises any tissue and the determinations are made using any immuno-cyto-histochemical method, any immunoassay including, ELISA, Elispot, RIA and others any blotting technique, including Western blotting, Southern blotting and others, any bioassay, any tissue culture technique, RT-PCR, flow cytometry, cytometric bead array, DNA microarray and/or proteomics.
- According to another preferred embodiment dys-regulatory mechanism substances in tissue from cancer patients, which substances suppress the immune mediated systemic protection resulting in establishment of micrometastases, are identified.
- According to another preferred embodiment patients suffering from potential risk are candidates for adjuvant treatment.
- According to another preferred embodiment the invention encompasses specific staining methods for IgG in PBMC or biopsies, whereby a first method for determining IgG/IC complexes using a staining, is characterized in that peripheral blood mononuclear cells are separated by centrifugation and spun onto microscope slides; the cells are pre-hydrated using Hank's balanced solution and Hepes solution and human serum albumin, are fixed in phosphate-buffered paraformaldehyde supplemented with glucose, are incubated with biotinylated protein G, followed by incubation with alkaline phosphatase-labelled streptavidin, are incubated in alkaline phosphatase substrate in Tris buffer with dimethylformamide, levamisole and Fast-Red TR salt, are counterstained in Mayer's haematoxylin and mounted in Glycergel; or alternatively, after fixation and a washing in Hank's balance solution containing goat serum, the cells are blocked in goat serum and are incubated with mouse anti-human IgG monoclonal antibody, are incubated with Envision, are then incubated with the alkaline phosphatase substrate, are then counterstained in Mayer's haematoxylin and are mounted in Glycergel;
-
- and a second method for determining IgG/IC complexes using a staining, is characterized in that a tissue sample is fixed using phosphate-buffered paraformaldehyde in the presence of glucose, is treated with Hank's balanced solution and Hepes solution, incubated with primary antibody, mouse IgG1 anti-human CD3, followed by incubation with goat-anti-mouse immunoglobulin, followed by incubation with PAP mouse monoclonal antibody; using 3,3′-Diaminobenzidine as a substrate resulting in a brown colour, whereby the presence of IgG is then identified using biotinylated protein G by incubation; followed by incubation with alkaline phosphatase-labelled streptavidin followed by incubation with alkaline phosphatase substrate, dimethylformamide, levamisole, and Fast-Red salt, the cells are then counterstained in Mayer's haematoxylin and mounted in Glycergel producing a a bright red staining for IgG, whereby double-stained cells appeared as red-brown
- A further aspect of the invention includes a kit for quantitative and/or qualitative analysis of amount of and/or certain pattern of dys-regulatory factor and/or factors inducing the production and/or activation of immunoregulatory substances, whereby prognosis of cancer can be determined and the therapeutic efficacy of any anti-cancer treatment can be predicted and monitored, comprising an indicator for the presence of said dys-regulatory factor/s including inducing factor/s.
- According to another preferred embodiment the kit comprises an indicator for the presence of any factor inducing immunoregulatory substances, including cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, and/or TNF-α, and others, activity.
- According to another preferred embodiment the kit comprises a nutrient for peripheral blood mononuclear cells and a determinant for inducing factor for inducing immunoregulatory substances including inducing factors of IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others.
- According to another preferred embodiment it comprises a urine dip stick comprising binding substance/s and/or colour developing reagents.
- According to another preferred embodiment the kit comprises determinants for enzymatic degradation products of tumour substances/extra cellular matrix, ECM.
- According to another preferred embodiment a matrix metalloproteinaseinhibitor is monitored.
- According to another preferred embodiment the kit comprises a determinant for dys-regulatory substances in tissue from cancer patients, which substances suppress the immune mediated systemic protection resulting in the establishment of micrometastases.
- According to another preferred embodiment the amount of cell bound immune complexes, CBIC, is determined.
- A still further aspect of the invention includes use of at least one regulatory mechanism controlling factor of at least one immunoregulatory substance, including inducing factor of the production or biological activity of immunoregulatory substances including cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, for the production of a pharmaceutical preparation to be used for therapeutic control and for minimisation of pathological production of immunosuppresive immunoregulatory substances, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, and/or TNF-α, and others or to stimulate production of immunosupportive immunoregulatory substances in a patient suffering from a cancer and to enhance the efficacy and/or possibility of therapeutic treatment of cancer or modulation of dys-regulatory factors to enhance performance status.
- According to another preferred embodiment a FcR modulating agent is used in the manufacture of a pharmaceuticai preparation for controlling immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, and/or TNF-α, and others, production in a patient suffering from cancer by therapeutically modulating FcR activity.
- According to another preferred embodiment a FcR modulating agent is used in the manufacture of a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, production in a patient suffering from cancer is modulated by therapeutically blocking FcR/FcγR activity.
- According to another preferred embodiment a FcR modulating agent is used in the manufacture of a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, production in a patient suffering from cancer is modulated by cross-linking FcR/FcγR activity.
- According to another preferred embodiment at least one immunoglobulin, FcR antibodies or fragments of antibodies or synthetic constructs including peptides directed to FcR is used in the manufacture of a pharmaceutical preparation for blocking or cross-linking FcR cross-linking.
- According to another preferred embodiment an agent modulating FcγR I, FcγR II and/or FcγR III used to stimulate IL-2 stimulation of clonal expansion of lymphocytes is used in the manufacture of a pharmaceutical preparation.
- According to another preferred embodiment FcR antibodies or fragments of FcR antibodies directed to FcR is used in the manufacture of a pharmaceutical preparation for blocking cross-linking of FcR.
- According to another preferred embodiment anti-FcγR I, FcγR II and/or FcγR III antibodies is used in the manufacture of a pharmaceutical preparation for blocking of FcγR.
- According to another preferred embodiment a compound being able to down-regulate the expression of FcR is used in the manufacture of a pharmaceutical preparation for down-regulating FcR.
- According to another preferred embodiment at least one FcR-blocking substance minimising production of interleukin-1 receptor antagonist is used in the manufacture of a pharmaceutical preparation for blocking the activity of interleukin-1.
- According to another preferred embodiment at least one FcR-modulating soluble receptor, fragment, peptide or synthetic construct directed to the Fc-part of immunoglobulins is used in the manufacture of a pharmaceutical preparation.
- According to another preferred embodiment at least one FcR-modulating enzyme inhibitor is used in the manufacture of a pharmaceutical preparation.
- According to another preferred embodiment at least one FcR-inhibiting matrix metalloproteinase inhibitor is used in the manufacture of a pharmaceutical preparation.
- According to another preferred embodiment any compound blocking production or biological activity of any factor inducing pathological production of one or more cytokines is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokines.
- According to another preferred embodiment any factor inducing IL-6 production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.
- According to another preferred embodiment any factor inducing IL-1β production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.
- According to another preferred embodiment any factor inducing IL-10 production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.
- According to another preferred embodiment any factor inducing IL-17 production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.
- According to another preferred embodiment any factor inducing TNF-α production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.
- According to another preferred embodiment any factor inducing IL-1Ra production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.
- According to another preferred embodiment a compound having the ability of inhibiting the activation and/or activity of enzymes generating immunomodulatory fragments is used in the manufacture of a pharmaceutical preparation for inhibiting the activation or activity of enzymes generating immunomodulatory fragments.
- According to another preferred embodiment antibodies directed to enzymes generating immuno-modulatory fragments are used in the manufacture of a pharmaceutical preparation.
- According to another preferred embodiment at least one monoclonal antibody, anti-integrin antibody, peptide and/or synthetic construct thereof is used in the manufacture of a pharmaceutical preparation.
- A further aspect of the invention includes a pharmaceutical composition comprising a regulatory mechanism controlling factor of an inducing factor of the production or biological activity of immunoregulatory substances including one or more cytokines, for the production of a pharmaceutical preparation to be used for therapeutically control and minimise pathological production of immunosuppresive immunoregulatory substances including one or more cytokine, or or to stimulate production of an immunosupportive immunoregulatory substance in a patient suffering from a cancer to enhance the efficacy and/or possibility of therapeutic treatment of cancer, optionally in combination with therapeutically inert additive to enhance performance status.
- According to another preferred embodiment a FcR modulating agent is present in a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokine production in a patient suffering from cancer by therapeutically modulating FcR activity.
- According to another preferred embodiment a FcR modulating agent is used in the manufacture of a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, production in a patient suffering from cancer is modulated by therapeutically blocking FcR/FcγR activity.
- According to another preferred embodiment at least one immunoglobulin, FcR antibodies or fragments of antibodies or synthetic constructs including peptides directed to FcR is used in the manufacture of a pharmaceutical preparation for blocking or cross-linking FcR activity.
- According to another preferred embodiment an agent modulating FcγR I, FcγR II and/or FcγR III is present to stimulate IL-2 stimulation of clonal expansion of lymphocytes.
- According to another preferred embodiment anti-FcγR I antibodies is present in a pharmaceutical preparation for blocking of FcγR.
- According to another preferred embodiment a compound being able to down-regulate the expression of FcR is present in the pharmaceutical preparation for down-regulating FcR.
- According to another preferred embodiment at least one FcR-blocking substance minimising production of interieukin-1 receptor antagonist is present in the pharmaceutical preparation for blocking the activity of interleukin-1.
- According to another preferred embodiment at least one FcR-modulating soluble receptor is used.
- According to another preferred embodiment at least one FcR-modulating enzyme innibitor is used.
- According to another preferred embodiment at least one FcR-inhibiting matrix metalloproteinase inhibitor is used.
- According to another preferred embodiment a compound having the ability of inhibiting the activation of enzymes generating immunomodulatory fragments is present in the pharmaceutical preparation for inhibiting the activation of enzymes generating immunomodulatory fragments.
- According to another preferred embodiment any factor inducing IL-6 production is used.
- According to another preferred embodiment any factor inducing IL-1β production is used.
- According to another preferred embodiment any factor inducing IL-10 production is used.
- According to another preferred embodiment any factor inducing IL-17 production is used.
- According to another preferred embodiment any factor inducing TNF-α production is used.
- According to another preferred embodiment any factor inducing IL-1Ra production is used in the manufacture of a pharmaceutical preparation for
- According to another preferred embodiment a compound blocking a factor inducing pathological production of immunoregulatory substainces, including one or more cytokine production is present in the pharmaceutical preparation for blocking a factor inducing pathological production of such immunoregulatory substances.
- According to another preferred embodiment antibodies directed to enzymes generating immuno-modulatory fragments are present.
- According to another preferred embodiment at least one monoclonal antibody, anti-integrin antibody, peptide and/or synthetic construct thereof, is used.
- Published data and the experimental results originally presented below are compatible with dys-regulation of the immune system in cancer patients described herein. Flow-
chart 1 shows a summary of the immunoregulatory mechanisms described in this invention. Connections between FcR mediated and dysregulatory factor mediated mechanisms are shown with Roman numericals. - There are two main categories of receptors through which IC can modulate the immune system, receptors for the Fc-part of immunoglobulins and complement receptors. IC can activate complement and receptors for various complement factors are expressed on different types of cells of the immune system. However, large ICs are more complement activating than small ones, which are more immunosuppressive. Thus, binding of complement factors activated by ICs is not a major pathway for induction of immunosuppression.
- It has been demonstrated beyond any doubt that Fc□R binding (Geissmann et al., 2001; Wolf et al., 1996) and cross-linking of FcγR plays a major role in normal immune regulation. (Gessner et al., 1998; Deo et al., 1997; Lin et al., 2001; Ravetch and Bollag, 2001). These receptors can be either stimulatory or inhibitory and their cross-linking modulates the production of a large number of cytokines by peripheral blood mononuclear cells (PBMC).
- Immune complexes, ICs, can influence the activity of various types of cells of the immune system. The effect is highly dependent on the type of cell, which is involved and the characteristics of the immune complexes. In particular the size and whether the immune cells are exposed to soluble or solid phase IC seems to be of importance. Immunocomplexes can be either immunostimulatory or inhibitory depending on their sizes and interaction with different FcRs on immune cells. Large ICs have been demonstrated to be stimulatory whereby small complexes in antigen excess have been demonstrated to be inhibitory to mitogen induced proliferation (e.g. Gupta and Morton, 1981). It has been demonstrated that there is a correlation between the tumour burden and the immunosuppressive activity of immune complexes.
- Serum blocking factors (SBRs) play a major role in immunosuppression in cancer. They have been shown to inhibit both cytotoxic and proliferative activity of lymphocytes from cancer patients (Baldwin, 1976; Bansal et al., 1976; Hellstrbm and Hellstrom, 1974). SBRs were demonstrated to be immunocomplexes (ICs), as their inhibitory activity was lost after dissociation at low pH, but reappeared after reconstitution at neutral pH (Sjögren et al.,1971). Tumour associated antigens can frequently be bound in IC (Kirkwood and Vlock, 1984; Vlock and Kirkwood, 1985). Removal of ICs from cancer patient sera, using protein A, also reduced the inhibitory effect of these sera.
- Data on the prognostic significance of circulating immunocomplexes (CICs) in cancer are somewhat conflicting. In some reports a good correlation to the tumour stage and prognosis has been demonstrated, whereby in others no such correlation was discovered. Based on the results herein this is hardly surprising. The methods used to determine CIC were quite unspecific and were developed to measure only circulating IC. ICs are bound to a large number of cell receptors and the modulatory function of the ICs is mediated via these receptors. It is therefore highly reasonable that ICs are bound to these receptors and that there will be no circulating IC until the receptors are saturated. Thus, cell bound IC will have a profound influence on the function of receptor bearing cells even in the absence of CICs.
- Th1 helper cells are considered to support the development of cytotoxic activity against the tumour. In malignant tumours, however, a predominance of Th2 over Th1 helper cells has been demonstrated repeatedly. Cross-linking of FcγRs is of importance also for this diversion of the immune system, as cross-linking induces production of PEG2 (e.g. Berger et al. 1996), which favours a Th2 situation with production of IL-4, IL-10, etc. IL-4 then inhibits the immune reactivity to the tumour partly by down-regulating monokine production in general, but also by stimulating the production of IL-1Ra . Further, IL-4 stimulates the expression of the inhibitory FcγR II, CD32b, and inhibits expression of the stimulatory receptor CD32a (Pricop et al., 2001). Thus blockade of the FcγR mediated triggering of the Th2 predominance in malignant tumours would certainly improve the immune reactivity to the tumour.
- Cross-linking of FcγR by IC can result in activation or inhibition. The latter can be mediated in several ways:
-
- expression of B7 on monocytes, necessary for co-stimulation in activation of T-cells, is down-regulated;
- increased production of pro-inflammatory monokines, IL-1β, IL-6, TNF-α by monocytes;
- production by monocytes of various substances inhibiting the immune reactivity, e.g., PGE2, TGF-β, sTNF-αR, and IL-1Ra;
- oxidative burst of O2 − radicals, resulting in down-regulation of the ζ-chain of the T-cell receptor;
- down-regulation of IL-12;
- production of interleukin-1 receptor antagonist (IL-1Ra), which blocks the activity of interleukin-1, necessary for immunostimulation, and expression of endothelial adhesion molecules, necessary for recruitment of inflammatory/immune effector cells to the tumours;
- modulation of endothelial cell function.
- Despite that these facts have been known for a very long period of time, it has so far not been suggested that modulation of FcRs/FcγRs is a very attractive therapeutic principle for treatment of the immune system in cancer patients in order that FcR/FcγR mediated immunosuppression is relieved, and the therapeutic efficacy can be significantly improved.
- In the present invention, interleukin-2 (IL-2) stimulated proliferation of PBMC and IL-1Ra production and was chosen as relevant markers for FcγR mediated immunostimulation/suppression.
- It is shown below, that solid phase IgG (mimicking large ICs) together with IL-2 results in a significantly increased proliferative response to PBMCs from healthy individuals, as well as cancer patients compared to cultures where solid phase binding was blocked by pre-incubation with human serum albumin (HSA). This effect is most clearly shown when the culture plates were pre-coated with HSA/IgG allowing a high degree of cross-iinking of FcγR. The proliferative response to IL-2 could be normalised in cancer patients (compared to controls) using this technique. A stimulatory effect of solid phase IgG was also seen when IgG from serum in the culture medium is allowed to bind to the surface of culture wells. This effect is very clear in cultures of PBMCs from healthy individuals but in about 50% of the cancer patients this stimulation is lost. This stimulatory effect in healthy individuals can be inhibited by adding serum from cancer patients to the culture medium. The mechanism for increased proliferative response to IL-2 in the presence of FcγR cross-linking is reasonably due to an increased production of supportive cytokines.
- In this model blockade of FcγR I (CD64), II (CD32), and III (CD16) with F(ab ′)2 fragments of monoclonal antibodies directed to these receptors showed that the enhanced proliferative response was inhibited mainly by anti-FcγR I antibodies. These F(ab ′)2 fragments thus block the receptors in a way similar to that of small immunocomplexes, ICs.
- An immunoregulatory role of CD64 has been demonstrated by (Sutterwala et al., 1998; Szabo et al., 1990 and 1991). The mechanism for the inhibitory effect of anti-CD64 F(ab ′)2 fragment as described below in cultures on solid phase IgG is presumably due to a difference in affinity of the F(ab′)2 fragment and the Fc-part of IgG. A higher affinity of the antibody to the receptor will allow blockade of the receptor despite the competition with solid phase IgG. However, if the immunosuppression of PBMC from cancer patients (low proliferative response to IL-2) is due to FcγR blockade by IC, this can actually be overcome by culturing patient PBMC together with IL-2 on solid phase IgG, that is cross-linking of a few FcγR, will be substituted for by a larger number of FcγRs resulting in stimulation.
- Based on these considerations one inhibitory mechanism, blockade of FcγR I, can be overcome by providing more extensive cross-linking similar to what is achieved in cultures with solid phase IgG.
- The immunomodulatory role of cross-linking of FcγR by solid phase IgG has furthermore been shown by analysing cytokine production in short term cultures of PBMCs with solid phase bound IgG, which in healthy individuals inhibited the production of IL-6. Similarly, in PBMC cultures from both cancer patients and healthy individuals (less frequently) the production of IL-6, IL-1β as well as TNF-α were frequently markedly increased when binding of serum IgG was blocked by pre-incubation of the culture wells with HSA. In accordance with these results the production of IL-1Ra, which is induced by IC or solid phase IgG, was reduced in cultures where solid phase binding of IgG was blocked by pre-incubation with HSA.
- Interleukin-1 (IL-1) plays a fundamental role for the initiation of an immune response. However, in order to avoid an over-reactivity of the immune system, there are several ways, in which the immunostimulatory activity of IL-1 can be kept under control, e.g., soluble IL-1 receptors, and IL-1 receptor antagonist (IL-1Ra), a very potent inhibitor of IL-1 mediated activity (Arend et al., 1998; Dinarello, 1997). The inhibitory role of IL-1Ra has been clearly demonstrated in studies on autoimmune diseases and rejection after allogen organ transplantation.
- The most potent inducer of IL-1Ra is IC. As demonstrated below the production of IL-1Ra is significantly increased by PBMCs isolated from cancer patients. Thus, cell bound immuno-complexes (CBICs), have been demonstrated to be involved in the dys-regulation of the immune system in cancer patients.
- IL-1Ra obviously plays a central role in down-regulation of immune reactivity. As demonstrated here it is frequently expressed in large areas of malignant tumours. This finding is highly compatible with the occurrence of tissue bound IgG in the tumours as IC or solid phase IgG are the most potent inducers of this cytokine.
- Thus two inhibitory mechanisms based on modulation of FcγR will be shown below, viz. blockade of FcγR, which inhibits IL-2 stimulation of clonal expansion of lymphocytes, and induction of the inhibitory cytokine IL-1Ra. In addition, a more extensive cross-linking of FcγR results in normalisation of the suppressed IL-2 induced proliferation in cancer patients.
- As pointed out below a large number therapeutic strategies can be used to avoid this type of down-regulation (Bowles et al., 1997; Fridman et al., 1993). It is demonstrated herein that blocking FcγR II (CD32) by a monoclonal F(ab)-fragment significantly reduces the production of IL-1Ra. An alternative therapeutic option is to inhibit the intra-tumoural protease activity, which is known to enhance the efficacy of FcγR II interaction (Isashi et al., 1998; van derWinkel et al., 1989).
- Thus, the inhibitory effect due to binding of IC to FcγR can be treated using various techniques, e.g. by blocking the inhibitory receptors (see below), by down-modulating the sensitivity of receptors by protease inhibitors or by overcoming the inhibitory effects using more competitive binders/more extensive cross-linking of the receptors. These strategies will be the base for efficient, new therapeutic strategies to overcome immunosuppression in cancer patients.
- An increased serum concentration of IL-6 is often found in cancer patients, especially in patients with advanced disease (Barton, 2001; Blay et al., 1992; Blay et al., 1997; Gadducci et al., 2001; Walther et al., 1998). The source of serum IL-6 is still somewhat unclear and it is generally assumed to be derived from the tumour. It is shown herein that this cytokine is produced in large amounts, in short term cultures, by PBMCs from cancer patients and to a much lesser extent, or not at all, by unstimulated PBMCs from healthy individuals. A high serum concentration of IL-6 is generally related to a paraneoplastic syndrome, poor response to immunotherapy and some types of chemotherapy, as well as a poor prognosis.
- It is shown that large amounts of IL-6 is produced by PBMCs from about 50% of the cancer patients, as shown in malignant melanoma, renal cell carcinoma, and colorectal cancer. An increased production of IL-6 is also found in patients with only a minimal tumour burden, as about 50% of the patients with radically resected stage III melanoma have a significantly increased production of IL-6.
- IL-6 is a pleiotropic cytokine, which acts as an autocrine growth factor in for example renal cell carcinoma and multiple myeloma. It promotes the inflammatory response, induces acute phase reactants as well as IL-1Ra and is involved in the detrimental chronic inflammatory reaction in patients with malignant tumours. It is thus a good marker for dysregulation of the immune system in cancer patients and the paraneoplastic syndrome.
- Production of IL-6 can be induced in various ways, e.g., by IL-1β, and TNF-α, and under certain circumstances also by cross-linking of FcR/FcγR. The degree of cross-linking is of importance for the regulatory effect on the production of IL-6. As shown below, the degree of cross-linking achieved by solid phase binding of serum IgG (from a culture medium) inhibits production of IL-6, as pre-coating the culture wells with HSA (thereby blockIng the binding of IgG) results in a significantly higher production of IL-6 in about 30% of cancer patients with various diagnoses. Similarly, IL-6 production was significantly inhibited in cultures of PBMCs from healthy individuals when the culture wells were coated with IgG instead of HSA alone.
- The mechanism by which isolated PBMCs continue to produce IL-6 in vitro has so far been unresolved. It is shown herein that serum from cancer patients added to PBMCs from healthy individuals, who by themselves do not produce IL-6, induce the production of large amounts of IL-6. As FcγR cross-linking modulates the production of IL-6, sera known to induce this cytokine, were adsorbed by a surplus of protein-G Sepharose to remove all IgG. These adsorbed sera still induced the production of IL-6 even to a greater extent than before adsorption. These results are compatible with that described herein, that is, a reduced interaction of IgG with PBMCs increase IL-6 production. This IL-6 inducing factor has been further characterised by fractionated ultrafiltration, which demonstrates a factor having a molecular weight of less than 50 kD. This factor has also been identified in the urine from cancer patients. The source of this factor was studied and various tumours were minced and extracted with physiological buffers. An IL-6 inducing factor, IL-6IF, is identified in about 60% of the analysed tumours. Similarly, an IL-6 inducing activity has been found in culture conditioned media from squamous cell carcinoma cell lines from the oral cavity.
- Thus this factor, IL-6IF, which has been found in serum and urine, seems to be produced intratumourally. It is neither IL-1β, TNF-α or interleukin-17, as these cytokines could not be found in fractions inducing IL-6.
- The identification of IL-6IF in the urine opens interesting diagnostic possibilities. Based on the urine concentration of IL-6IF a simple diagnostic test can be developed which will give essential information about prognosis and the likelihood of therapeutic success, in particular for treatment where IL-6 is related to a poor response rate. This test will of course also be extremely valuable when it comes to treatment strategies dealing with the elimination of IL-6IF/treatment of the chronic inflammatory reaction in cancer patients.
- Similar to the situation with IL-6 we have also found inducing activity for TNF-α IL-1β and IL-10 in serum and ultra-filtered urine. The number of inducing factors is for the moment unknown but TNF-α inducing activity was found in samples not inducing IL-6. Thus, reasonably several inducing factors are involved in dysregulation of the immune system in cancer.
- The immunosuppressor factor in trauma patients (Easter et al., 1988; Hoyt et al., 1988) was also found to inhibit migration of inflammatory cells. This mechanism might be of importance in immunosuppression in cancer as in untreated patients, inflammatory cells recruited to the tumour generally are found in the stromal areas surrounding the tumour nodules presumably because of inhibition of their migration close to the tumour cells. As fibronectin is of importance for migration it can be envisioned that if the cell receptors normally binding to fibronectin or other ECM-substances in the migration process are blocked by fragments of these substances the cells will no longer be able to migrate. In this context the phenomenon of leukocyte adherence inhibition is of interest as PBMCs from cancer patients under certain conditions demonstrate a highly reduced ability to adhere to plastic or glass surfaces.
- IL-6 has by others been shown to be an inducer of IL-1Ra. However, in the present work based on the available malignant melanoma and renal cell carcinoma materials no correlation between IL-6 and IL-1Ra has been found rather the contrary. FcγR cross-linking inhibits production of IL-6 as shown herein and stimulates IL-1Ra production.
- The role of IL-6IF containing sera in the immunoregulation in cancer is demonstrated by its effect on the proliferative response to IL-2. The type of solid phase IgG binding is obviously of importance for the effect of IL-2. Coating the wells with purified IgG mixed with HSA gives a more powerful stimulatory signal than binding of serum IgG from the culture medium (uncoated cultures). There is thus a marked difference in the proliferative rate in uncoated cultures and HSA coated cultures with a higher proliferative activity in the presence of solid phase IgG. This difference can be inhibited by sera containing IL-6IF, either by interfering with stimulatory mechanisms or by modulating monocytes to increased production of inhibitors, such as PGE2 or IL-1Ra. The inhibitory effect has not been shown in IgG coated cultures, probably because the more forceful effect on the proliferative response to IL-2 under the conditions used.
- The importance of serum factors/soluble factors in dysregulation of the immune system in cancer is furthermore shown by the concomitant immunity phenomenon, which means that immune mediated anti-tumour reactivity can be suppressed in the primary tumour allowing local progression of this tumour while there is still a systemic protection against distant metastases (North, 1985). When, however, the tumour burden is increasing the systemic protection will break down. According to the concept described in this document there will at a certain tumour burden and/or a certain intra-tumoural enzymatic activity be a sufficient systemic concentration of suppressor substances to suppress the immune mediated systemic protection resulting in the establishment of micro-metastases. Thus, by analysing these dysregulatory substances in serum or urine from cancer patients, the patients at high risk of systemic mlcro-metastases can be identified and these patients are those who should be offered adjuvant treatment.
- Matrixmetalloproteases (MMPs), frequently found in tumour tissue, can be induced by inflammatory cytokines and are of importance for degradation of extra cellular matrix proteins (ECMs). This activity is considered to be a pre-requisite for metastatic spread, and neo-angiogenesis. Occurrence of MMPs has, in several studies been shown to correlate to a poor prognosis. Obviously, the proteolytic activity of MMPs will result in various types of degradation products, some of which are known to modulate angiogenesis and the activity of chemokines. The low molecular weight fraction, IL-6IF, described herein can be a proteolytic fragment. The presence of the factor in tumour extracts and in culture conditioned media from squamous cell carcinoma cell lines from the oral cavity suggests this origin. It has also been shown in a large number of studies by others that culture conditioned media contain immunomodulatory/immunosuppressive factors (e.g. Ménétrier-Caux et al., 1999; Heimdal et al., 2000; Heimdal et al., 2001). A similar factor with immunosuppressor activity, supposed to be derived from proteolytic degradation of serum fibronectin, has been described in trauma patients (Easter et al., 1988; Hoyt et al., 1988). Factors derived from enzymatic degradation of ECM can most likely be both stimulatory and inhibitory as various cytokine patterns have been induced by various fibronectin fragments (Beezhold and Personius, 1992 ; López-Moratlla et al., 1995; Takizawa et al., 1995) and also it was recently demonstrated that the expression of various MMPs in malignant melanoma was related to therapeutic response and prognosis (Nikkola et al., 2001).
- The generally found immunosuppressive effect of malignant tumours can thus very well be due to the increased enzymatic/proteolytic activity of the turnours resulting in various immunomoduiatory fragments/fragments of ECM or other tumour substances. In addition to this, the proteolytic activity can also explain the frequent occurrence of a large number of soluble factors of importance for immune reactivity in cancer patients (Salih et al., 2001; Sheu et al., 2001), e.g. sIL-2 receptor, sTNF-α receptors, sCD8, sCD4, sICAM-1, sMHC I, sFcR etc. Intra-tumoural enzymatic activity also seems to be of importance for activtion of pro-TGF-β to active TGF-β (Huber et al., 1992). Based on these considerations intra-tumoural proteolytic activity seems to be a fundamental mechanism by which the malignant tumour manage to divert the tumour bearers defence to the disease.
- The occurrence of proteolytic fragments of ECM in serum and urine from cancer patients (Katayama et al., 1993) also opens the possibility to identify various types of fragments and analyse their prognostic significance. Furthermore, the therapeutic efficacy of matrixmetalloprotease inhibitors (MMPIs) resulting in a reduction/inhibition of the production of fragments of certain importance can be determined by analysing the amount of these fragments in serum or urine. Determination of these fragments will thus be proper surrogate endpoints for MMPI therapy and have the potential to significantly increase the therapeutic activity of these drugs by allowing monitoring whereby efficacious dose schedules can be developed.
- Dysregulation of the immune system by enzymatic/proteolytic fragments from various tumour substances (derived from tumour tissue or plasma proteins) has so far not been described. A large number of inhibitory as well as stimulatory fragments can be produced as a result of the intra-tumoural enzymatic activity. This provides for a new understanding of immunosuppression in cancer patients and new therapeutic possibilities based on proper diagnostic tests.
- All together the data of this invention demonstrate mechanisms whereby dysregulatory factors give rise to a pathological production of proteolytic enzymes and inflammatory cytokines, which also induce the production of proteolytic enzymes by tumour cells, the activity of these enzymes results in an enhanced release of dysregulatory factors, which then further enhance the production of inflammatory cytokines and proteolytic enzymes, thus creating an autocrine loop. The end result of this loop will then be proteolytic enzymes, which will promote angiogenesis and the metastasising potential and divert the immune reactivity to the tumour.
- The dysregulatory inducing factors were further characterised by using 2D-gel electrophoresis and identified after fragmentation using masspectrometry and N-terminal sequence analysis (proteomics technique). The low molecular weight fraction (<30 kD) from urine was analysed by comparing samples from normal healthy controls with samples from patients; by comparing urine samples with and without IL-6 inducing activity; by comparing samples adsorbed and not adsorbed with a surplus of normal PBMCs (responding to IL-6IF). Several proteins/fragments of potential immunoregulatory activity were thereby identified as described below, e.g. fragments of β2-microglobulin, serum albumin and immunoglobulin.
- As these fragments were identified based on their adsorption to PBMCs, demonstrating a high degree of binding, the occurrence of receptors for these protein fragments/peptides on normal PBMCs sensitive to IL-6IF can be postulated. As albumin and β2-microglobulin do not normally bind to these cells, it can be further postulated that fragmentation of these proteins results in conformational changes exposing new structures with a specific binding to receptors on PBMCs. As demonstrated herein. this results in modulation of the immune system. Thus, the basis for a quite new mechanism of immunomodulation in diseases characterised by a high proteolytic activity, e.g. inflammation and cancer, has been discovered.
- Based on identification of IgG and albumin fragments when 2-D gels were compared as described above, these proteins were incubated with MMPs under well-defined conditions. IL-6 inducing activity was found in the supernatants after incubation with MMPs in two different fragmentation buffers. Inducing activity was analysed in cultures with normal PBMCs. In particular incubation of albumin with MMP-1, -2, -3, -13 and incubation of IgG with MMP-2, -3, -7, -13 released IL-6 inducing/modulating activity. Degradation of IgG by MMPs has previously been described (Gearing et al., 2002) and it was suggested that IgG fragments possibly could have a modulatory activity on antibody dependent cellular cytotoxicity (ADCC), but the possibility that these fragments have an immunoregulatory activity in cancer has to our knowledge never been suggested.
- In an other experiment, fragments of an extra cellular matrix substance, collagen, was found to have a strong inhibitory effect on IL-2 induced proliferation.
- It has been described herein described that IL-6IF can be extracted from malignant tumours, e.g. malignant melanoma, renal cell carcinoma, colorectal cancer. These results were confirmed in a new series of experiments, where homogenised tumours were washed three times in PBS or RPMI in order to collect cytokine inducing factors already present in the tumours, so called “preformed inducing factors” (PIF).
- The tumour sections/homogenates (after being thoroughly washed) were incubated for 24 hours at 37° C. together with MMP-2. IL-6 inducing activity could then be demonstrated in of supernatants from several tumours.
- Potentially a large number of proteolytic enzymes can be involved in degradation of various tumour substances, therefore adding possible substrates to homogenised, washed tumour tissue might enhance the production of immunoregulatory factors/fragments. In order to further explore the nature of immunomodulating substances/fragments in tumours and based on the observation, mentioned above, that fragments of albumin, IgG and β2-microglobulin efficiently binds to normal PBMCs, we added albumin or IgG to thoroughly washed tumour sections/homogenates and incubated for 24 h at 37° C. It was then found that addition of IgG and in particular albumin markedly increased the production of IL-6IF as determined in PBMC cultures. Control experiments showed that the enhanced IL-6 inducing activity was not due to any protective activity of the added proteins. Thus it is herein demonstrated that immunomodulating IgG and albumin fragments are produced in the intra-tumoural milieu
- Based on our previous results it might seem amazing that incubation of PBMCs with IgG fragments results in an increased production of IL-6 as pre-coating of culture plates with IgG from serum or an albumin/IgG mixture inhibited IL-6 production. A reasonable explanation to this effect is that the IgG fragments produced by proteolytic degradation manage to block the inhibitory effect of natural IgG. This opens up further interesting possibilities to modulate FcR mediated immune regulation.
- Further analyses of PIF-fractions by isoelectric focusing and preparative electrophoresis have identified two fractions with IL-6 inducing activity, with different pI. Preparative electrophoresis also identified two fractions, of different moiecuiar weight, with activity.
- Conclusions
- Factors dys-regulating the immune system in cancer patients were found in tumour tissue, conditioned culture media from cancer cell lines, serum and urine.
- Control of the intra-tumoural enzymatic/proteolytic activity is thus a fundamental mechanism to control the malignant tumour management of diverting the immune mediated defence system of the tumour bearer against the disease.
- Thus both FcγR cross-linking and dysregulatory inducing factors (ECM enzymatic/proteolytic fragments) play a fundamental role in immunosuppression in cancer patients. Therapeutic control of these dys-regulatory mechanisms will thus improve quality of life, therapeutic response and increased over-all survival.
- As IL-6 is only one product of the dys-regulated inflammatory reaction mentioned herein and often is correlated to production of other cytokines such as IL-1 and TNF-α; the strategy is to block the fundamental dys-regulatory mechanisms in order to down-regulate the detrimental chronic inflammatory reaction.
- The present invention is thus not based on suppression of the activity of e.g., IL-1β, IL-1Ra, IL-6, IL-10, IL-17, and/or TNF-α, and others, but to prevent or minimise their production.
- Definitions
- In the present description the term “tissue” shall be understood to encompass whole blood, serum, plasma, lymphatic fluid, saliva, urine, faeces, ascites, pleural effusion, pus, as well as any tissue, as such including inflammatory cells.
- In the present description the term cancer means: Any new and abnormal growth, specifically a new growth of tissue in which the growth is uncontrolled and progressive.
- Therapeutic Possibilities to Improve Immune Reactivity in Cancer by Modulation of FcRs
- By modulation of FcR either relief of immunosuppression or an enhanced immune activation can be achieved as demonstrated in the present document. Several substances can be used to block FcRs e.g. antibodies or fragments thereof (e.g. F(ab′)2 or Fab-fragments, of Mab directed to FcγR) , peptides (e.g. from the Fc-part of IgG) or synthetic constructs. The interaction between receptor binding ligands and the receptor can also be achieved by blocking the binding site of the ligand by using, soluble FcRs (recombinant) or peptides or synthetic constructs with a specific high binding affinity. Finally, the signal transduction resulting from ligand binding to FcRs can be inhibited by signal transduction inhibitors. In addition to these modes of interfering with FcRs, their reactivity is influenced by proteolytic activity and can thus be modulated by protease inhibitors. In this context MMPIs can be of special interest.
- Alternatively the ligands of FcRs, immunoglobulins or complexed immunoglobulins, can be eliminated and their immunosuppressive activity can thereby be avoided. Recombinant FcRs or synthetic constructs with this reactivity of proper affinity and size can be administered in order that CIC (especially small CICs) are bound and eliminated. To further enhance the elimination of CICs binders of these substances can be linked to small microspheres (less than 3-5 mm if diameter, possibly degradable) which are rapidly taken up by the reticulendothelial system/monocyte macrophage phagocyte system.
- Another therapeutic possibility is to reduce the number of FcRs which can have a negative effect of the immune reactivity to the malignant tumour, e.g. by increasing their shedding or by down-regulation of their expression.
- An alternative to block FcRs, which result in down-regulation of the immune reactivity, can, as has been demonstrated in this document, be to cross-link FcRs in order to overcome immunosuppression. Several possibilities can be used for this pupose, e.g. complexed immunoglobulines/monoclonal antibodies or fragments (Fc) thereof binding to the receptors or synthetic FcR-binding constructs, cross-linking FcR to a degree (number of FcRs of one or several types) achieving optimal immune activation.
- Therapeutic Possibilities to Improve Immune Reactivity in Cancer by Controlling Dys-Regulatory Inducing Factors.
- Inhibition of the fragment's biological activity (e.g. by monoclonal antibodies or fragments or synthetic constructs binding to and inhibiting the biologic activity of the fragments, synthetic constructs binding to the receptors mediating the biologic effect of the fragments, blockade of the receptors on immune cells, protein fragments/peptides interfering with the receptor interaction of the fragments and thereby inhibiting the biological activity of the fragments.); Elimination of the fragments from the body (e.g. by monoclonal antibodies (or fragments) or other “binders” binding to and eliminating the fragments); Signal transduction inhibitors, blocking the effect of receptor binding; Blocking the activity of the “dysregulated signal substances/cytokines.
- If these factors are generated by enzymatic activity resulting in release of immunomodulatory fragments, the following therapeutic possibilities can be envisioned: Inhibition of the production and activation of the relevant enzymes (e.g. by anti-integrin antibodies or suitable peptides); Inhibition of these enzyme activities (e.g. by low molecular weight inhibitors, monoclonal antibodies or peptides);
- Materials and Methods
- Cytospin preparations for immunocytological demonstration of IgG Peripheral blood mononuclear cells (PBMC) were separated as described below and immediately spun down on pre-cleaned microscope slides in a Shandon Cytospin (Shandon Scientific Ltd, UK) at 1000 RPM for 7 min using 100 μl of the PBMC suspension at 5×105/ml. The slides were left to dry at room temperature over night, were then wrapped in parafilm and stored −70° C. until further processed. The cells were pre-hydrated in BSS-HSA (Hank's balanced salt solution (BSS, Gibco BRL, UK) supplemented with 0.01M. Hepes solution and 1% human serum albumin (HSA, Pharmacia&Upjohn,SE), for 15 minutes, fixed in phosphate-buffered 4% paraformaldehyde (PFA, Riedel-de Haen Ag, Germany) supplemented with 5.4 g./l. of glucose for 5 minutes and then washed three times in BSS-HSA, incubated with biotinylated protein G (Sigma Chemical Co, US) at 50 μg/ml for 30 minutes, washed in BSS-HSA followed by incubation with alkaline phosphatase-labelled streptavidin (Dakopatts AB, SE) at a {fraction (1/100)} dilution in BSS-HSA for 30 minutes. After washes in Tris buffered saline (TBS) and incubation for 20 minutes in alkaline phosphatase substrate consisiting of Naphtol AS-MX Phosphate (Sigma) in 0.1 M Tris buffer with Dimethylformamide, 1 M Levamisole (Sigma) and Fast-Red TR salt (Sigma), the sections were again washed in TBS. They were then counterstained in Mayer's haematoxylin for 1 minute and mounted in Glycergel (Dakopatts AB). All incubations were performed in a moist chamber and all antibody and protein-G solutions were prepared in BSS-HSA. Alternatively, after fixation and washing in BBS containing 2% goat serum, the cells were blocked in 10% goat serum for 20 minutes and incubated with mouse anti-human IgG monoclonal antibody (Nordic Immunology) at 1 or 10 μg/ml, washed in BSS containing 2% goat serum, incubated with Envision (Dakopatts AB, SE) for 30 minutes, washed in TBS and incubated with the alkaline phosphatase substrate for 20 minutes after which the sections were again washed in TBS. They were then counterstained in Mayer s haematoxylin for 1 minute and mounted in Glycergel (Dakopatts AB,SE). All incubations were performed in a moist chamber and all antibody solutions contained 2% normal goat serum.
- Preparation of tumour biopsies and immunological staining of tissue sections for IgG
- Biopsies from the resected metastases were immediately snap frozen and stored at −700C until further processed. Frozen tissue sections, 6-7 μm thick, were fixed with 4% PFA for 5 minutes and then washed three times in BSS-HSA. For double-staining, sections were incubated with primary antibody, mouse IgGl anti-human CD3 (Dakopatts AB), at 1 μg/ml for 30 minutes, washed in BSS-HSA followed by incubation with goat-anti-mouse immunoglobulin (Dakopatts AB, SE) at a {fraction (1/25)} dilution in BSS-HSA. Monoclonal mouse IgG1 against an irrelevant antigen (Dakopatts AB, SE) was used as a negative control. The sections were then incubated with PAP mouse monoclonal antibody (Dakopatts AB, SE) at a {fraction (1/25)} dilution in BSS-HSA for 30 minutes. 3,3′-Diaminobenzidine (DAB, Sigma) was used as a substrate, which resulted in a brown colour. The presence of IgG was then identified using 1 or 10 μg/ml biotinylated protein G (Sigma) which was incubated for 30 minutes, washed in BSS-HSA, followed by incubation with alkaline phosphatase-labelled streptavidin (Dakopatts AB, SE) at a {fraction (1/100)} dilution in BSS-HSA for 30 minutes. After washes in TBS and incubation with alkaline phosphatase substrate for 20 minutes, the sections were again washed in TBS. They were then counterstained in Mayer's haematoxylin for 1 minute and mounted in Glycergel (Dakopatts AB, SE). All incubations were performed in a moist chamber and all antibody and protein-G solutions were prepared in BSS-HSA. The alkaline phosphatase staining resulted in a bright red staining for IgG. Double-stained cells appeared as red-brown.
- Preparation of tumour biopsies and immunological staining of tissue sections for interleukin-1 receptor antagonist (IL.1Ra). Paraffin sections, 6-7 μm thick, were de-paraffinised by cooking in a pressure cooker in BSS with 0.01 M Hepes solution and 1% saponin (Sigma) (BSS-saponin) for 6 minutes. The sections were first blocked with 10% normal human AB-serum before staining and were then incubated with biotinylated goat IgG antibodies directed either to interleukin-la or interleukin-1 receptor antagonist (both from R&D Systems, UK) at 10 μg/ml over night, washed in BSS-saponin, incubated with alkaline phosphatase-labelled streptavidin (DAKO, SE) at a {fraction (1/100)} dilution in BSS-saponin containing 2% human AB-serum for 30 minutes. After washes in TBS and incubation with the alkaline phosphatase substrate for 20 minutes, the sections were again washed in TBS and were then counterstained in Mayer s haematoxylin for 1 minute and mounted in Glycergel (Dakopatts, Sweden). All incubations were performed in a moist chamber and all immunoglobulin solutions were prepared in BSS-saponin containing 2% human AB-serum. Staining for interleukin-la was used as a negative control in this context.
- Preparation of peripheral blood mononuclear cells (PBMC) Venous blood was drawn from healthy volunteers or from cancer patients in glass vacuum tubes with acid dextrose citrate solution A as an anti-coagulant (Vacutainer, Becton & Dickinson, N.J.). Erythrocytes were removed by sedimentation on 2% dextrane T500 solution (Amersham Pharmacia Biotech AB, SE) in 0.9% NaCl. Mononuclear cells were then isolated by Ficoll-paque Plus (Pharmacia AB, SE) density gradient centrifugation after which the cells were washed twice in RPMI1640 Dutch's modification (RPMI) (Gibco BRL, Scotland) with 2% human serum albumin (HSA) (Pharmacia & Upjohn, SE). Cell viability was assessed by exclusion of 0.05% Trypan Blue and was always above 95%. The cell suspension was stained with Turks solution and the number of lymphocytes and monocytes in the PBMC preparation were counted in a hemocytometer. PBMCs were suspended in RPMI with 2% HSA and the cell concentration were adjusted to 5×105 lymphocytes/ml.
- PHA stimulated proliferation of PBMC with and without chlorambucil Venous blood was drawn at the indicated time points from RCC patients undergoing IL-2 (Proleukin, Chiron, NL) therapy. Mononuclear cells were isolated by Ficoll-Isopaque (Pharmacia, SE) density gradient centrifugation. 5×104 PBMC in a final volume of 200 μl were seeded into round-bottomed microtiter plates (Corning Inc. NY, US) in culture medium consisting of RPMI 1640 supplemented with 100 IU/ml Penicillin, 100 μg/ml Streptomycin (Flow laboratories) and 10% heat-inactivated, autologous fresh serum. Phytohemagglutinin (PHA, Sigma Chemical Co, MO, US), at a final concentration of 20 μg/ml, and Chlorambucil (CHL, Sigma), at a final concentration of 1 μg/ml, were then added. Cells were cultured for 3 days in a humidified 5% CO2 atmosphere at 37° C. Proliferation was assayed by incorporation of 1.6 □Ci/well of [3H]thymidine (Amersham Int, UK) during the last 18 hr. Mean values of dpm (disintegrations per minute) of triplicate cultures were used for the calculations.
- Measurement of TNF-□□in PHA stimulated cultures PHA-stimulated cultures with or without chlorambucil (1 □g/ml) were set up in parallel as described above for mitogen-stimulated cultures. Supernatants were collected after 72 hours and cells were removed by centrifugation for 5 minutes at 4000 RPM. The SNs were frozen immediately and stored at −70° C. The amount of TNF-α in the SNs was evaluated with an ELISA kit from Immunotech S.A., FR, according to the manufacturer's instructions. The lower limit of detection in this assay was 10 μg/ml.
- Pre-coating of culture plates with HSA and HSA/IgG Round-bottomed, 96−well tissue culture plates (Costar, Corning Inc. NY, US) were pre-coated with HSA only or HSA and pooled human IgG for intravenous injection (Gammagard, Baxter AS, DK). HSA was diluted in RPMI1640 without supplements to a concentration of 10 mg/ml. In some experiments, 1 mg/ml IgG was mixed into a solution of 9 mg/ml HSA in RPMI (HSA/IgG). 200 μl of HSA or HSA/IgG were then added to each well of the plate. The plates were incubated at 4° C. for 30 minutes after which the wells were washed twice with 200 μl of RPMI1640. The coated plates were used immediately.
- IL-2 induced proliferation of PBMC in uncoated and coated culture plates
- 100 μl of RPMI1640 supplemented with 200 IU/ml penicillin, 200 μl/ml streptomycin, 4 mM L-glutamine (all from Sigma Chemical Co. MO, US) and 20% heat-inactivated human serum (autologous or from cancer patients) were added to uncoated, HSA or HSA/IgG coated tissue culture microtiter plates. PBMC, isolated from healthy individuals or patients with metastatic renal cell carcinoma, were diluted in RPMI/2% HSA at a concentration of 5×105/ml and 100 μl were added to the microtiter wells. Interleukin-2 (IL-2, Proleukin, Chiron, NL), at a final concentration of 120 IU/well, was added to some wells. Cells were cuitured for 7 days in a humidified, 5% CO2-atmosphere at 37° C. Proliferation was assayed by incorporation of 1.6 μCi/well of [3H]-thymidine (Amersham Int., UK) during the last 18 hrs. Mean values of dpm (disintegrations per minute) of triplicates were used for the calculations.
- Inhibition of IL-2 induced proliferation of PBMCs by monoclonal antibodies to FcγR.
- Cultures for IL-2 induced proliferation were set up with PBMC from healthy individuals as described above with the exception that the PBMC were first pre-incubated with antibodies against human FcγR as follows: PBMC, at a concentration of 5×105/ml in RPMI/2% HSA, were incubated at room temperature for 30 minutes with 25 μg/ml of F(ab′)2 mouse anti-human CD16 (FcγR III), CD 32 (FcγR II), or CD 64 (FcγR I) (all purchased from Ancell Co. MN, US). 100 μl of the respective antibody-containing cell suspension was then added to the microtiter wells.
- Generation of cell culture supernatants for
monokine determination 100 μl of culture medium consisting of RPMI1640 supplemented with 200 IU/ml penicillin, 200 μg/ml streptomycin, 4 mM L-glutamine (Sigma Chemical, MO, US) and 20% fresh heat-inactivated autologous serum were added to un-coated or −pre-coated microtiter plates followed by 100 μl of PBMC suspension (5×104 lymphocytes) in RPMI/2% HSA. In some experiments Lipoplysaccharide (LPS, Sigma Chemical Co, MO, US) was added at a concentration of 0.05 ng/ml. Cells were cultured in a humidified, 5% CO2 atmosphere at 37° C. Supernatants (SNs) were harvested after 24 hrs and residual cells were removed by centrifugation in a refrigerated centrifuge (Beckman) at 2600×g for 5 minutes. SNs were frozen and stored at −70° C. until monokine concentrations were measured by ELISA. - Monokine ELISAs
- Monokines were assessed by ELISA using the DuoSet ELISA development system for human IL-6, TNF-α or IL-1β (R&D Systems Europe, Ltd. UK) following the manufacturer's recommended procedures. Lower limit of detection was 3.1 μg/ml for IL-6, 15.6 pg/ml for TNF-α and 3.9 μg/ml for IL-1β. IL-10 was detected with a kit from Diaclone Research, FR. The lower limit of detection was 5 μg/ml. Human IL-1Ra was detected with a quantitative sandwich ELISA using a monoclonal mouse anti-human IL-1Ra as capture antibody and a biotinylated goat anti-human IL-1Ra as developing antibody (both from R&D Systems). Briefly, enhanced binding 96-well microtiter plates (Labsystems AB, SE) were coated overnight at room temperature with 10 μg/ml of capture antibody diluted in PBS. After washing in PBS with 0.05% Tween 20 (Sigma Chemical, MO, US) plates were blocked with a blocking buffer consisting of 1% bovine serum albumin (BSA, Sigma), 5% sucrose (Sigma) and 0.05% NaN3 in PBS. PBMC culture SNs or recombinant human IL-1Ra standard (R&D Systems) were diluted in 0.1% BSA and 0.01
% Tween 20 in PBS (dilution buffer) and incubated over night at room temperature. After washing, the biotinylated-developing antibody was added at 100 ng/ml in dilution buffer. This was incubated for 1 hr at room temperature. Plates were washed and alkaline phosphatase (ALP)-conjugated Extravedin (Sigma), at a dilution of 1:10000 in Tris buffered saline with 0.1% BSA was added. Following incubation for 1 hr at room temperature, plates were washed and the amount of bound IL-1Ra was measured by hydrolysis of paranitrophenyl phosphate (Sigma). Optical density was read at dual wavelengths, 405 nm and 570 nm, respectively, in a Multiscan EX microplate reader (Labsystems). The lower limit of detection in this assay was 39 pg IL-1Ra/ml - Inhibition of IL-1Ra Production by PBMC with Antibodies against FcγR II PBMCs, isolated from healthy volunteers were pre-incubated at 1×106/ml in RPMI1640+2% HSA with 5 or 50 μg/ml of azide-free, mouse anti-human CD32 Fab (Medarex Inc. NJ, US) for 1 hr at 37° C. under gentle agitation. The cells (5×105/well) were immediately seeded onto s uncoated or HSA/IgG coated tissue culture microtiter plates in RPMI1640 with 10% heat-inactivated, pooled human AB sera. Supernatants were harvested after 24 hrs, as described under “generations of cell culture supernatants”, and the production of IL-1Ra was measured by ELISA.
- Inhibition of IL-1Ra Production by PBMC with Tosyl
- PBMC (2×106/ml) from healthy volunteers were pre-incubated with various concentrations of Na-p-Tosyl-L-lysine chloromethyl ketone (Tosyl, Sigma) diluted in RPMI1640/20% HSA for 30 minutes at 37° C. after which the cell suspensions were washed three times in RPMI/2% HSA. 100 μl of culture medium consisting of RPMI1640 supplemented with 200 IU/ml penicillin, 200 μg/ml streptomycin, 4 mM L-glutamine (all from Sigma) and 20% fresh heat-inactivated autologous serum were added to the HSA or HSA/IgG pre-coated microtiter plates followed by 100 μl of the PBMC suspensions (5×104 lymphocytes) in RPMI/2% HSA. Cells were cultured in a humidified, 5% CO2 atmosphere at 37° C. Viability of cultured PBMCs were also assessed after 24 hrs by Trypan blue exclusion and found to be 100%. SNs were harvested after 24 hrs and residual cells removed by centrifugation in a refrigerated centrifuge at 2600×g for 5 minutes. SNs were frozen and stored at −70° C. until IL-1Ra concentration was determined by ELISA.
- Preparation of samples for testing of monokine-inducing activity Below it will be described the handling of various samples that were co-cultured with PBMCs from healthy individuals in order to assess monokine-inducing activity. The sampies included human serum and urine (collected from cancer patients and normal healthy individuals), extracts from tumour biopsies and conditioned media from human tumour cell lines. The numbers assigned to patient samples and control PBMcs in the result tables are only valid for that particular table.
- Affinity Chromatography of Human Sera with Protein G-Coupled Sepharose
- Heat-inactivated human serum was passed over a HiTrap protein G-Sepharose HP affinity column (Amersham Pharmacia Biotech AB, SE). The non-binding fraction was eluted with RPMI1640, giving a final dilution effect of ⅕ (20% ) of the original serum. 200 IU/ml penicillin, 200 μg/ml streptomycin, 4 mM L-glutamine (all from Sigma) were added. The eluate was then sterile filtered with a 0.45 μm Millex syringe filter (Millipore Co. MA, US) and used immediately for culture with control PBMC. 100 μl medium with 20% original serum or with 20% protein G non-binding serum from the same source was added to uncoated or HSA-coated microtiter plates together with 100 μl PBMC suspension (5×105/ml). Cell-free SNs were harvested after over-night incubation and tested for monokine activity by ELISA, as described above.
- Ultra Filtration
- All ultra filtrations were carried out using Amicon Centriplus centrifugal filter devices (Millipore Co. MA, US) sterilised by autoclave. Filters with a 3000, 50000, or 100000 molecular weight cut-off were used. The Centriplus filters were washed with RPMI1640 prior to use. The Centriplus filters were spun on a refrigerated centrifuge with a swing-out rotor at 3000×g. Retentates were recovered by inverse centrifugation at 2000×g.
- Serum Samples
- Sera, collected from cancer patients or from normal healthy individuals, were heat-inactivated for 30 minutes at 56° C. and frozen at −70° C. After thawing, sera were diluted in RPMI1640 to a concentration of 20% and either used unfiltered or ultra-filtered, as described below, in co-culture experiments for monokine-induction with control PBMC. Ultra filtered serum fractions consisted of filtrates from 100000 mw cut-off filters, retentates or filtrates from 50000 mw cut-off filters or retentates from serum fractions that had been sequentially spun on a 50000 mw cut-off filter followed by concentration on a 3000 mw cut-off filter. Retentates were reconstituted in RPMI1640 with 200 IU/ml penicillin, 200 μg/ml streptomycin, 4 mM L-glutamine (Sigma) to their original volume. 100 μl of diluted sera (20% ) or ultra filtered serum fractions were added to uncoated or HSA-coated microtiter plates together with 100 μl PBMC suspension (5×105/ml). Cell-free SNs were harvested after over-night incubation and tested for monokine activity by ELISA, as described above.
- Urine Samples
- Approximately 15 ml of urine were collected from cancer patients with renal cell carcinoma or malignant melanoma or from normal healthy individuals. The samples were centrifuged for 10 minutes at 3000×g followed by filtration over a 0.45 μm Millex-HV syringe filter (Millipore). Next the samples were ultra filtered through a 50000 mw cut-off Centriplus filter and the filtrate concentrated on a 3000 mw cut-off filter. The volume of the retentate, collected from the 3000 mw filter was adjusted to 1 ml with RPMI1640. The sample was then again filtered on a 0.45 μm Millex-HV syringe filter and frozen at −70° C. Immediately before co-culture with normal PBMC, the samples were thawed and buffer exchange was performed to RPMI1640 with 200 IU/ml penicillin, 200 μg/ml streptomycin, 4 mM L-glutamine (Sigma) by gel filtration over a Sephadex-G25 (PD-10) desalting column (Pharmacia, SE).
- Extracts from Tumour Biopsies
- Human tumour biopsies from patients with renal cell carcinoma, malignant melanoma or colon carcinoma, were embedded in glycergel (Dakopatts AB, SE) and frozen at −70° C. For generation of tumour extracts, approximately 8 to 20, 50 μm cryostat sections were cut and transferred to 4 ml of cold RPM1640 with 200 IU/ml penicillin, and 200 μg/ml streptomycin (RPMI/PEST) (Gibco BRL) and kept on ice. The sections were centrifuged and resuspended in 0.5 ml fresh RPMI/PEST after-which they were disaggregated in a Medimachine (Dako A/S, DK) using a
sterile Medicon 50 □m unit. The disaggregated sample was suspended in 2 ml RPMI/PEST, vortexed and kept on ice for 0.5 to 2 hrs. The sample was centrifuged 10 minutes at 300×g and the supernatant was harvested. The supernatant was then filter sterilised through a 0.45 μm Millex-HV syringe filter (Millipore). For generation of extracts from fresh tumour biopsies, a newly excised biopsy (about 5 mm3) was disaggregated in a Medimachine (Dako AS), using asterile Medicon 50 μm unit and resuspended in a total volume of 5 ml TCN buffer (50 mM Tris, 50 mM NaCl, 10 mM CaCl2+200 IU/ml penicillin and 200 μg/ml streptomycin). The cell suspension was incubated on ice for 1 hr. The sample contained 2.7×106 cells/ml with a viability of 15%. A cell-free supernatant was harvested after the cells had been pelleted for 10 minutes at 300×g. The supernatant was then filtered through a 0.45 μm Millex-HV syringe filter (Millipore). Supernatants, extracted from frozen or fresh biopsies were then ultra filtered as described above. Before co-culture with control PBMC, the TNC buffer was exchanged to RPMI1640 with 200 IU/ml penicillin, 200 μg/ml streptomycin, 4 mM L-glutamine (Sigma) by gel filtration over a Sephadex-G25 (PD-10) desalting column (Pharmacia). SNs, 100 μl, were added to uncoated microtiter plates together with 100 μl PBMC suspension (5×105/ml). Cell-free SNs were harvested after over-night incubation and tested for monokine activity by ELISA, as described above. - Conditioned Media from Tumour Cell Lines
- Established human, squamous cell carcinoma cell lines, UT-SCC-10 and UT-SCC-20A (a gift from Dr. R. Grenman, University of Turku, Finland) were cultured in 5 ml media consisting of Dulbecco's modified Eagle's medium (DMEM) supplemented with 1 mM L-glutamine, 18 mM Hepes, 0.9% non-essential amino acid solution, 100 IU/ml penicillin, 100 μg/ml streptomycin (all from Gibco) and 100/% heat-inactivated human AB-serum (DMEM) in 25 cm3 cell culture flasks (Costar) at 37° C. and 5% CO2. The medium was decanted off and replaced every 2 to 3 days. When the cells had reached confluence they were trypsinated and reseeded in new flasks. The decanted medium was centrifuged at is 1000×g to remove residual cells and debris and then ultra filtered on Centriplus filters with a 50000 mw cut-off. The filtrate was then concentrated on a 3000 mw filter. In some experiments the retentate from the 50000 mw cut-off filter was also saved. Retentates were resuspended in RPMI1640 to 2.5 ml. Before culture with PBMCs the medium was exchanged to RPMI1640 with 200 IU/ml penicillin, 200 μg/ml streptomycin, 4 mM L-glutamine (Sigma) by gel filtration over a Sephadex G-25 (PD-10) desalting column (Pharmacia). In some experiments parallel culture flasks containing only culture medium and no tumour cell lines were set up as a control. Supernatants from these flasks were treated exactly the same as supernatants from flasks containing cells. Filtrates and retentates were saved at 4° C. before co-culture with normal PBMC. SNs, 100 μl, were added to uncoated or HSA-coated microtiter plates together with 100 μl PBMC suspension (5×105/ml). Cell-free SNs were harvested after over-night incubation and tested for monokine activity by ELISA, as described above.
- Affinity chromatography with gelatine-coupled Sepharose
- Pre-swelled gelatine Sepharose 4B (Pharmacia Biotech AB, SE) was washed three times in PBS or RPMI1640. 0.3-0.5 ml Sepharose gel was incubated together with the 3-50 kD fractions of ultra filtered serum, diluted in 2-2.5 ml RPMI1640 for 30 minutes at room temperature. The gel was mixed gently by inversion approximately every 10 minutes. An equal portion of the ultra filtered serum sample was incubated in parallel without gelatine Sepharose, as a negative control. The gel was allowed to settle and the supernatant collected. Buffer exchange to RPMI1640 with 200 IU/ml penicillin, 200 μg/ml streptomycin, 4 mM L-glutamine (Sigma) was performed by gel filtration over a Sephadex-G25 (PD-10) desalting column (Pharmacia) followed by filtration on a 0.45 μm Millex-HV syringe filter (Millipore). SNs, 100 μl, were added to uncoated microtiter plates together with 100 μl of control PBMC suspension (5×105/ml). Cell free SNs were harvested after over-night incubation and tested for monokine activity by ELISA as described above.
- Sample Preparation for Proteomics
- Urine samples (100-450 ml) from cancer patients or healthy controls were ultra centrifuged on Jumbosep centrifugal devices (Pall Life Science, MI, US) using a 30 K membrane insert or alternatively, with a Proflux M12 system using a 30
K Pellicon 2 mini filter (Millipore, Mass., US) followed by concentration on Jumbosep with a 3K membrane insert. The urine fraction, 3-30 KD, was tested for monokine-inducing activity as previously described herein. Protein concentrations were determined by Bio-Rad protein assay (Bio-Rad Laboratories, CA, US). Samples were desalted over a Sephadex-G25 (PD-10) column (Amersham Biosciences, SE), lyophilised and dissolved in rehydration buffer (8M urea, 4% CHAPS, 10 mM DTT, 0.5% v/v IPG buffer and a trace of orange G). Samples were centrifuged to remove undissolved material. - 2-DE Gel Electrophoresis
- 2-DE was performed in a horizontal 2-DE set-up (Multiphore/IPGphore, Pharmacia Biotech, SE) as described (Lindahl M. et.al 1998) based on isoelectric focusing (IEF) in the first dimension and molecular mass in the second dimension. Briefly, samples (230 μg, 350 μg, 600 μg) were applied to IPG gels, pH 4-7, (Amersham Pharmacia Biotech, SE) and focused overnight for 48000 Vh. SDS-PAGE was then carried out with 16% T/1% C polyacrylamide casted slab gels. Molecular weight standards were included in each run. Separated proteins were detected by Coomassie blue staining or SYPRO Ruby staining. The protein patterns in the gels were analyzed as digitised images using a CCD (Charged-Coupled Device) camera (1340×1040 pixels) in combination with a computerized imaging 12-bit system, PDQuest Version 6.1.0, in the case of fluorescent stained gels using UV scanning illumination mode (Fluor-S Multi-imager, Bio-Rad). The amount of protein in a spot was assessed as background-corrected optical density, integrated over all pixels in the spot and expressed as integrated optical density (IOD).
- Mass Spectrometry
- Tryptic digests of excised protein spots were performed using MALDI_TOF MS (Voyager-DE PRO, Applied Biosystems, CA, US) as previously described (Ghafouri B. et al. 2002)
- Electrotransfer and N-terminal Sequence Analysis
- Selected protein spots were electro transferred to PVDF membranes and subjected to N-terminal sequence analysis by Edman degradation in a Procise cLC or a Procise HT sequencer (PE-Applied Biosystems) at the Protein Analysis Center, Karolinska Institute, Stockholm, Sweden.
- Proteomics on PBMC-adsorbed urine fractions from cancer patients PBMC were prepared from buffy coat peripheral blood from normal controls as described above. Monokine production by the PBMCs in response to urine fractions from cancer patients was verified as described above. Remaining PBMC were frozen at −70° C. until use. For adsorption of urine fractions, the PBMCs were thawed and washed carefully in cold phosphate buffered saline (PBS). Approximately 50×106 PBMC were added to 2.7 or 2.6 ml, respectively, of ultra centrifuged (3-30 KD) urine fractions pooled from two patients with renal cell carcinoma or from one patient with malignant melanoma. Unabsorbed urine fractions, used as controls, received the equivalent volume of PBS without PBMC. The urine fractions were incubated for 1½ hour at 4° C. The PBMC were then removed by centrifugation. The adsorbed urine fractions were tested for monokine-inducing activity in fresh, normal PBMC as described above. Remaining urine fractions were stored at −70° C. until determination of protein concentration and analysis with 2-D gel electrophoresis, mass spectrometry and N-terminal sequencing as described above.
- Fragmentation of IgG and Serum Albumin using Matrix Metalloproteinases (MMPs)
- MMP -1, -2, -13 (R&D Systems) and MMP-3 and -7 (Chemicon, UK) were activated according to instructions of the manufacturer. 1-50 ng/ml of the indicated MMPs were then incubated with 1 mg/ml of either human serum albumin (HSA, Octapharma, SE) or pooled human IgG for intravenous injection (IvIg, Gammagard, Baxter, DK) as substrate in RPMI or in 50 mM Tris-HCl, pH 7.5 (containing 0.15 M NaCl, 10 mM CaCl2 and 0.05% Brij35). The mixtures were incubated for 5-20 hours at 37° C. Parallel incubations of MMP or the substrates alone, in respective buffer, were set up as controls. The mixtures were buffer exchanged to RPMI as described previously and filtered through a 0.45 μm Millex-HV syringe filter (Millipore, Mass., US). Storing of mixtures, when needed, was performed at −70° C. until analysing by gel-electrophoresis and testing for monokine inducing activity in fresh, normal PBMC as described above.
- IL-2 Induced Proliferation of PBMC in the Presence of Collagen/Collagen Fragments
- Purified collagen from human skin (Sigma) at a concentration of 100 □g/ml was incubated in 100 mM Tris-HCl, pH 7.6, containing 0.15 M NaCl, 10 mM CaCl2 and 0.05% Brij35 over night at 37° C. The buffer was then exchanged to RPMI1640 by gel filtration through a Sephadex-G25 (PD-10) column (Amersham Biosciences) and filtered through a 0.45 μm Millex-HV syringe filter (Millipore) and frozen at −70° C. until use. The collagen was tested for effect on IL-2 stimulated proliferation of PBMC from healthy donors in the presence of autologous serum as described. Final concentration of collagen in the proliferation assay was 26 ug/ml.
- Homogenisation of Tumour Biopsies
- Frozen, human tumour biopsies, embedded in Tissue-Tek OCT Compound (Sakura, NL) or cryostat sections from patients with renal cell carcinoma, malignant melanoma or colon carcinoma were transferred to 3-10 ml of cold RPMI or PBS with 200IU/ml penicillin and 200 μg/ml streptomycin (RPMI/PEST, PBS/PEST) (Gibco BRL) and kept on ice. The tissue was washed three times by centrifugation and resuspension in 3-10 ml cold RPMI/PEST or PBS/PEST. The pelleted, washed tissue was cut into pieces of approximately the same size and each piece was homogenised using a Mikro-Dismembrator U (B. Braun Biotech International, GE). The tissue was transferred to a PTFE shaking flask together with 1 ml RPMI/PEST or PBS/PEST and a tungsten carbide grinding ball and homogenised during 15-20 seconds with a shaking frequency of 1500-2000 RPM. The homogenised tissue suspension was transferred to a test tube and kept on ice.
- Extraction of Preformed Immunomodulationg Factors (PIF) from Homogenised Tumour Tissue
- Human tumour biopsies or cryostat sections were homogenised as described above. The homogenous tissue suspension was washed three times by centrifugation in a final volume of 1.5 ml, 10 ml or 23 ml cold PBS/PEST or RPMI/PEST, as appropriate. The supernatants, containing PIF, was collected, pooled and kept on ice. PIF was then filtered through a 0.45 μm Millex-HV syringe filter (Millipore) and stored at −70° C. Before testing for monokine inducing activity in fresh, normal PBMC as described above, PIF was buffer exchanged to RPMI as described previously and filtered through a 0.45 μm Millex-HV syringe filter (Millipore).
- Homogenised, Washed Tumour Tissue Incubated with Matrix Metalloproteinase-2
- The collection, washing and homogenisation of tumour cryo sections (3×300 μm) were carried out as described above. The pelleted tumour tissue was suspended in 0.5 ml cold RPMI/PEST. MMP-2 (R&D Systems, UK), activated according to instructions from the manufacturer, was added at a final concentration of 5 ng/ml. The tumour tissue suspension was incubated with MMP-2 for 20 h at 37° C. and the supernatant collected after centrifugation. Parallel incubation of tumour tissue with no addition of MMP-2 was set up as a control. The mixtures were buffer exchanged to RPMI by gel filtration through a Sephadex-G25 (PD-10) column (Amersham Biosciences, SE) and filtered through a 0.45 μm Millex-HV syringe filter (Millipore, Mass., US). Finally, the mixtures were analysed by gel-electrophoresis and tested for monokine inducing activity in fresh normal PBMC as described above.
- Homogenised Tumour Tissue and PIF Incubated with Serum Albumin or IgG
- The pelleted homogenised tumour tissue formed during preparation of PIF (se above) was kept on ice and stored at −70° C. PIF were prepared as described above. In one experiment, the homogenised sections were washed once more to collect a fourth supernatant, used as a control reflecting the IL-6 inducing activity in tumour sections before incubation. The fourth supernatant was divided into two parts, to one of which was added 20 mg/ml of HSA and directly frozen at −70° C. The mixtures of homogenised tumour tissue with 20 mg/ml HSA or with 10 mg/ml pooled human IgG for intravenous injection (IvIg), as well as the mixtures of PIF with 20 mg/ml HSA or with 10 mg/ml IvIg, all in RPMI/PEST, were incubated for 18-21.5 h at 37° C. Parallel incubations of tumour tissue and PIF with no addition of HSA or IvIg, as well as RPMI/PEST with addition of HSA or IvIg, were set up as controls. The mixtures were centrifuged and supernatants collected. The supernatants were buffer exchanged to RPMI as described previously and filtered through a 0.45 μm Millex-HV syringe filter (Millipore, Mass., US) and stored at −70° C. until testing for monokine inducing activity in fresh, normal PBMC as described above.
- Statistical Analysis
- Comparisons of the means of different patient groups or different test occasions were performed using an unpaired t-test. Time to progression and survival was analyzed using the Kaplan-Meier method and Logrank test.
- Comparisons between the proliferative response to PHA in different groups or at different test occasions were done on logarithmated mean values of dpm of triplicates using unpaired t-test. For the determination of the effect of addition of CHL on the proliferative response of PHA-stimulated PBMCs, a modulation index (MI) was calculated according to the following formula:
MI=log (dpm PHA+drug/dpm PHA).
Results on Immunoregulatory Mechanisms of Relevance for the Present Invention
Demonstration of Intratumoural IL-1Ra - As described above IL-1Ra is a potent inhibitor of immune stimulation/reactivity as it blocks the activity of IL-1. It is therefore of considerable importance that it is frequently expressed by tumour cells and tumour infiltrating mononuclear cells. Based on the results presented in the above, it is highly reasonable to assume that tissue bound IgG is the inducer of this cytokine. Thus either tissue bound antibodies or intra-tumourally precipitated ICs can play a major role in intra-tumoural down-regulation of the immune response.
FIG. 1 shows melanoma biopsies stained for the expression of IL1Ra. Different patterns are hereby found, viz. A) tumour cells are generally stained with some positive infiltrating mononuclear cells, and B) large numbers of infiltrating cells staining for IL-1Ra, tumour cells only faintly positive. - Production of IL-1Ra in Cultures of PBMC
- Production of IL-1Ra can be induced by some cytokines (Tilg et al., 1994), but FcγR cross-linking by solid phase IgG or ICs seems to be the most efficient inducer of this substance. It has been shown that in cultures where binding of IgG to the surface of the culture well is allowed (uncoated wells) the production of IL-1Ra is significantly enhanced (p<0.0001) compared to cultures where binding of IgG has been reduced by pre-coating with HSA. This immunomodulatory effect has been studied in healthy individuals, patients with malignant melanoma and renal cell carcinoma (
FIG. 2 ). If purified human IgG is added to the HSA in coated wells (HSA/IgG), IL-1Ra production by control PBMC is restored. Based on these results it is obvious that solid phase IgG will play a major role in immune regulation. - In cultures where the wells have been pre-coated with HSA (
FIG. 3A ) a significant difference in IL-1Ra production was found between PBMCs from normal healthy individuals (K; n=46) and melanoma (MM1; n=43) and renal cell carcinoma patients (RCC 1; n=37) with metastatic disease (p=0.017 and p<0.008, respectively). In melanoma patients with radically resected stage III disease (MM 0; n=29) there was only a slight increase in IL-1Ra production. These results provides evidence for an immunomodulating role of cell bound IgG/ICs and that sera from cancer patients contain factors which are bound to PBMCs and are more potent in inducing IL-1Ra than serum factors from normal healthy individuals. It is reasonable to believe that this serum factor is comprised of complexed IgG. In cultures where PBMCs are exposed to solid phase serum IgG (FIG. 3B , uncoated wells) the production is significantly increased as described above and differences between healthy individuals and cancer patients are masked. - The occurrence of tissue bound IgG exposing the Fc-parts, in tumour tissue inducing production of IL-1Ra as described herein is thus highly relevant to the down-regulation of the anti-tumour immune reactivity.
- Inhibition of IL-1Ra production by anti-CD32 fragments. Based on the results described above blockade of the receptor(-s) involved in the induction of IL-1Ra production is a therapeutic strategy. It is demonstrated that pre-incubation of PBMCs from normal, healthy individuals and cancer patients with an anti-CD32 Fab fragment before these cells were set up in cultures on either uncoated or HSA/IgG coated microtitre plates significantly inhibits the production of this cytokine.
TABLE 1 Effect of antibodies to FcγR II, anti-CD32 Fab, on IL-1Ra production by normal PBMC Anti-hu CD32 Fab effect on Anti-hu CD32 Fab effect on cultured PBMC on uncoated cultured PBMC on HSA/IgG culture plates precoated culture plates Anti-hu Anti-hu Anti-hu Anti-hu CD32, CD32, CD32 CD32 None 5 μg/ ml 50 μg/ ml None 5 μg/ ml 50 μg/ ml Ctrl 11) N.D.4) N.D. N.D. 6275 N.D. 2210 Ctrl 229853) N.D. 725 6620 N.D. 1530 Ctrl 34905 2380 560 3075 925 570 Ctrl 46014 N.D. 1926 4969 N.D. 1782 Ctrl 5N.D. N.D. N.D. >10 000 N.D. 5824 Ctrl 6N.D. N.D. N.D. >10 000 N.D. >10 000 Pat. 12) 4330 3095 2200 4195 1520 630 Pat. 2 1180 700 685 1170 735 910 Pat. 3 2870 1415 870 1350 340 180 Pat. 4 >10 000 N.D. 3260 N.D. N.D. N.D.
1)Control PBMC from healthy donors
2)PBMC from cancer patients
3)IL-1Ra, pg/ml
4)Not done
Note:
All PBMCs were pre-incubated with anti-human CD32 Fab 1.o hr, 37° C. before culturing.
- Thus various strategies, which interfere with the cross-linking of the IL-1Ra inducing Fc receptor, are the base of therapeutic strategies, which will relieve immunosuppression and thereby improve the prospect for successful immunostimulating treatment.
- Modulation of FcγR activity by protease inhibitors It has been demonstrated that proteolytic activity increases the reactivity of FcγRII (Isashi et al., 1998 ; van der Winkel et al., 1989). The proteolytic activity is enhanced in malignant tumours; thus protease inhibitors will reduce the reactivity of CD32. Herein it is demonstrated that culturing PBMCs in the presence of non-toxic concentrations of a protease inhibitor, Tosyl, resulted in a significantly reduced production of the immune inhibitory cytokine ILlRa. Thus inhibition of intra-tumoural proteolytic activity offer an excellent therapeutic strategy for treating cancer.
FIG. 4 shows inhibition of ILlRa production by Tosyl. The effect of Tosyl on IL-1Ra production by PBMC from healthy individuals (n=9) in 10% autologous sera cultured in microtiter plates pre-coated with A) HSA, and B) HSA/IgG. - Immunostimulation by FcγR Cross-Linking
- It is demonstrated herein that PBMC cultured on HSA/IgG coated microtitre plates have a dramatically enhanced proliferative response to IL-2 in both normal healthy individuals and cancer patients compared to cultures in HSA coated wells. A similar effect is found when cultures, where IgG from serum in the culture medium is allowed to bind to the microtitre plates (uncoated cultures) and HSA coated cultures are compared.
FIG. 5 shows IL-2 induced proliferation by PBMC from normal healthy individuals (first three bars) and PBMC from RCC patients (last three bars) cultured in 10% autologous sera on uncoated and pre-coated microtiter plates. Significant (p<0.011) difference in proliferation between PBMC from healthy individuals and RCC patients on uncoated plates. - As the same effect on IL-2 induced proliferations are seen in HSA/IgG coated cultures and uncoated cultures; this effect is due to the same mechanism. Solid phase IgG results in a broad cross-linking, which can elicit stimulation of the immune response in normal healthy individuals by eliciting a cytokine cascade including TNF-α and IL-1, which sensitises the response to IL-2 (increased numbers of receptors). This model reflects the situation when opsonised antigens or large ICs elicits an immune response. In HSA coated wells this stimulatory cross-linking can not take place, which results in a significantly lower response to IL-2. Alternatively, the difference in IL-2 induced proliferative response can be due to an immunomodulatory effect by the cross-linking per se and not a stimulatory cytokine cascade. Inhibitory signals in monocytes/macrophages might be overcome by broad cross-linking of FcγR.
- In cancer patients stimulation by FcγR cross-linking (uncoated cultures) does not properly support the proliferative response to IL-2, as demonstrated above. The type of cytokines produced can be inhibitory and does not support an optimal response to IL-2. Preliminary data suggests that serum factor(-s) is of importance for the reduced response of PBMCs from cancer patients in uncoated cultures (
FIG. 6 ). - Effect of FcγR blockade on IL-2 stimulated proliferation The stimulatory effect in HSA/IgG coated cultures is to various degree inhibited by F(ab′)2 Mabs directed to FcγRs, in particular to FcγR I (CD64). This can reflect the effect of small inhibitory ICs.
TABLE 2 Inhibition of IL-2 induced proliferation of PBMC with F(ab′)2 monoclonal antibodies against Fc receptors. Anti-FcRec Mab Coat HSA Uncoated Coat HSA/ IgG Experiment 1 None 30 361 1) 65 030 146 337 Anti-CD16 62 072 84 173 109 417 Anti-CD32 35 106 82 628 126 363 Anti-CD64 30 526 3 219 25 533 Experiment 2None 16 3151) 97 446 102 863 Anti-CD16 10 315 39 023 97 572 Anti-CD32 26 976 56 226 93 153 Anti-CD64 19 634 35 620 45 858
1)3H-Thymidine uptake in counts per minute (cpm) onday 7. Mean of triplicate wells.
Background in wells without IL-2 did not exceed 750 cpm. - Flow cytometry was performed to verify binding of the F(ab′)2 monoclonal antibodies to PBMC. The inhibitory anti-CD64 antibodies bound to a higher percentage of monocytes that anti-CD16, but fewer monocytes than anti-CD32 antibodies, in both experiments. Furthermore, the mean fluorescent intensity of both anti-CD16 and anti-CD32 binding was higher than anti-CD64 in both experiments. Thus, increased binding of the anti-CD64 F(ab′)2 antibody, compared to anti-CD16 and anti-CD32 does not explain the inhibitory effect.
- Effect of FcγR cross-linking on the production of IL-6 in cultures of PBMC
- These results follow under the discussion of modulation of IL-6 production.
- The culture model described above provides for excellent opportunities of studying immunosuppressive regulatory mechanisms in cancer patients.
- Cell bound IgG/ICs in tumor tissue and on PBMCs from cancer patients As IC in cancer patients cause dys-regulation of the immune system, it is important, using suitable diagnostic tools, to identify patients with this kind of dys-regulation in order that patients, who are most likely to respond to therapeutic strategies based on elimination of FcγR inhibitory signals, can be selected. In this context determination of cell-bound ICs (CBIC) is the important invention as these might very well have full activity even in the absence of CIC (circulating immuno complex).
- CBIC can be directly demonstrated by means of
-
- IgG+PBMC (peripheral blood mononuclear cells)
- IgG+TIMC (tumour infiltrating mononuclear cells, demonstrated in surgical or fine needle biopsies, FNA)
- CBIC can also be demonstrated by means of functional parameters such as
-
- production of O2 −
- down-regulation of the ζ-chain of TCR
- down-regulation of CD80 and/or CD86
- induction of IL-1Ra,demonstrated in biopsies and FNA
- induction of other monokines,
whereby a number of these parameters can be demonstrated immunohistochemically.
- Immune complexes (ICs) can be determined in different ways. Standard methods for determining circulating ICs (CIC) are by indirect non-functional parameters as complement binding and activation, PEG-precipitation, phagocytosis, platelet aggregation.
- Determination of CIC, to obtain prognostic information or to diagnose possible occurrence of ICs modulating the immune system, is likely to be irrelevant, as IC has to be bound to cellular receptors to have any immunomodulatory effect. Thus CBIC will have full immunomodulatory effect long before the amount of ICs is enough to saturate these receptors and ICs appear in the circulation. In the present case direct methods has been used to demonstrate the presence of cell/tissue bound IgG or ICs.
- Two methods based on the binding of either a monoclonal antibody or protein G to the Fc part of IgG were used to demonstrate the occurrence of tissue bound IgG or IC. The Mab was directed to the Fc part of all subclasses of human IgG and protein G was genetically modified, binding only to the Fc part of IgG. Thus CBIC can be demonstrated using flow cytometry, or CBIC on blood cells has been demonstrated using immunocytochemistry (IHC) on cytospin preparations. Further CBIC has been demonstrated in tumour tissue (tumour cells, endothelium, tumour infiltrating inflammatory cells) using IHC.
- If the immunohistochemical distribution pattern of stained IgG/IC exclusively coincides with the pattern of the low affinity receptors for IgG (CD16 and CD32) the identified substance is considered being IC. Otherwise it is not possible to discriminate between IgG and IC as the monoclonal antibody and protein G might be able to bind to monomeric IgG as well. However, if IgG is bound to the tissue directly or in IC might be of minor importance as it will anyhow be recognised as “solid phase” IgG.
- Immunocytochemistry of Tumour Tissue
- Several quite different staining patterns have been found in biopsies from untreated and treated melanoma metastases. In the majority of untreated and treated metastases with a poor infiltration of inflammatory cells and with no or only minor tumour regressive changes IgG was found in perivascular areas of the intra-tumoural micro-vessels. In these patients—tumours—the endothelial cells of larger vessels were stained indicating a systemic distribution of IC as endothelial only express CD32 and the bound IgG has to be in the form of complexes.
FIG. 7 shows tumour biopsies stained for the presence of tissue bound IgG/IC (red) and T-lymphocytes (brown) using a double staining technique with recombinant protein G (not binding to albumin). Different staining patterns are shown, viz. A) staining of vascular areas/endothelial cells and some lymphocytes for IgG. Some lymphocytes are not stained for IgG/IC. Low numbers of tumour infiltrating mononuclear cells, B) a diffuse staining of the tumour tissue for IgG/IC, whereby the majority of the lymphocytes are not stained for IgG/IC, C) staining tumour infiltrating macrophages and some lymphocytes for IgG/IC, but tumour cells are generally negative, D) extensive staining of vascular areas for IgG/IC with very low numbers of infiltrating mononuclear cells. - These results show that tissue bound IgG exposing Fc parts, are inversely correlated to the presence of tumour infiltrating mononuclear cells and hence plays a major role in the down-regulation of the immune response to the tumour.
- Immunocytochemistry of PBMC
- Based on the results described above the occurrence of IC binding circulating blood cells was studied in cytospin slides stained using the two methods described. Preliminary results show that a very low frequency of positive monocytes was found in .he majority of heaIthy individuals in contrast to patients with cancer. As monocytes from healthy individuals were generally negative the stained IgG represents IC indicated by the staining of platelets. (
FIG. 8 ). - Chronic inflammatory reaction in cancer using IL-6 as a marker Chronic inflammatory reaction is often found in cancer patients. Interleukin-6 is a proinflammatory cytokine of importance for the initiation of immune reactivity (Barton, 1996; Barton, 2001). However, in cancer patients, its occurrence has a number of detrimental effects. Inflammatory cells, vascular endothelium and several types of tumour cells produce it. It has activity as autocrine growth factor in at least some malignancies, e.g., myeloma and renal carcinoma. It can interfere with the cytotoxic activity of cisplatinum (Borsellino et al., 1995; Mitzutani et al., 1995). It participates in the induction of acute phase reactants, e.g., fibrinogen and CRP. In this context it can be involved in a positive regulatory loop as the production of fibrin split products have been found to be inducers of IL-6. This is one of the cytokines, which seems to be involved in the paraneoplastic syndrome of cancer patients and high serum levels of this cytokine are often associated with poor response to immunotherapy. Besides, these cytokines are not produced in healthy individuals. In cancer patients, however, PBMCs (as shown above) are triggered to produce considerable amounts of IL-6 in vivo and continue to do so also in vitro. Except for cytokines, such as IL-1β, IL-17 and TNF-α, a cross-linking of FcγR is a mechanism by which monocytes are triggered to produce IL-6. Thus, CBIC is of importance for the dys-regulation of the immune system in cancer.
- Various cytokines, IL-1β, IL-6, TNF-α, PGE2, TGF-β are often increased in cancer patients. (Mocellin et al., 2001) Several of these IL-1β, IL-6, and TNF-α are supposed to be involved in the paraneoplastic syndrome characterized by low-grade fever, anorexia, weight-loss, and fatigue.
- An increased systemic concentration of IL-6 has been reported to correlate with a poor prognosis and poor response to chemotherapy (Borsellino et al., 1995; Mitzutani et al., 1995). Furthermore, it is well documented that patients with high IL-6 serum levels (increased CRP) can not be successfully treated with immunotherapy. (Blay et al. 1992; Deehan et al., 1994; Lissoni et al., 1999; Tartour et al., 1996).
- PGE2 is well known to be a potent inhibitor of immune reactivity. Thus patients with high serum levels of PGE2 before treatment or having an increased production of PGE2 during the early treatment period will not respond to immunotherapy. (Deehan et al., 1994)
- An increased production of O2 − radicals by monocytes has been demonstrated to down-regulate the ζ-chain of the T-cell receptor resulting in a non-functional state of these cells. (Kono et al., 1996;Otsuji et al., 1996)
- Therapeutic control of the dys-regulatory mechanisms of IL-6 production will thus improve quality of life, therapeutic response to immuno- and chemotherapy, and increase over-αll survival.
- As IL-6 is only one product of the dys-regulated inflammatory reaction mentioned, and often correlates to production of the other cytokines such as IL-1β and TNF-α, the strategy is to find the fundamental dys-regulatory mechanisms and block them in order to completely down-regulate the inflammatory reaction.
- IL-6 production in cancer patients, correlation to prognosis The present analysis includes IL-6 production from PBMCs from three types of cancer patients. As shown in Table 3, 30 patients with radically resected stage III melanoma (MMO), 43 patients with previously untreated metastatic melanoma (MR1) 36 with previously untreated metastatic renal cell carcinoma (RCC1) and 46 patients with primary colorectal cancer (CRC) were studied. The cytokine production is, compared to that of healthy individuals (K), significantly increased in all categories. It is obvious that IL-6 production is not restricted to patients with advanced disease as IL-6 is produced also by PBMCs from patients with primary colorectal cancers and radically resected stage III melanoma (MM 0), whereby in the latter group no metastatic lesions could be demonstrated by clinical or radiological investigations. A correlation between IL-6 production by PBMCs and other clinical parameters was demonstrated for colorectal cancer and renal cell carcinoma.
- The serum concentration of IL-6 was determined in melanoma, colon and renal cell carcinoma patients and was generally below the detection limit of the ELISA-technique used. In only a few cases measurable amounts of IL-6 were found but these were quite negligible compared to those found in cultures.
TABLE 3 Production of IL-6 by PBMCs from healthy individuals and various types of cancer patients. t-test No of Mean value compared Group patients pgIL-6/ml +SE with controls K 49 214 85 — MM 030 2444 978 p > 0.0001 MM 143 3838 1279 p > 0.0001 RCC 136 4003 935 p > 0.0001 K 12 379 133 — CRC 46 5973 1362 p = 0.042
Colorectal Cancer - As shown in
FIG. 9 , the IL-6 production increases with more advanced primary tumour, the difference between T2N0 and T3-4N0 achieved statistical significance after stimulation with bacterial lipopolysaccharide (LPS) (p=0.05). Also the lymph node status had an impact on the production of this cytokine with higher IL-6 production by PBMCs from patients with lymph node metastases (p=0.02).FIG. 9 shows the production of IL-6 by PBMCs from different subsets of colorectal cancer patients, viz. A), without LPS stimulation and B) with LPS stimulation. - In renal cell carcinoma IL-6 production is of prognostic significance as evident from
FIG. 10 . Patients that produced<2500 pg/ml IL-6 in short term cultures (n=18) showed significantly longer survival than patients that produced>2500 pg/ml (n=23). - Effect of FcγR cross-linking on IL-6 production by PBMCs in vitro The culture conditions have a marked impact on the production of IL-6. If IgG from serum in the culture medium was allowed to bind to the surface of the culture wells, the IL-6 production was significantly lower, compared to cultures, wherein the wells were pre-coated by HSA, in about one third of the patients with malignant melanoma and colorectal cancer (both malignancies analysed together, p=0.001).
- The inhibitory effect of FcγR cross-linking was further demonstrated in PBMC cultures from healthy individuals wherein the culture wells were either pre-coated with HSA/IgG or HSA alone. Also in this situation, solid phase IgG significantly reduced the production of IL-6 by PBMCs from some individuals (
FIG. 11 ). FcγR cross-linking induced by solid phase IgG thus inhibits production of IL-6 in some patients. - The occurrence of this phenomenon in cultures with PBMCs from healthy individuals, as well, is not surprising, as this evidently is one of the normally occurring immunoregulatory mechanisms, the magnitude of which is increased in cancer patients. The difference between patients with and without this type of inhibition is evidently due to triggering of the monocytes or due to the influence of other factors. One explanation may be that a high concentration of a serum factor can induce IL-6 production despite the inhibitory action of FcγR cross-linking. At low concentrations of this factor, the inhibitory action of FcγR cross-linking will take over.
- The evidence given shows the interaction of the two immunoregulatory mechanisms described herein based on the analysis of the results of the different experiments carried out.
- Occurrence and Characterisation of a Serum Factor Inducing IL-6 Production by PBMCs
- Production of IL-6 by PBMCs from in particular cancer patients in vitro, means that either are the producing cells triggered in vivo and maintain this status when placed in culture or there is a serum factor which continuously stimulates production of IL-6. In order to discriminate between these two alternatives, sera from cancer patients, with a high IL-6 production in autologous PBMC cultures, were used in the medium of five cultures with PBMCs from healthy individuals. A high IL-6 production was induced in all these cultures demonstrating occurrence of an IL-6 inducing serum factor.
TABLE 4 IL-6 inducing activity in sera from cancer patients cultured with PBMCs from healthy individuals with blood group 0.Sera IL-6, pg/ ml Patient 1 13129 Patient 22440 Patient 35313 Patient 44951 Patient 525276 Control 11)31.2 Control 231.2 Control 331.2 Patient 62)115 Patient 72)31.2
1)Control from healthy individuals
2)Sera from patients who did not produce IL-6 in vitro
None of the control PBMC made detectable amounts IL-6 when cultured with autologous, normal sera.
Effect of ProteinG-Sepharose affinity chromatography of sera on IL-6 inducing activity - As cancer patients have an increased incidence of CIC and as it has been shown that cross-linking of FcγR can induce IL-6 production by monocytes, the IgG fraction was removed from these sera using affinity chromatography with proteinG-Sepharose. When sera treated in this way were tested in cultures with PBMCs from the same healthy individuals, the IL-6 production was not only maintained but also even increased.
TABLE 5 Effect of ProteinG-Sepharose affinity chromatography of sera on IL-6 inducing activity Autologous Patient sera 1 Patient sera 2Patient sera 3sera (CC1) (CC) (MM2) — Prot G Prot G — Prot G — Prot G Control <31.23 N.D.4 5313 8599 4951 12648 PBMC 1Control <31.2 N.D. 9551 15243 13099 18618 PBMC 2Control <31.2 <31.2 25276 30316 PBMC 3Control <31.2 <31.2 11342 12806 PBMC 4
1CC = colon carcinoma
2MM = malignant melanoma
3pg/ml of IL-6
4N.D. = not done
Patient sera 3 did not contain detectable, endogenous IL-6.Patient sera - Thus, CIC are not involved in inducing IL-6 production, but either CIC or IgG obviously modulate the production as it increased when IgG was removed from the culture medium. This is compatible with the results above where FcγR cross-linking by solid phase IgG inhibited IL-6 production. When IgG is removed from the culture medium, the inhibitory effect is relieved. Affinity chromatography with proteinG-Sepharose had no effect on control sera not inducing IL-6 production. Determination of IgG after affinity chromatography did not find detectable amounts of IgG (<0.01 mg/ml).
- Characterisation of IL-6 inducing factor (IL-6IF) by ultrafiltration In order to confirm that CIC are not the inducer of IL-6 production by PBMCs in cancer patients and also to further characterise the IL-6 inducing factor, sera from cancer patients and healthy individuals were diluted (1:5) and ultrafiltered with a filter cut-off at 100, 50 and 3 kD. In some analyses only a factor with a molecular weight of less than 50 kD was identified, whereas in others IL-6IF was at least to some extent also found in the other fractions, but this activity could always be demonstrated in the less than 50 kD fraction. IL-6 inducing activity was generally not found in the fraction with a molecular weight of less than 3 kD. These results show that IL-6IF has a low molecular weight and thus IgG or CIC can not be involved. The occurrence of this factor in some experiments, also in fractions having a molecular weight >50 kD, indicates either that the IL-6 inducing activity can depend on molecules of different sizes or that a small factor is bound to other serum proteins. The former case is compatible with the assumption that this factor is a proteolytic fragment of some large molecule, and that the activity is present in fragments of different sizes. If the IL-6IF were a small fragment it is certainly likely that it is bound to other serum proteins as it would otherwise immediately be excreted in the urine.
TABLE 6 Activity of ultrafiltered serum fractions Activity of ultrafiltered serum fractions from cancer patients that previously had a stimulating effect on autologous cells and control serum from healthy individuals unfiltered <50 kD1) <3 kD Control sera 12) <31.23) 461 101 Control sera 2<31.2 394 40 Control sera 3<31.2 74 42 Patient sera 14)<31.2 1264 43 Patient sera 2<31.2 1404 <31.2 Patient sera 334 212 <31.2 Patient sera 413 129 9480 N.D.5) Patient sera 52440 986 N.D.
1)Size of ultrafiltered proteins
2)Control serum from healthy individuals
3)IL-6, pg/ml
4)Serum from cancer patients with malignant melanoma
5)N.D. = not done
(Note: All serum fractions were cultured with PBMC from healthy individuals withblood group 0. None of the serum fractions had IL-6 activity when cultured without PBMC)
- The fractions obtained during ultrafiltration of sera described above were also analysed using PAGE electrophoresis of reduced proteins. In the fractions with the highest IL-6 activity a band having a molecular weight of about 20 kD was identified. This was either very weak or not present in all fractions of control sera or patient sera with no IL-6 inducing activity.
- Affinity chromatography of serum using gelatine-Sepharose To further characterise the IL-6IF and also to demonstrate a possible similarity to the “immunesuppresive factor” described by others (Easter et al., 1988;Hoyt et al., 1988) its binding to gelatine-Sepharose was studied. Despite a surplus of the binding gel, IL-6 inducing activity was not reduced when serum, prepared in this way was tested in cultures with control cells.
- IL-6 Inducing Activity in Urine
- As IL-6IF was found to have a molecular weight of less than 50 kD, it is assumed that this factor will at least, to some extent be excreted in the urine. Thus the less than 50 kD fraction was prepared and concentrated using the 3 kD filter. When these fractions from cancer patients were tested for IL-6 production in cultures with PBMCs from healthy individuals an IL-6 inducing activity was found.
TABLE 7 IL-6 inducing activity in ultrafiltered fractions (3 to 50 kD) from urine of cancer patients and healthy individuals Urine Control Control Control from Control PBMC 1PBMC 2PBMC 3PBMC 4Patient 10532 1 (RCC1) Patient >2000 2 (RCC) Patient 1716 3 (RCC) Patient >2000 4 (RCC) Patient >2000 5 (MM3) Control 1698 291 Control 2— 497
1RCC = Renal cell carcinoma
2IL-6, pg/ml
3MM = malignant melanoma
None of the control PBMCs produced detectable amounts (<31.2 pg/ml) of IL-6 when cultured without urine fractions.
- The identification of IL-6IF, or any other inducing factor of an immunoregulatory substance, in the urine opens interesting diagnostic and therapeutic possibilities. When concentration of IL-6IF of urine is related to the serum concentration a simple diagnostic test is made which provides essential information about prognosis and the likelihood of therapeutic success. The diagnosis will also be of value to determine treatment strategies dealing with the elimination of IL-6IF—treatment of the chronic inflammatory reaction in cancer patients.
- IL-6 Inducing Activity in Tumour Extracts
- The origin of IL-6IF is so far unknown. However, it is related to the presence of a malignant tumour. The observation that IL-6IF has a low molecular weight is compatible with its being an enzymatic fragment of some large molecule. It is assumed that this factor is produced in the tumour or by substances released from the tumour. In order to verify this, tumours were minced using a stainless steel mesh and extracted in physiological buffer during various times. In fact, 5 out of 7 analysed tumours produced the factor when the extracts were tested in cultures of PBMCs from healthy individuals. These findings are in agreement with the increased enzymatic activity of tumours as well as the poor prognosis of patients with a high expression of several proteolytic enzymes.
TABLE 8 IL-6 inducing activity in extracts from frozen tumour biopsies and fresh tumour Tumour extracts IL-6 produced by control PBMC CC 1 5641) MM 1313 RCC 1<31.2 RCC 2<31.2 RCC 31078 RCC 41025 RCC 52)1554
1)pg/ml
2)Fresh biopsy
None of the tumour extracts contained detectable endogenous IL-6 activity
None of the control PBMCs produced detectable amounts of IL-6 when cultured in autologous sera without tumour extracts.
All control PBMCs produced >1200 pg/ml of IL-6 when cultured in the presence of Lipopolysaccharide (LPS).
IL-6 Inducing Activity in Conditioned Culture Media from Tumour Cell Lines - Immunomodulating factors have been identified in large numbers at studies of either tumour extracts or conditioned culture media from tumour cell lines. It has now turned out that IL-6IF is produced by squamous cell carcinomas from the oral cavity. Conditioned media were collected and tested using PBMCs from healthy individuals as described. An IL-6 inducing activity was demonstrated and this will facilitate studying therapeutic possibilities such as reduction of IL-6IF by inhibiting different types of tumour related enzymes, such as MMPIs.
TABLE 9 IL-6 inducing activity in ultrafiltered (3 to 50 kD) condition media from a squamous cell carcinoma (SCC) cell line grown in media with fetal calf serum (FCS) or pooled human AB-sera from two different batches AB7, and AB8, respectively. No PBMC Conditioned Control Control Control Control Control Control ( endogenous media PBMC 1 PBMC 2PBMC 3PBMC 4PBMC 5PBMC 6activity) UT- 15591) 925 <31.2 SCC- 10 in FCS Media 221 <31.2 <31.2 FCS, no cells UT- >2000 1753 287 SCC- 10 in AB7 Media 939 718 <31.2 AB7, no cells UT- 3043 6821 <31.2 SCC- 10 in AB 8Media <31.2 2975 <31.2 AB8, no cells
1)IL-6, pg/ml
- Similar to the situation with IL-6 we have also found inducing activity for TNF-□ and IL-1β (Table 10) and IL-10 in serum and ultrafiltered urine. IL-10 was found in four sera/serum fractions and one urine fraction also inducing IL-6. In addition, one serum and one urine fraction inducing IL-6 did not induce IL-10.
TABLE 10 TNF-α and IL-1β inducing activity in IL-6 inducing serum and ultrafiltered urine from cancer patients IL-6 TNF-α IL-1β Source Control PBMC pg/ml pg/ml pg/ ml Patient serum 1 None <31.3 N.D. N.D. Patient serum 1PBMC 113129 1774 414 Patient serum 2None <31.2 86 8 Patient serum 2PBMC 2153 153 14 Patient serum 2PBMC 32440 762 136 Patient urine 1None <31.2 <31.2 <7.8 Patient urine 1PBMC 4>2000 123 147 Patient urine 1PBMC 5>2000 199 128 Patient urine 2None <31.2 <31.2 <7.8 Patient urine 2PBMC 4>2000 166 >500 Patient urine 2PBMC 5>2000 582 >500
N.D. = not done
None of the control PBMCs made detectable levels of IL-6, TNF-α or IL-1β, when cultured in autologous serum.
Possibility to predict therapeutic response to drug therapy of cancer based on induction of cytokines. - We have previously shown that an immune status that correlates to response to immunotherapy can be identified by analysing the effect of immunomodulating drugs on PHA stimulated PBMCs from renal cell carcinoma patients. An increased proliferation in cultures where cimetidine is added identifies responders to interferon-αlpha and a reduced proliferative response to chlorambucil identifies responders to interleukin-2 (
FIG. 12 ). Now we demonstrated that there is a correlation between the effect of chlorambucil on the proliferative response to PHA and on the production of TNF-α in this type of cultures (FIG. 13 ). Thus, in non-responders TNF-α production is more stimulated than in responders. This opens up the possibility to analyse the pattern of inducing factors for these two subsets of patients and thereby identify responders to immunotherapy. - Characterisation of Dysregulating Factors
- Analysis of Cytokine Inducing Factors in Urine
- As described above factors inducing IL-1β, IL-6, IL-10 and TNF-α have been identified in the 3-30 kD fraction in tumour extracts, conditioned culture media from cancer cell lines, and cancer patient sera and urine. These urine factors were further characterised by using 2D-gel electrophoresis and identified after fragmentation using masspectrometry and N-terminal sequence analysis.
- Comparison between healthy controls and cancer patients Comparisons were made between a pool of 11 healthy controls (control pool) and four individual controls and 1. a pool of one breast and one pancreas cancer patient, 2. a pool of two renal cell carcinoma patients and 3. three individual melanoma patients.
- Proteins or fragments of proteins found in the urine fraction from different types of cancer patients but not in healthy controls are shown in Table 11. Some proteins/fragments were found in the urine of several different cancer patients, e.g. albumin/albumin fragments, CD59, plasma retinol binding protein and prostaglandin D2 synthase
TABLE 11 Proteins/protein fragments found in urine fractions from cancer patients, but not in the pool of healthy controls Breast/pancreas Renal cell Malignant Proteins cancer carcinoma melanoma Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Albumin fragments X Alpha-amylase, pancreatic X chain 1 Beta microsemino protein X CD59 X X X Extracellular superoxide X dismutase Heparan sulphate proteoglycan X (Perlecan) Immunoglobulin gamma 1 X chain, C region Immunoglobulin kappa light X chain, C region Immunoglobulin kappa light X chain, C region Immunoglobulin kappa light X chain, C region Immunoglobulin kappa light X chain, C region Immunoglobulin kappa light X chain, C region Inter-alpha-trypsin-inhibitor, X fragment of chain 2Lithostathine 1 alphaX Plasma retinol binding protein X X Prostaglandin D2 synthase X X X Secreted LY-6/uPar related X protein/Anti-neoplastic urinary protein Splice isoform 2 of tropomysin X alpha 3 chain Zinc-alpha-2-glycoprotein, X fragment of chain 3
Comparison between Urine Fractions with and without IL-6 Inducing Activity - In order to further characterise and identify the cytokine inducing factors, comparisons were made between urine samples from melanoma patients with and without IL-6IF activity. As shown in Table 12 several fractions were present in considerably higher amount in urine with IL-6 inducing activity.
TABLE 12 Comparison between melanoma patients with and without IL-6 inducing activity. Proteins over represented in urine fraction from patient with IL-6 inducing activity Alternative protein/s Protein according to spot on Protein/protein fragment analysed masspectormetry 2D gel by masspectometry analysis 1 Beta- microsemino protein 2 CD59 3 CD59 4 CD59 5 Colipase Inhibin beta 6 Extracellular superoxide dismutase 7 Heparan sulphate proteoglycan (Perlecan) 8 Immunoglobulin kappa light chain 9 Immunoglobulin superfamily LIR- D1 precursor member 8 10 IL-13 receptor alpha-1 chain Urokinase plasmin activator surface 11 Inter-alpha-trypsin inhibitor, chain 2Endoplasmic reticulum protein ERP29 12 Lithostathine 1alpha 13 Lithostathine 1 alpha - Analyses of urine fractions before and after adsorption with PBMCs Identification of inducing factors was next done in two experiments by adsorbing urine, containing IL-6IF, with purified PBMCs from healthy controls. The cells chosen for adsorption were shown to be stimulated to produce IL-6 by these urine fractions. The IL-6 inducing activity was significantly reduced by the adsorption procedure (Table 13).
TABLE 13 IL-6 and TNF-alpha inducing activity in adsorbed and unabsorbed urine fractions Urine fraction pooled from two renal cell carcinoma patients Urine fraction added to IL-6 TNF-alpha control Control Control Control Control Control Control PBMCs PBMC 1 PBMC 2PBMC 3PBMC 1PBMC 2PBMC 3None <31.21) 392 <31.2 <31.2 225 67 Unadsorbed 778 942 1433 74 207 179 Adsorbed 311 1031 620 <31.2 59 49 Urine fraction from a patient with malignant melanoma Urine fraction added to IL-6 TNF-alpha control Control Control Control Control Control Control PBMCs PBMC 4 PBMC 5PBMC 6PBMC 4PBMC 5PBMC 6None 167 <31.2 <31.2 94 121 <31.2 Unadsorbed >2000 >2000 55 348 531 38 Adsorbed 1187 1365 <31.2 78 203 <31.2
1)pg/ml
The urine fractions did not contain endogenous IL-6 or TNF-alpha.
- In agreement with this, several proteins disappeared or were found in significantly reduced amounts in the adsorbed fractions as shown in 2D-gel electrophoresis (
FIG. 14 and 15). Reduction in the amount of the proteins was recorded visually and confirmed using densitometry. Adsorbed proteins were identified using masspectrometry. In addition the amino acid sequence of nine proteins/fragments was determined using the Edman sequencing technique. The identified proteins are shown in Table 14 and 15. Amazingly, the majority of these fractions were found to be fragments of normally occurring proteins, such as IgG, β2-microglobulin and serum albumin.TABLE 14 Proteins/protein fragments adsorbed from an IL-6-inducing urine fraction pooled from two patients with renal cell carcinoma by purified normal PBMC. Fragment starting with Spot Protein Sequenced position 1 Albumin fragment No NA 2 Albumin fragment No NA 3 Albumin fragment No NA 4 Albumin precursor Yes 253 5 Albumin precursor Yes 253 6 Albumin precursor Yes 253 7 Albumin precursor Yes 517 8 Albumin precursor Yes 101 9 Alpha-1-microglobulin Yes 21 10 Alpha-1-microglobulin Yes 21 11 Beta-2-microglobulin Yes 22 12 Beta-2-microglobulin Yes 47 13 IgG kappa light chain No NA 14 IgG kappa light chain No NA 15 IgG kappa light chain No NA 16 Zinc-alpha-2- No NA glycoprotein
NA = Not applicable
-
TABLE 15 Proteins/protein fragments adsorbed from an IL-6-inducing urine fraction from a patient with malignant melanoma by purified normal PBMC. Alternative protein/s according to mass Spot Protein spectometry analysis 1 Colipase chain 1Inhibin beta B chain 2 CD59 3 Extracellular superoxide dismutase 4 IL-13 Receptor alpha chain 1Urokinase plasminogen activator 5 Similar to cytokeratin 8IgG heavychain v region, Cell division protein kinase, GMP reductase 2, Vacuolarprotein sorting 26 8 Tumor endothelial marker 1precursor - As these fragments were identified based on their adsorption to PBMCs, demonstrating a high degree of binding, the occurrence of receptors for these protein fragments/peptides on normal PBMCs sensitive to IL-6IF can be postulated. As albumin and 132-microglobulin do not normally bind to these cells, it can be further postulated that fragmentation of these proteins results in conformational changes exposing new structures with a specific binding to receptors on PBMCs. As demonstrated herein this results in modulation of the immune system. Thus, the basis for a quite new mechanism of immunomodulation in diseases characterised by a high proteolytic activity, e.g. inflammation and cancer, has been discovered.
- In conclusion, a large number of fragments, which were not consistently present in urine from healthy control persons, were found in urine from cancer patients. A difference in low molecular weight urine fragments was found between two patients, the urine of whom was either IL-6 inducing or not. This might reflect a significant difference in tumour related proteolytic activity in these two patients. Furthermore, several of these fragments could be adsorbed by PBMCs and different fragments were adsorbed in the two experiments presented herein, again indicating a difference in tumour related proteolytic activity between different patients. As a large number of fragments are generated the further characterisation of dysregulatory inducing factors was done using preparative proteomics, allowing determination of functional activity during preparation, that is after isoelectric focusing and preparative gel-electrophoresis.
- Fragmentation of IgG and Serum Albumin using Matrix Metalloproteinases (MMP)
- Based on the results described above on the binding of IgG and albumin fragments to PBMCs, IgG or serum albumin was incubated with MMPs under well-defined conditions. Two different buffer systems were used in these experiments (
FIG. 16 ). The supernatants were analysed using gel-electrophoresis and their cytokine inducing activity was analysed in cultures with normal PBMCs. As demonstrated inFIG. 16 several MMPs released fragments of IgG and serum albumin, which induced or modulated IL-6 inducing production. In particular, MMP-1, -2, -3, -13 released active fragments from albumin and MMP-2, -3, -7 and −13 from IgG. - Immunomodulating Activity of Extracellular Matrix Substance (ECM) Fragments
- In another experiment, fragments of an extra cellular matrix substance, collagen, was added to IL-2 stimulated cultures of PBMCs from healthy donors. Commercially available collagen contained a large number of fragments and these fragments were found to have a strongly inhibitory effect on IL-2 induced proliferation (
FIG. 17 ). - Extraction of Cytokine Inducing Factors from Tumour Tissue
- We have, in this document, described that IL-6IF can be extracted from malignant tumours, e.g. malignant melanoma, renal cell carcinoma, colorectal cancer. These results were confirmed in a new series of experiments, where homogenised tumours were washed three times in PBS or RPMI in order to collect cytokine inducing factors already present in the tumours, so called “preformed inducing factors” (PIF).
- The occurrence of cytokine inducing factors in these washings was determined in short term cultures with normal PBMCs. As shown in Table 16, a high IL-6 inducing activity was repeatedly found in the PIF-fractions. These fractions were then further analysed using isoelectric is focusing and preparative electrophoresis.
TABLE 16 Induction of IL-6 production in PBMCs from healthy blood donors by factor/s extracted from homogenised tumours by RPMI, so called preformed inducing factors, PIF. Two PIF fractions were tested on PBMCs from 9 and 14 controls, respectively. As can be seen, these fractions efficiently induce production of IL-6 whereas cultures with the buffer, RPMI, alone showed no or only a very low inducing activity. IL-6 Tumor production PIF Control (pg/mL) preparation PBMCs RPMI RPMI + LPS RPMI + PIF 1 1 <6.25 >400 >400 1 2 <6.25 >400 >400 1 3 <6.25 >400 >400 1 4 <6.25 >400 >400 1 5 <6.25 >400 >400 1 6 <6.25 >400 >400 1 7 <6.25 >400 >400 1 8 <6.25 >400 >400 1 9 <6.25 >400 >400 2 10 <6.25 >400 >400 2 11 14 >400 >400 2 12 35 >400 >400 2 13 13 >400 >400 2 14 <6.25 >400 >400 2 15 <6.25 >400 >400 2 16 <6.25 >400 >400 2 17 <6.25 >400 >400 2 18 20 >400 >400 2 19 217 >400 >400 2 20 38 >400 >400 2 21 21 >400 >400 2 22 14 >400 >400 2 23 109 >400 >400
Release of Cytokine Inducing Factors by Incubation of Homogenised, Washed Tumour Tissue with MMPs - In order to reduce the amount of preformed cytokine inducing factors (PIFs) present in the tumours, tissue sections/homogenates were thoroughly washed before addition of proteolytic enzymes, such as MMPs. The tumour sections/homogenates were then incubated for 20 hours at 37° C. IL-6 inducing activity of the supernatants was then analysed in cultures of normal PBMCs. As shown in
FIG. 18 , addition of MMP-2 modulated the release of IL-6 inducing activity. In gel electrophoresis of these supernatants, the albumin band was found to be better preserved in incubations, to which MMP-2 was added. This is reasonably due to an effect of MMP-2 on the degradation of enzymes degrading albumin. It can thus be concluded that MMPs can degrade tumour tissue substances into fragments with cytokine inducing activity. The effect of MMP-2 on the preservation of albumin in these incubations also demonstrates that proteolytic enzymes are involved in the regulation of the intra-tumoural proteolytic activity. A complex interaction of proteolytic enzymes is thus demonstrated and this results in generation and/or modulation of the production of dysregulatory inducing factors. - Increased production of cytokine inducing factors by addition of IgG or serum albumin to washed tumour homogenates/tissue sections. In order to further explore the nature of immunomodulating substances/fragments in tumours and based on the observation, mentioned above, that fragments of albumin, IgG and β2-microglobulin efficiently binds to normal PBMCs, we added albumin or IgG to thoroughly washed tumour sections/homogenates and incubated for 18-22 h at 37° C. It was then found that addition of IgG and in particular albumin markedly increased the production of cytokine inducing factors as determined in PBMC cultures (
FIG. 19 ). In order to rule out that the effect of adding albumin to these incubations was due to a protective action, such as reducing loss because of proteolytic degradation or binding to plastic surfaces, albumin was added to fresh PIF-fractions and incubated at 37° C. for 18 h. Compared to parallel incubations with no addition of albumin, the IL-6 inducing activity was lower when albumin was added, which shows that the markedly increased IL-6 inducing activity after adding albumin to washed homogenates is not due to any protective activity of albumin but rather that albumin acts as a substrate for intra-tumoural proteolytic enzymes. Thus it is demonstrated that immuno-modulating IgG and albumin fragments are produced in the intra-tumoural milieu. - Based on our previous results it might seem somewhat amazing that incubation of PBMCs with IgG fragments results in an increased production of IL-6 as pre-coating of culture plates with IgG from serum or an albumin/IgG mixture inhibited IL-6 production. A reasonable explanation to this apparent discrepancy in effect is that the IgG fragments manage to block the inhibitory effect natural IgG. Thus resulting in an enhanced pathological production of IL-6. This opens up interesting possibilities to modulate FcR mediated immune regulation.
- Analysis and Characterisation of Immunomodulating Factors in Tumour Extracts using “Preparative Proteomics”
- Further analysis of PIF-fractions by isoelectric focusing and preparative electrophoresis has identified two fractions with IL-6 inducing activity, with different pI. Preparative electrophoresis also identified two fractions, of different molecular weight, with activity.
- Abbreviations
-
- ALP; Alkaline phosphatase
- APC; Antigen presenting cell
- BSA; Bovine serum albumin
- BSS; Hank's balanced salt solution
- CBIC; Cell bound immune complex
- CIC, Circulating immune complex
- ConA; Concanavalin A
- CRC; Colorectal carcinoma
- CRP; C-reactive protein
- CTL; Cytotoxic T-lymphocyte
- DAB; 3,3′-Diaminobenzidine
- ECM; Extracellular matrix
- ELISA; Enzyme linked immunosorbent assay
- ESR; Erythrocyte sedimentation rate
- FcR; Fc receptor
- GAH; Goat anti-human IgG antibody
- HSA; Human serum albumin
- IC; Immune complex
- IHC; Immunohistochemistry
- ICAM-1; Intracellular adhesion molecule-1
- IL-1β; Interleukin-1β
- IL-4; Interleukin-4
- IL-6; Interleukin-6
- IL-10; Interleukin-10
- IL-12; Interleukin-12
- IL-17; Interleukin-17
- IL-1Ra; Interleukin-1 receptor antagonist
- IL-6IF; Interleukin-6 inducing factor
- LPS; Lipopolysaccharide
-
MHC 1;Major histocompatibility complex 1 - MM; Malignant melanoma
- MMP; Metalloprotease
- NK-cell; Natural killer cell
- PAP; Peroxidase anti-peroxidase
- PBMC; Peripheral blood mononuclear cell
- PBS; Phosphate buffered saline
- PFA; Paraformaldehyde
- PGE2; Prostaglandin E2
- PHA; Phytohemagglutinin A
- RCC; Renal cell carcinoma
- RIA; Radioimmuno assay
- RtPCR; Reverse transcriptase polymerase chain reaction
- SBR; Serum blocking factors
- TAA; Tumour associated antigen
- TAM; Tumour infiltrating macrophage
- TBS; Tris buffered saline
- TGF-β; Transforming growth factor beta
- Th1;
T helper 1 - Th2;
T helper 2 - TIL; Tumour infiltrating lymphocyte
- TIMC; Tumour infiltrating mononuclear cell
- TNFα; Tumour necrosis factor α
References - Arend W P, Malyak M,
Guthridge C 3, Gabay C. 1998. Interleukin-1 receptor antagonist: Role in biology. Annu Rev Immunol 16:27-55. - Baldwin R W, Robins R A. 1976. Factors interfering with immunological rejection of tumours. Br Med Bull 32:118-123.
- Bansal S C, Bansal B R, Boland J P. 1976. Blocking and unblocking serum factors in neoplasia. Curr topics Microbiol Immunol 75: 45-76.
- Barton B E. 1996. The biological effects of
interleukin 6. Med Res Rev 16:87-109. - Barton B E. 2001. IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation. Immunol Res 23:41-58.
- Beezhold D H. Personius C. 1992. Fibronectin fragments stimulate tumour necrosis factor secretion by human monocytes. J Leuk Biol 51:59-64.
- Berger S, Ballo H,
Stutte H 1. 1996. Immune complex-induced interleukin-6, interleukin-10 and prostaglandin secretion by human monocytes: a network of pro- and anti-inflammatory cytokines dependent on the antigen: antibody ratio. Eur J Immunol 26:1297-1301. - Blay J Y, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani J M, Moskovtchenko 3 F, et al. 1992. Serum level of
interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52:3317-22. - Blay J Y, Rossi J F, Wijdenes J, Menetrier-Caux C, Schemann S, Negrier S, Philip T, Favrot M. 1997. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 72:424-30.
- Borsellino N, Belldegrun A, Bonavida B. 1995.
Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 55:4633-9. - Bowles Goldsmith E, Erickson B W, Thompson N L. 1997. Synthetic peptides from mouse Fc receptor (MoFcγRII) that alter the binding of IgG to MoFcγRII. Biochemistry 36: 952-9.
-
Deehan D 3, Heys S D, Simpson W G, Broom J, Franks C, Eremin O. 1994. In vivo cytokine production andrecombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses. Br J Cancer 69: 1130-5. - Deo Y M, Graziano R F. Repp R, van
de Winkel J G 3. 1997. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies. Immunol Today 18:127-135. - Dinarello C A. 1997. Induction of Interleukin-1 and Interleukin-1 receptor antagonist. Semin Oncol 24: S9-81-S9-93.
- Easter D W, Hoyt D B, Ozkan A N. 1988. Immunosuppression by a Peptide from the Gelatin Binding Domain of Human Fibronectin. J Surg Res 45:370-375. Fridman W H, Teillaud J-L, Bouchard C, Teillaud C, Astier A, Tartour E, Galon J, Mathiot C, Sautes. 1993. Soluble Fcy receptors. J Leuk Biol 54:504-512.
- Gearing A J H, Thorpe S J, Miller K, Mangan M, Varley P G. Dudgeon T, Ward G. Turner C, Thorpe R. 2002. Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin. Immunol Lett 81:41-48.
- Gadducci A, Cosio S, Fanucchi A, Genazzani AR. 2001. Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management. Anticancer Res 21:2941-7.
- Geissmann F, Launay P, Pasquier B, Lepelletier Y, Leborgne M, Lehuen A, Brousse N, Monteiro RC. 2001. A subset of human dendritic cells expresses IgA Fc receptor (CD89), which mediates internalization and activation upon cross-linking by IgA complexes. J Immunol 166:346-52.
- Gessner J E, Heiken H. Tamm A, Schmidt R E. 1998. The IgG Fc receptor family. Ann Hematol 76:231-48.
- Ghafouri B. Stahlbom B, tagesson C, Lindahl M. 2002. Newly identified proteins in human nasallavage fluid from non-smokers and smokers using two-dimensional gel electrophoresis and peptide mass fingerprinting. Proteomics 2:112-120.
- Goldin A, Nicolin A Bonmassar E. 1980. Chemoteraphy immunogenicity. Recent Results Cancer Res 75:185-94.
- Gupta R K, Morton D L. 1981. Possible clinical significance of circulating immune com-ipiexes iri melanoma patients. If Saunders, Serrou,
- Rosenfeld and Denney eds. Fundamental mechanisms in human cancer immunology. Elsevier North Holland Inc. 305-320.
- Heimdal J H, Aarstad H J,
Olofsson J 2000. Monocytes secrete Interleukin-6 when co-cultured in vitro with benign or malignant autologous fragment spheroids from squamous cell carcinoma patients. Scand J Immunol 51: 271-278. - Heimdal J H, Aarstad H J, Olsnes C, Olofsson J 2001. Human autologous monocytes and monocyte-derived macrophages in co-culture with carcinoma F-spheroids secrete IL-6 by a non-CD14-dependent pathway. Scand J Immunol 53: 162-170.
- Hellström K E, Hellström I. 1974. Lymphocyte-mediated cytotoxicity and blocking serum activity to tumour antigens. In Dixon F J and Kunkel H G. Eds. Advances in Immunology. Academic Press. 209-277.
- Hoyt D, Ozkan N, Ninnemann J, Hansbrough J, Pinney E, Wormsley S. 1988. Trauma peptide induction of lymphocyte changes predictive of sepsis. J Surg Res 45: 342-8.
- Huber D, Philipp J, Fontana A. 1992. Protease inhibitors interfere with the transforming growth factor-beta-dependent but not the transforming growth factor-beta-independent pathway of tumour cell-mediates immunosuppression. J Immunol 148:277-84.
- Isashi Y. Yamashita T, Nagasawa S, Tanaka K, Murakaml M, Uede T. 1998. The mechanism by which proteolysis enhances the ligand-binding activity of guinea pig type II Fc receptor for IgG (FcγRIIB). J Biochem 123: 959-67.
- Katayama M, Kamihagi K, Nakagawa K, Akiyama T, Sano Y, Ouchi R, Nagata S, Hino F, Kato I. 1993. Increased fragmentation of urinary fibronectin in cancer patients detected by immunoenzymometric assay using domain-specific monoclonal antibodies. Clinica Chimica Acta 217: 115-128.
-
Kirkwood 3, Vlock D. 1984. Augmentation of autologous antibody to human melanoma following acid dissociation and ultrafiltration of serum. Cancer Res 44: 4177-4182. - Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K,
- Nakazawa T. Anderson P, Kiessling R. 1996. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity.
- Euro Immunol. 26(6):1308-13.
- Lin S-Y, Kinet J-P. 2001. Giving inhibitory receptors a boost. Science 291:445-86.
- Lindahl M, Stahlbom B, Svartz J, Tagesson C. 1998. Protein patterns of human nasal and bronchoalveolar lavage fluids analyzed with two-dimensional gel electrophoresis. Electrophoresis 19:3222-9.
- Lissoni P, Brivio F. Viviani S, Fumagalli L. 1999. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy? J Biol Regul Homeost Agents 13:110-4.
- López-Moratalla N, del Mar Calonge M, López-Zabalza M, Pérez-Mediavilla A, Subirá M, Santiago E. 1995. Activation of human lymphomononuclear cells by peptides derived from extracellular matrix proteins. Biochimica et Biophysica Acta 1265: 181-8.
- Ménétrier-Caux C, Bain C, Favrot M C, Duc A, Blay J Y. 1999. Renal cell carcinoma induces
interleukin 10 and prostaglandin E2 production by monocytes. Br J Cancer 79: 119-130. - Milas L. 2001. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumour radioresponse. Semin Radiat Oncol 11:290-9
- Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O. 1995. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by
anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 55:590-6. - Mocellin S, Wang E, Marincola F M. 2001. Cytokines and immune response in the tumour microenvironment. J Immunother 24:392-407.
- Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari V M, Pyrhonen S. 2001. High collagenase-1 expression correlates with a favourable chemoimmunotherapy response in human metastatic melanoma. Melanoma Res 11:157-66.
- North R. 1985. Down-regulation of the antitumor immune response. Advances in Cancer Research 45:1-43.
- Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. 1996. Oxidative stress by tumour-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci USA 93:13119-24.
- Pawelec G, Heinzel S, Kiessling R, Muller L, Ouyang Q, Zeuthen J. 2000. Escape mechanisms in tumour immunity: a
year 2000 update. Crit Rev Oncog 11:97-133. - Pricop L, Redecha P, Teillaud J-L, Frey J, Fridman W, Sautes-Fridman C,
Salmon 3. 2001. Differential modulation of stimulatory and inhibitory Fcy receptors on human moncytes by Th1 and Th2 cytokines. J Immunol 166: 531-7. - Ravetch J V, Bolland S. 2001. IgG Fc receptors. Annu Rev Immunol 19:275-90.
- Salih HR, Schmetzer HM, Burke C, Starling GC, Dunn R, Pelka-Fleischer R, Nuessle V, Kiener PA. 2001. Soluble cd137 (4-lbb) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies. J Immunol 167:4059-66.
- Sheu B C, Hsu S M, Ho H N, Lien H C, Huang S C, Lin R H. 2001. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 61:237-242.
- Sjogren H O, Hellström I, Bansal S C, Hellstrbm K E. 1971. Suggestive evidence that the “blocking antibodies” of tumour-bearing individuals may be antigen-antibody complexes. Proc Nat Acad Sci USA. 68:1372-5.
- Sulitzeanu D. 1993. Immunosuppressiv factors in human cancer. Adv Cancer Res 60:247-267. Sutterwala FS, Noel GJ, Salgame P, Mosser DM. 1998. Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I. J Exp Med 188:217-22.
- Szabo G, Miller-Graziano C, Wu J H, Takayama T, Kodys K. 1990. Differential tumour necrosis factor production by human monocyte subsets. 3 Leuk Biol 47:206-216.
- Szabo G, Kodys K, Miller-Graziano C. 1991. Elevated monocyte interleukin-6 (IL-6) production in immunosuppressed trauma patients. I. Role of FcγRI cross-linking stimulation. J Clin Immunol 11:326-335.
- Takizawa T, Nishinarita S, Kitamura N,
Hayakawa 3, Kang H, Tomita Y, Mitamura K, Yamagaml K, Horie T. 1995. Interaction of the cell-binding is domain of fibronectin with VLA-5 integrin induces monokine production in cultured human monocytes. Clin Exp Immunol 101:376-382. - Tartour E, Blay J Y, Dorval T, Escudier B, Mosseri V, Douillard J Y. Deneux L, Gorin I, Negrier S, Mathiot C, Pouillart P, Fridman W H. 1996. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol 14:1697-703.
- Tilg H, Trehu E, Atkins M B, Dinarello C A, Mier J W. 1994. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumour necrosis factor receptor p55. Blood 83:113-8.
- Walther M M, Johnson B, Culley D, Shah R, Weber J, Venzon D, Yang J C, Linehan W M, Rosenberg S A. 1998. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol 159:718-22.
- van de Winkel J G J, van Ommen R, Huizinga T W J, de Raad M A H V M, Tuijnman W B. Groenen P J T A, Capel P J A, Koene R A P, Tax W J M. 1989. Proteolysis induces increased binding affinity of the monocyte type II FcR for human IgG. J Immunol 143:571-578.
- Vlock D R, Kirkwood J M. 1985. Serial studies of autologous antibody reactivity to melanoma. J Clin Invest. 76: 849-854.
- Wolf H M, Hauber I, Guile H, Samstag A, Fischer M B, Ahmad R U, Eibl M M. 1996. Anti-inflammatory properties of human serum IgA: induction of IL-1 receptor antagonist and FcaR (CD89)-mediated down-regulation of tumour necrosis factor-alpha (TNF-α) and IL-6 in human monocytes. Clin Exp Immunol 105:537-43.
- Vose B M, Vanky F, Klein E. 1977. Human tumour-lymphocyte interaction in vitro. V. Comparison of the reactivity of tumour-infiltrating blood and lymph-node lymphocytes with autologous tumour cells. Int J Cancer 20:895-902.
Figure Legends -
FIG. 1 shows melanoma biopsies stained for the expression of IL1Ra. Different patterns are hereby found, viz. A) tumour cells are generally stained with some positive infiltrating mononuclear cells, and B) large numbers of infiltrating cells staining IL-1Ra, tumour cells only faintly positive. -
FIG. 2 shows production of IL-1Ra in short term cultures of PBMC from healthy controls and cancer patients. The effect of pre-coating of the culture wells is shown. -
FIG. 3 shows comparison of IL-1Ra production by PBMCs from healthy individuals and melanoma and renal cell carcinoma patients, cultured in A) HSA pre coated wells or B) uncoated wells. -
FIG. 4 shows inhibition of IL1Ra production by Tosyl. The effect of Tosyl on IL-1Ra production (mean ±S.E.) by PBMC from 9 healthy individuals in 10% autologous sera cultured in microtiter plates pre-coated with A) HSA, and B) HSA/IgG. -
FIG. 5 shows IL-2 induced proliferation in healthy individuals and RCC patients. IL-2 induced proliferation (mean ±S.D.) by PBMC from normal healthy individuals (grey bars, 21-29 individuals) and PBMC from RCC patients (black bars, 12-18 individuals) cultured in 10% autologous sera on uncoated and pre-coated microtiter plates. Significant (p=0.011) difference in proliferation between PBMC from healthy individuals and RCC patients on uncoated plates, but not on HSA coated or on HSA/IgG coated plates. Significant (p=0.0045) difference in proliferation between PBMC from RCC patients cultured on uncoated and HSA/IgG coated plates. -
FIG. 6 shows normal PBMC cultured in autologous sera (black bars) or sera from cancer patients (open bars) in the presence of IL-2. Proliferation was measured by 3H-uptake onday 7.Patients patient 112 did not. -
FIG. 7 shows tumour biopsies stained for the presence of tissue bound IgG/IC and T-lymphocytes using a double staining technique with recombinant protein G (not binding to albumin). Different staining patterns are shown, viz. A) staining of vascular areas/endothelial cells and some lymphocytes for IgG. Some lymphocytes are not stained for IgG/IC. Low numbers of tumour infiltrating mononuclear cells, B) a diffuse staining of the tumour tissue for IgG/IC, whereby the majority of the lymphocytes are not stained for IgG/IC, C) staining tumour infiltrating macrophages and some lymphocytes for IgG/IC, but tumour cells are generally negative, D) extensive staining of vascular areas for IgG/IC with very low numbers of infiltrating mononuclear cells. -
FIG. 8 shows cytospins of PBMC from two patients with malignant melanoma stained for the presence of IgG/IC, using recombinant protein-G (A) or monoclonal directed against the Fc-part of IgG. -
FIG. 9 shows IL-6 production by PBMCs from different subsets of colorectal cancer patients. A) without LPS stimulation and B) with LPS-stimulation. -
FIG. 10 shows survival in renal cell carcinoma patients according to IL-6 production by PBMCs in short term cultures where the microtitre plates were coated with HSA. High production is >2500 pg/ml. -
FIG. 11 shows inhibition of IL-6 production by IgG. Production of IL-6 by control PBMCs after culture on uncoated tissue culture wells (n=37), HSA-coated (n=37), or wells coated with HSA/IgG (n=36). -
FIG. 12 shows the effect of chlorambucil on PHA-induced proliferation of PBL from RCC patients before treatment with IL-2. Modulation Index (MI) was calculated as described under Materials and Methods. The assays were performed at the following time points: 1) before start of treatment, 2) one week later, 48 hours after five days of IL-2 treatment, 3) after one week without IL-2 administration and 4) after an additional week, 48 hours after another five days of IL-2 treatment combined with chlorambucil. -
FIG. 13 shows the effect of chlorambucil (CHL) on TNF-α production and proliferation of PHA-stimulated PBMC from RCC patients. PBMC were cultured with PHA in the presence or absence of CHL for 72 hours and the cellular 3H-uptake and the TN-α concentration in cell-free culture supernatants were assessed. Modulation Index was calculated as described under Materials and Methods. Each circle represents one patient. -
FIG. 14 . 2D gel electrophoresis of PBMC-adsorbed and unadsorbed urine fractions pooled from two patients with renal cell carcinoma. 230 ug of protein was loaded per 2D gel. Separated proteins (based on isoelectric focusing in the first dimension and molecular mass in the second dimension) were detected by SYPRO Ruby staining. -
FIG. 15 . 2D gel electrophoresis of PBMC-αdsorbed and unadsorbed urine fractions from a patient with malignant melanoma. 350 ug of protein was loaded per 2D gel. Separated proteins (based on isoelectric focusing in the first dimension and molecular mass in the second dimension) were detected by SYPRO Ruby staining. -
FIG. 16 . Generation of IL-6 inducing factors by incubation of IgG (A and C) and albumin (B and D) with MMPs. Two experiments using different buffer systems are shown (as described in Material and Methods). The substrates were incubated with MMPs for 20 hours in experiments A, B, C and for 5 hours in experiment D. The production of IL-6 was then tested in cultures of PBMCs from healthy controls. -
FIG. 17 . Effect of collagen/collagen fragments on the proliferative response (measured as incorporation of 3H-TdR) of normal PBMCs to IL-2. As can be seen a strong inhibitory effect was demonstrated in two out of three experiments. -
FIG. 18 . Modulation of IL-6 inducing factors by incubation of homogenised, washed tumour tissue with MMP-2. A and B represent two separate experiments with two different tumour tissues in each. The effect of this enzyme varies, dependent on the intra-tumoural milieu of different tumours, but it is clearly shown that MMP-2 has a modulatory effect on the production of IL-6 inducing factor/activity, which was tested in cultures of PBMCs from healthy controls. -
FIG. 19 . Generation of IL-6 inducing factors/activity by incubation of IgG and albumin with homogenised, washed tumour tissue. A and B represent two separate experiments. As shown in these two experiments adding IgG and in particular albumin to tumour tissue markedly increases the production of IL-6 inducing factor/activity, which was tested in cultures of PBMCs from healthy controls.
Claims (78)
1. Method for analysing the amount of tumour derived substances, including receptor-bound immune complexes and proteolytic fragments of tumour tissue substances, wherein said tumor derived substances is a fragment of extracellular matrix, including collagen, fibronectin, and laminin, or a fragment of blood proteins, including albumin, immunoglobulin, and fibrinogen isolated from tumour tissue, blood or urine from cancer patients, characterised in that they have an activity at a molecular weight of 3 to 30 kDa, that they have a capacity to bind to tumour or immune cell receptors and induce the production of cytokines determined in cultures of normal peripheral blood mononuclear cells, whereby the amount of such dys-regulatory mechanism substances is determined by utilising binding substances including antibodies directed to these substances or probes complementary to their DNA and/or RNA in a tissue sample, whereby the prognosis of a subject suffering from cancer can be determined and/or the therapeutic efficacy of any anti-cancer treatment can be predicted and monitored.
2. Method according to claim 1 , for diagnosis of concomitant immunity phenomena by analysing the presence of dysregulatory factors of claim 1 .
3. Method according to claim 1 , wherein tissue is whole blood, serum, plasma, lymphatic fluid, saliva, urine, faeces, ascites, pleural effusion, pus, as well as any tissue, including inflammatory cells.
4. Method according to claim 1 , wherein any compound having the ability of inhibiting the production, activation or activity of enzymes generating fragments of intra-tumoural tissue are determined.
5. Method according to claim 1 , wherein any fragment or new epitopes generated by the activity of intratumoural enzymes is determined in any tissue from a cancer patient.
6. Method according to claim 3 , wherein the activity of any compound having the ability of inhibiting the production, activation or activity of enzymes generating fragments is monitored by determining these fragments or new epitopes exposed by the enzymatic activity in any tissue from a cancer patient.
7. Method according to claim 6 , wherein the inhibiting compound is a matrix metalloproteinase inhibitor.
8. Method according to claim 1 , wherein any compound blocking production or biological activity of a factor inducing pathological production of any dys-regulatory mechanism of immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others including enzymes, production, is determined.
9. Method according to claim 1 , wherein the amount of any inducing factor or mRNA thereof inducing the production of immunoregulatory substances, including one or more cytokines including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α and others, found in tissue, is determined by determining the production of immunoregulatory substances, including cytokines, including IL-1Ra, IL-6, IL-1β and/or TNF-α and others produced by PBMC after exposure to these factors.
10. Method according to claim 1 , wherein samples are obtained in a way, including tubes and syringes, not binding or inactivating immunoregulatory substances, including inducing factors.
11. Method according to claim 1 , wherein the amount of any inducing factor inducing the production of immunoregulatory substances, including one or more cytokines including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, is determined directly.
12. Method according to claim 1 , wherein the amount of any urine present inducing factor inducing the production of immunoregulatory substances, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, is determined by using an urine dip stick containing binding substance/s binding said inducing factor and/or colour developing reagents to said inducing factor.
13. Method according to claim 1 , wherein the amount of cell bound immune complexes, CBIC, is determined.
14. Method according to claim 1 , wherein peripheral blood mononuclear cells PBMC being positive for any immunoglobulin staining are determined.
15. Method according to claim 1 , wherein IL-1Ra is determined.
16. Method according to claim 1 , wherein down-regulation of CD28 on CD4+ and/or CD8+ lymphocytes is determined.
17. Method according to claim 1 , wherein down-regulation of CD80 and/or CD86 is determined.
18. Method according to claim 1 , wherein determination of any other modulation of other immunoregulatory substances is made.
19. Method according to claim 18 , wherein the assay utilises any tissue and the determinations are made using any immuno-cyto-histochemical method, as electrophoresis, chromatography, any immunoassay including, ELISA, Elispot, RIA and others any blotting technique, including Western blotting, Southern blotting and others, any bioassay, any tissue culture technique, RT-PCR, flow cytometry, cytometric bead array, DNA microarray and/or proteomics.
20. Method according to claim 1 , wherein dys-regulatory mechanism substances in tissue from cancer patients, which substances suppress the immune mediated systemic protection resulting in establishment of micrometastases, are identified.
21. Method according to claim 1 for diagnosing of presence/absence of cancer by identifying pathological immunoregulatory substances in cancer and diagnosis of cancer related/tumour derived tissue factor of importance for a cancer patient's performance status, immune mediated anti-tumour reactivity, systemic protection of metastatic disease of a patient suffering from cancer and response to treatment including immuno-, chemo-, bio- and radiotherapy.
22. Method according to claim 21 , wherein said factor is present in tumour tissue and body fluids.
23. Method according to claim 21 , wherein said factor has the ability of inducing cytokines or other immunoregulatory substances.
24. Method according to claim 21 , wherein said factor directly or indirectly has the ability of inducing production of proteolytic enzymes by tumour cells or inflammatory cells.
25. The use of at least one regulatory mechanism controlling factor of at least tumour derived substances, including receptor-bound immune complexes and proteolytic fragments of tumour tissue substances, wherein said tumor derived substances is a fragment of extracellular matrix, including collagen, fibronectin, and laminin, or a fragment of blood proteins, including albumin, immunoglobulin, and fibrinogen isolated from tumour tissue, blood or urine from cancer patients, characterised in that they have an ctivity at a molecular weight of 3 to 30 kDa, that they have a capacity to bind to tumour or immune cell receptors and induce the production of cytokines determined in cultures of normal peripheral blood mononuclear cells, for the production of a pharmaceutical preparation to be used for therapeutic control and for minimisation of pathological production of immunosuppresive immunoregulatory substances, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, and/or TNF-α, and others, including enzymes or to stimulate production of immunosupportive immunoregulatory substances in a patient suffering from a cancer and to enhance the efficacy and/or possibility of therapeutic treatment of cancer or modulation of dys-regulatory factors to enhance performance status.
26. Use according to claim 25 , wherein a FcR modulating agent is used in the manufacture of a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, and/or TNF-α, and others, production in a patient suffering from cancer by therapeutically modulating FcR activity, such as blocking FcR/FcγR activity or cross-linking FcR/FcγR activity.
27. Use according to claim 25 , wherein at least one immunoglobulin, FcR antibodies or fragments of antibodies or synthetic constructs including peptides directed to FcR is used in the manufacture of a pharmaceutical preparation for blocking or cross-linking FcR cross-linking.
28. Use according to claim 26 , wherein an agent modulating FcγR I, FcγR II and/or FcγR III used to stimulate IL-2 stimulation of clonal expansion of lymphocytes is used in the manufacture of a pharmaceutical preparation.
29. Use according to claim 26 , wherein at least one FcR-modulating soluble receptor, fragment, peptide or synthetic construct directed to the Fc-part of immunoglobulins is used in the manufacture of a pharmaceutical preparation.
30. Use according to claim 26 , wherein at least one FcR-modulating enzyme inhibitor is used in the manufacture of a pharmaceutical preparation.
31. Use according to claim 26 , wherein at least one FcR-inhibiting matrix metalloproteinase inhibitor is used in the manufacture of a pharmaceutical preparation.
32. Use according to claim 25 , wherein any compound including any enzymes, blocking production or biological activity of any factor inducing pathological production of one or more cytokines is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokines.
33. Use according to claim 25 , wherein a compound having the ability of inhibiting the activation and/or activity of enzymes generating immunomodulatory fragments is used in the manufacture of a pharmaceutical preparation for inhibiting the activation or activity of enzymes generating immunomodulatory fragments.
34. Use according to claim 25 , wherein antibodies directed to enzymes generating immuno-modulatory fragments are used in the manufacture of a pharmaceutical preparation.
35. Use according to claim 25 , wherein at least one monoclonal antibody, anti-integrin antibody, peptide and/or synthetic construct thereol is used inl tile manufacture of a pharmaceutical preparation.
36. A pharmaceutical composition comprising a regulatory mechanism controlling factor tumour derived substances, including receptor-bound immune complexes and proteolytic fragments of tumour tissue substances, wherein said tumor derived substances is a fragment of extracellular matrix, including collagen, fibronectin, and laminin, or a fragment of blood proteins, including albumin, immunoglobulin, and fibrinogen isolated from tumour tissue, blood or urine from cancer patients, characterised in that they have an-ctivity at a molecular weight of 3 to 30 kDa, that they have a capacity to bind to tumour or immune cell receptors and induce the production of cytokines determined in cultures of normal peripheral blood mononuclear cells or cell lines, to be used for therapeutically control and minimise pathological production of immunosuppresive immunoregulatory substances including one or more cytokine, or to stimulate production of an immunosupportive immunoregulatory substance in a patient suffering from a cancer to enhance the efficacy and/or possibility of therapeutic treatment of cancer, optionally in combination with therapeutically inert additive to enhance performance status.
37. Pharmaceutical composition according to claim 36 , wherein a FcR modulating agent is present in a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokine production in a patient suffering from cancer by therapeutically modulating FcR activity.
38. Pharmaceutical composition according to claim 37 , wherein a FcR modulating agent is used in tihe manufacture of a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, including enzymes, production in a patient suffering from cancer is modulated by therapeutically blocking FcR/FcγR activity.
39. Pharmaceutical composition according to claim 37 , wherein at least one immunoglobulin, FcR antibodies or fragments of antibodies or synthetic constructs including peptides directed to FcR is used in the manufacture of a pharmaceutical preparation for blocking or cross-linking FcR activity.
40. Pharmaceutical composition according to claim 39 , wherein an agent modulating FcγR I, FcγR II and/or FcγR III is present to stimulate IL-2 stimulation of clonal expansion of lymphocytes.
41. Pharmaceutical composition according to claim 39 , wherein anti-FcγR I antibodies is present in a pharmaceutical preparation for blocking of FcγR.
42. Pharmaceutical composition according to claim 39 , wherein any compound blocking production or biological activity of any factor inducing pathological production of one or more cytokines is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokines.
43. Pharmaceutical composition according to claim 36 , wherein a compound having the ability of inhibiting the production, activation of enzymes generating immunomodulatory fragments is present in the pharmaceutical preparation for inhibiting the activation of enzymes generating immunomodulatory fragments.
44. Pharmaceutical composition according to claim 36 , wherein a compound blocking a factor inducing pathological production of immunoregulatory substances, including one or more cytokine production is present in the pharmaceutical preparation for blocking a factor inducing pathological production of such immunoregulatory substances.
45. Pharmaceutical composition according to claim 36 , wherein antibodies directed to enzymes generating immuno-modulatory fragments are present.
46. Pharmaceutical composition according to claim 36 , wherein at least one monoclonal antibody, anti-integrin antibody, peptide and/or synthetic construct thereof, is used.
47. Cancer related/tumour derived tissue factor of importance for a cancer patient's performance status, immune mediated anti-tumour reactivity, systemic protection of metastatic disease of a patient suffering from cancer and response to treatment including immuno-, chemo-, bio- and radiotherapy.
48. Factor according to claim 47 , wherein said factor is present in tumour tissue and body fluids.
49. Factor according to claim 47 , wherein said factor has the ability of inducing cytokines or other immunoregulatory substances.
50. Factor accordinrg to claim 47 , wherein said factor directly or indirectly has the ability of inducing production of proteolytic enzymes by tumour cells or inflammatory cells.
51. Factor according to claim 47 , wherein said factor is a fragment of extra cellular matrix, including collagen, fibronectin and laminin.
52. Factor according to claim 47 , wherein said factor is a fragment of at least one serum protein.
53. Factor according to claim 52 , wherein said factor is a fragment of serum albumin.
54. Factor according to claim 47 , wherein said factor is a fragment of at least one immunoglobulin.
55. Factor according to claim 47 , wherein said factor is a fragment of fibrinogen.
56. Method for increasing efficacy and/or possibility of therapeutic treatment of cancer, wherein, tumour derived substances, including receptor-bound immune complexes and proteolytic fragments of tumour tissue substances, wherein said tumor derived substances is a fragment of extracellular matrix, including collagen, fibronectin, and laminin, or a fragment of blood proteins, including albumin, immunoglobulin, and fibrinogen isolated from tumour tissue, blood or urine from cancer patients, characterised in that they have an activity at a molecular weight of 3 to 30 kDa, that they have a capacity to bind to tumour or immune cell receptors and induce the production of cytokines determined in cultures of normal peripiheral blood mononuclear cells or cell lines, whereby the amount of such dys-regulatory mechanism substances is therapeutically controlled to minimise pathological production or biological activity of such immunoregulatory substances being immunosuppresive, or to stimulate the production of such immunoregulatory substances being immunosupportive to enhance the performance status of the patient and/or to enhance the therapeutic control of a malignant tumour in a subject suffering from a cancer.
57. Method according to claim 56 , wherein the cytokines IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, are therapeutically controlled.
58. Method according to claim 56 , wherein any dys-regulatory mechanism of immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α and others, production in a patient suffering from cancer is modulated by therapeutically treating the patient to provide a FcR modulation by administering a therapeutically effective amount of a FcR modulating agent, such as a FcR/FcγR blocking agent or a FcR/FcγR cross-linking agent.
59. Method according to claims claim 58 , wherein blocking or cross-linking of FcR is carried out using a therapeutically active amount of at least one immunoglobulin, FcR antibodies or fragments of antibodies or synthetic constructs including peptides directed to FcR.
60. Method according to claim 56 , wherein a compound having the ability of inhibiting the production, activation or activity of enzymes generating immunomodulatory fragments is administered in a therapeutically effective amount.
61. Method according to claim 60 , wherein the inhibiting compound is a monoclonal antibody, an anti-integrin antibody, peptides and/or synthetic constructs.
62. Method according to claim 58 , wherein the modulating substance is an enzyme inhibitor.
63. Method according to one or more of the preceding claims claim 58 , wherein the inhibiting compound is a matrix metalloproteinase inhibitor.
64. Method according to claim 57 , wherein any compound blocking the factor inducing IL-6 production is administered in a therapeutically effective amount.
65. Method according to claim 57 , wherein any compound blocking the factor inducing IL-1β production is administered in a therapeutically effective amount.
66. Method according to claim 57 , wherein any compound blocking the factor inducing IL-10 production is administered in a therapeutically effective amount.
67. Method according to claim 57 , wherein any compound blocking the factor inducing TNF-α production is administered in a therapeutically effective amount.
68. Method according to claim 57 , wherein any compound blocking the factor inducing IL-1Ra production is administered in a therapeutically effective amount.
69. Method according to claim 57 , wherein monoclonal antibodies directed to enzymes generating immuno-modulatory fragments are administered in a therapeutically effective amount.
70. Method according to claim 57 , wherein at least one anti-integrin antibody, peptide or construct is administered in a therapeutically effective amount.
71. Method according to claim 56 , for treating cancer by administering a therapeutically active amount of compound to a person suffering from a cancer, which compound inhibits the production and/or biological activity of at least one factor of importance for the performance status of a patient suffering from cancer, immune mediated anti-tumour reactivity of a patient suffering from cancer, systemic protection of metastatic disease of a patient suffering from cancer and response to treatment including immuno-, chemo-, bio- and radiotherapy of a patient suffering from cancer.
72. Method according to claim 71 , wherein the fragment to be inhibited is extra cellular matrix derived fragment matrix, including fragments of collagen, fibronectin and laminin.
73. Method according to claim 71 , wherein the fragment to be inhibited is a serum protein fragment.
74. Method according to claim 73 , wherein the fragment to be inhibited is a serum albumin derived fragment.
75. Method according to claim 71 , wherein the fragment to be inhibited is an immunoglobulin derived fragment.
76. Method according to claim 71 , wherein the fragment to be inhibited is a fibrinogen derived fragment.
77. Method according to claim 71 , wherein a matrix metalloprotease inhibitor having the ability of inhibiting the proteolytic effect of matrix metalloproteases in forming a tissue factor of cancer.
78. Method according to claim 77 , wherein the inhibitor has the ability of inhibiting the proteolytic effect of one or more of the matrix metalloproteases, including the group of MMP-1, MMP -2, MMP -3, MMP-7, MMP-13.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/997,985 US20050153329A1 (en) | 2002-05-27 | 2004-11-29 | Method for determining immune system affecting compounds |
US12/822,013 US8182983B2 (en) | 2002-05-27 | 2010-06-23 | Method for determining immune system affecting compounds |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0201563-4 | 2002-05-27 | ||
SE0201563A SE0201563D0 (en) | 2002-05-27 | 2002-05-27 | Method for determining immune system affecting compounds |
US41151702P | 2002-09-18 | 2002-09-18 | |
PCT/SE2003/000869 WO2003099312A1 (en) | 2002-05-27 | 2003-05-27 | Method for determining immune system affecting compounds |
US10/997,985 US20050153329A1 (en) | 2002-05-27 | 2004-11-29 | Method for determining immune system affecting compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2003/000869 Continuation WO2003099312A1 (en) | 2002-05-27 | 2003-05-27 | Method for determining immune system affecting compounds |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/822,013 Continuation US8182983B2 (en) | 2002-05-27 | 2010-06-23 | Method for determining immune system affecting compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050153329A1 true US20050153329A1 (en) | 2005-07-14 |
Family
ID=29586115
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/997,985 Abandoned US20050153329A1 (en) | 2002-05-27 | 2004-11-29 | Method for determining immune system affecting compounds |
US12/822,013 Expired - Fee Related US8182983B2 (en) | 2002-05-27 | 2010-06-23 | Method for determining immune system affecting compounds |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/822,013 Expired - Fee Related US8182983B2 (en) | 2002-05-27 | 2010-06-23 | Method for determining immune system affecting compounds |
Country Status (5)
Country | Link |
---|---|
US (2) | US20050153329A1 (en) |
EP (1) | EP1507548B1 (en) |
AU (1) | AU2003232872A1 (en) |
CA (1) | CA2526950C (en) |
WO (1) | WO2003099312A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007103770A2 (en) * | 2006-03-02 | 2007-09-13 | Ppd Biomarker Discovery Sciences, Llc | Compositions and methods for analyzing renal cancer |
WO2008136736A2 (en) * | 2007-05-08 | 2008-11-13 | Canimguide Therapeutics Ab | Immunoregulatory structures from normally occurring proteins |
US20090081649A1 (en) * | 2005-04-15 | 2009-03-26 | Therim Diagnostica Ab | Diagnostic method for detecting cancer by measuring amount of cytokine like il -6 |
US20100298329A1 (en) * | 2007-09-19 | 2010-11-25 | Massachusette Institute Of Technology | Tolperisone and tolperisone-like drugs for the treatment of k-ras associated cancers |
US20100323370A1 (en) * | 2002-05-27 | 2010-12-23 | Canimguide Therapeutics Ab | Method for determining immune system affecting compounds |
US8021614B2 (en) | 2005-04-05 | 2011-09-20 | The General Hospital Corporation | Devices and methods for enrichment and alteration of cells and other particles |
US8133688B2 (en) | 2004-10-20 | 2012-03-13 | Canimguide Therapeutics Ab | Immunoregulation in cancer, chronic inflammatory and autoimmune diseases |
US8304230B2 (en) | 2002-09-27 | 2012-11-06 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US9017942B2 (en) | 2006-06-14 | 2015-04-28 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
TWI503545B (en) * | 2010-12-24 | 2015-10-11 | Methods of Screening Probiotics for Individual Differences | |
CN109655624A (en) * | 2019-02-11 | 2019-04-19 | 臻和(北京)科技有限公司 | A kind of preparation method of marker and its application for predicting cancer immunotherapy effect, kit and kit |
US11378498B2 (en) | 2006-06-14 | 2022-07-05 | Verinata Health, Inc. | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
JP4800384B2 (en) * | 2005-06-08 | 2011-10-26 | ヒタチ ケミカル リサーチ センター インコーポレイテッド | Methods for predicting immune responses against neoplastic diseases based on mRNA expression profiles in tumor cells and stimulated leukocytes |
JP5027209B2 (en) | 2006-04-07 | 2012-09-19 | 日立化成工業株式会社 | Enhanced T cell receptor-mediated tumor necrosis factor superfamily and chemokine mRNA expression in peripheral blood leukocytes of patients with Crohn's disease |
CN101855367A (en) | 2007-11-14 | 2010-10-06 | 日立化成工业株式会社 | Enhanced fc receptor-mediated tumor necrosis factor superfamily mrna expression in peripheral blood leukocytes in patients with rheumatoid arthritis |
WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
US9580752B2 (en) | 2008-12-24 | 2017-02-28 | Cedars-Sinai Medical Center | Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy |
EP3639841B1 (en) | 2013-03-27 | 2023-09-06 | Cedars-Sinai Medical Center | Treating fibrosis by inhibiting tl1a |
EP4105236A1 (en) | 2013-07-19 | 2022-12-21 | Cedars-Sinai Medical Center | Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease |
CN105744944B (en) | 2013-09-09 | 2020-07-07 | 卡尼姆盖德治疗学公司 | Immune system regulator |
WO2016144650A1 (en) | 2015-03-06 | 2016-09-15 | Canimguide Therapeutics Ab | Immune system modulators and compositions |
DE112016003948T5 (en) | 2015-08-31 | 2018-05-09 | City Of Sapporo | MOLECULAR METHODS FOR EVALUATING A UROTHIAL DISEASE |
WO2017161342A1 (en) | 2016-03-17 | 2017-09-21 | Cedars-Sinai Medical Center | Methods of diagnosing inflammatory bowel disease through rnaset2 |
WO2020069408A1 (en) | 2018-09-28 | 2020-04-02 | Canimguide Therapeutics Ab | Pharmaceutical formulations of peptide inhibitors |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6216430A (en) * | 1985-07-12 | 1987-01-24 | Ajinomoto Co Inc | Interleukin receptor expression inducing substance a |
DE378732T1 (en) | 1989-01-20 | 1991-05-02 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A., Rom/Roma | SERUM PROTEINS RELATING TO AUTOIMMUNE DISEASES. |
CA2015515C (en) | 1990-01-03 | 1999-12-07 | Jean-Marie Saint-Remy | Pharmaceutical compositions containing antigen-antibody complexes and uses therefor |
US6737057B1 (en) | 1997-01-07 | 2004-05-18 | The University Of Tennessee Research Corporation | Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
US6355683B1 (en) * | 1998-09-11 | 2002-03-12 | Ilexus Pty Limited | Fc receptor modulators and uses thereof |
WO2000028072A1 (en) | 1998-11-06 | 2000-05-18 | Emory University | Biomarkers for oxidative stress |
JP2004509978A (en) * | 2000-06-05 | 2004-04-02 | ユニバーシティ オブ テネシー コーポレイション | Compositions and methods for endocytic presentation of immunosuppressive factors |
CA2425779C (en) | 2000-10-12 | 2013-08-06 | University Of Rochester | Compositions that inhibit proliferation of cancer cells |
AU2002312410A1 (en) | 2001-06-08 | 2002-12-23 | Target Protein Technologies, Inc. | Tissue-specific endothelial membrane proteins |
DK1432431T3 (en) * | 2001-10-04 | 2017-07-10 | Genetics Inst Llc | Methods and compositions for modulating interleukin-21 activity |
AU2003232872A1 (en) | 2002-05-27 | 2003-12-12 | Ostergotlands Lans Landsting | Method for determining immune system affecting compounds |
BR0316111A (en) | 2002-11-21 | 2005-09-13 | Wyeth Corp | Methods to diagnose rcc and other solid tumors |
JP4068538B2 (en) | 2003-09-12 | 2008-03-26 | 株式会社サン・クロレラ | Cytokine release inhibitor |
SE0402536D0 (en) | 2004-10-20 | 2004-10-20 | Therim Diagnostica Ab | Immunoregulation in cancer, chronic inflammatory and autoimmune diseases |
EP1875246B1 (en) | 2005-04-15 | 2016-10-05 | CanImGuide Therapeutics AB | Diagnostic method for detecting cancer by measuring amount of a cytokine like il-6 |
ES2747363T3 (en) | 2007-05-08 | 2020-03-10 | Canimguide Therapeutics Ab | Normally found protein immunoregulatory structures |
-
2003
- 2003-05-27 AU AU2003232872A patent/AU2003232872A1/en not_active Abandoned
- 2003-05-27 EP EP03728207.6A patent/EP1507548B1/en not_active Expired - Lifetime
- 2003-05-27 WO PCT/SE2003/000869 patent/WO2003099312A1/en not_active Application Discontinuation
- 2003-05-27 CA CA2526950A patent/CA2526950C/en not_active Expired - Fee Related
-
2004
- 2004-11-29 US US10/997,985 patent/US20050153329A1/en not_active Abandoned
-
2010
- 2010-06-23 US US12/822,013 patent/US8182983B2/en not_active Expired - Fee Related
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100323370A1 (en) * | 2002-05-27 | 2010-12-23 | Canimguide Therapeutics Ab | Method for determining immune system affecting compounds |
US8182983B2 (en) | 2002-05-27 | 2012-05-22 | Canimguide Therapeutics Ab | Method for determining immune system affecting compounds |
US11052392B2 (en) | 2002-09-27 | 2021-07-06 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
US10081014B2 (en) | 2002-09-27 | 2018-09-25 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
US8986966B2 (en) | 2002-09-27 | 2015-03-24 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
US8895298B2 (en) | 2002-09-27 | 2014-11-25 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
US8372579B2 (en) | 2002-09-27 | 2013-02-12 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
US8304230B2 (en) | 2002-09-27 | 2012-11-06 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
US8133688B2 (en) | 2004-10-20 | 2012-03-13 | Canimguide Therapeutics Ab | Immunoregulation in cancer, chronic inflammatory and autoimmune diseases |
US9688746B2 (en) | 2004-10-20 | 2017-06-27 | Canimguide Therapeutics Ab | Immunoregulation in cancer, chronic inflammatory and autoimmune diseases |
US8021614B2 (en) | 2005-04-05 | 2011-09-20 | The General Hospital Corporation | Devices and methods for enrichment and alteration of cells and other particles |
US9174222B2 (en) | 2005-04-05 | 2015-11-03 | The General Hospital Corporation | Devices and method for enrichment and alteration of cells and other particles |
US10786817B2 (en) | 2005-04-05 | 2020-09-29 | The General Hospital Corporation | Devices and method for enrichment and alteration of cells and other particles |
US8585971B2 (en) | 2005-04-05 | 2013-11-19 | The General Hospital Corporation | Devices and method for enrichment and alteration of cells and other particles |
US9956562B2 (en) | 2005-04-05 | 2018-05-01 | The General Hospital Corporation | Devices and method for enrichment and alteration of cells and other particles |
US20090081649A1 (en) * | 2005-04-15 | 2009-03-26 | Therim Diagnostica Ab | Diagnostic method for detecting cancer by measuring amount of cytokine like il -6 |
US8110347B2 (en) | 2005-04-15 | 2012-02-07 | Canimguide Therapeutics Ab | Diagnostic method for detecting cancer by measuring amount of cytokine like IL-6 |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
WO2007103770A2 (en) * | 2006-03-02 | 2007-09-13 | Ppd Biomarker Discovery Sciences, Llc | Compositions and methods for analyzing renal cancer |
US20070292869A1 (en) * | 2006-03-02 | 2007-12-20 | Ppd Biomarker Discovery Sciences, Llc | Compositions and Methods for Analyzing Renal Cancer |
WO2007103770A3 (en) * | 2006-03-02 | 2008-09-04 | Ppd Biomarker Discovery Scienc | Compositions and methods for analyzing renal cancer |
US9273355B2 (en) | 2006-06-14 | 2016-03-01 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US9017942B2 (en) | 2006-06-14 | 2015-04-28 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US11781187B2 (en) | 2006-06-14 | 2023-10-10 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US9347100B2 (en) | 2006-06-14 | 2016-05-24 | Gpb Scientific, Llc | Rare cell analysis using sample splitting and DNA tags |
US11378498B2 (en) | 2006-06-14 | 2022-07-05 | Verinata Health, Inc. | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US10155984B2 (en) | 2006-06-14 | 2018-12-18 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
WO2008136736A3 (en) * | 2007-05-08 | 2009-02-26 | Canimguide Therapeutics Ab | Immunoregulatory structures from normally occurring proteins |
US9796777B2 (en) | 2007-05-08 | 2017-10-24 | Canimguide Therapeutics Ab | Methods of treating malignant tumors |
EP3636667A3 (en) * | 2007-05-08 | 2020-07-29 | CanImGuide Therapeutics AB | Immunoregulatory structures from normally occurring proteins |
EP2226334A3 (en) * | 2007-05-08 | 2010-12-29 | CanImGuide Therapeutics AB | Immunoregulatory structures from normally occuring proteins |
WO2008136736A2 (en) * | 2007-05-08 | 2008-11-13 | Canimguide Therapeutics Ab | Immunoregulatory structures from normally occurring proteins |
US9120874B2 (en) | 2007-05-08 | 2015-09-01 | Canimguide Therapeutics Ab | Methods of immunoregulation by albumin neo-structures |
US20100298329A1 (en) * | 2007-09-19 | 2010-11-25 | Massachusette Institute Of Technology | Tolperisone and tolperisone-like drugs for the treatment of k-ras associated cancers |
TWI503545B (en) * | 2010-12-24 | 2015-10-11 | Methods of Screening Probiotics for Individual Differences | |
CN109655624A (en) * | 2019-02-11 | 2019-04-19 | 臻和(北京)科技有限公司 | A kind of preparation method of marker and its application for predicting cancer immunotherapy effect, kit and kit |
Also Published As
Publication number | Publication date |
---|---|
US20100323370A1 (en) | 2010-12-23 |
WO2003099312A8 (en) | 2004-04-22 |
AU2003232872A1 (en) | 2003-12-12 |
CA2526950A1 (en) | 2003-12-04 |
EP1507548B1 (en) | 2014-10-01 |
EP1507548A1 (en) | 2005-02-23 |
CA2526950C (en) | 2012-06-26 |
WO2003099312A1 (en) | 2003-12-04 |
US8182983B2 (en) | 2012-05-22 |
AU2003232872A8 (en) | 2003-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8182983B2 (en) | Method for determining immune system affecting compounds | |
US20200048331A1 (en) | Immunoregulatory structures from normally occuring proteins | |
JP6886816B2 (en) | Immune system regulator | |
US20160000914A1 (en) | Combination of tumor-associated surface protein antigens and tumor-associated sugars in the treatment and diagnosis of cancer | |
CA2658274A1 (en) | Use of soluble cd160 to suppress immunity | |
US20200206343A1 (en) | Anti-dc-hil antibodies for cancer diagnosis, prognosis and therapy | |
Rohrer et al. | Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes | |
DK1507548T3 (en) | Method for Determining Compounds Affecting the Immune System | |
CA3099968A1 (en) | Use for preventing and treating myeloid-derived suppressor cell-related diseases | |
JP2003515535A (en) | Compositions and methods for modulating tumor-associated antigen expression | |
CA2502663C (en) | Methods to prevent tumor recurrence by blockade of tgf-.beta. | |
KR102415341B1 (en) | Method of measuring of nk cell activity using bispecific antibody and diagnosing of nk cell activity-mediated disease | |
CN116970086A (en) | Recombinant antibody and application thereof | |
AICHINGER et al. | SOLUBLE LOW AFFINITY INTERLEUKIN-2 RECEPTOR (IL-2R) ELISA IN THE MONITORING OF IMMUNOLOGICAL DISEASE AND IMMUNOTHERAPY | |
JP2022518187A (en) | antibody | |
Ralph | Modulation of T regulatory activity for cancer therapy | |
Zhang | Response In Vivo | |
Ilkovitch | Mechanisms involved in the anti-tumor activity of MUC1/sec |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CANIMGUIDE THERAPEUTICS AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HAKANSSON, LEIF;REEL/FRAME:019395/0226 Effective date: 20070130 |
|
AS | Assignment |
Owner name: CANIMGUIDE THERAPEUTICS AB,SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THERIM DIAGNOSTICA AB;REEL/FRAME:024408/0040 Effective date: 20100418 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |